var title_f5_25_5520="Lateral malleolar fracture";
var content_f5_25_5520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Lateral malleolar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 390px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGGAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5lamGnmmGgBDSUppKAENFFFAEqGp4zzVdDU8Z5oEaEB4rUtG+YVkQHpWnanketUiJHq3w0f8Aczj0aum1PJuST6CuT+GTHy7n6iuq1M4n49B2rojscctzQt8mwXnpXFX/ABfTf71dpaZNgucd642/4v5v96myUdl4I/4825/jNdZIR5JrkvBH/HkwP96utc4joQjMn7gVTc4Jz+FXJiMk96ptjdzTERqM8mnqeSc/hTBgkkZwKUEBfxoAljbEqkdKn1QbrZselVY8eYMVcuQGtj9KAPnbxUnl6tdr/tmuWuBgmuz8cp5euXQx1INcZP1Nc89ztpbFKTrVd6sS9arv1rM2ID1pKU9aSgYq9a6z4aeH08Q+J4YLhN1pCvnTD1A6L+JxXJr1r1/9n1U+1awTjzNsQH0y1VBXZnVlywbRV+LPi6YXj+H9Ik8iztwI5vL43tj7nH8I6YqKXw3pHifw/ZjwcqjUrZFN4JGKk5U9c8E7genauC8Rs517UjL/AKz7TLuz67zXZ/DW703TtC1u5m1V7HUmjMaAOB8uMghT1OeParveWpm48kU4nF6fqN9omoGS1laGaNtrL2ODyCO9VdTuzf6hcXTKFaZy5UdATUUjM7szklmOST61HWZvZXuJSUppM0hhRRRQAtPj60ynx9RQBu6cTtXHrXodqSbRT7CvO9P/ANWK9A08g2Kn/ZFa0zlrl6xPzg+lUfE3SM+9XLLh6qeJBmFSPWtehitzDUkVIp9ahU1IDWaNGb3hr/j4au6tz+6IPSuE8M5+0NXdQn9zWsdjCW5XmPzHFVnPbIqeY5qq59OppiFBpyuMCq+7kg0oOSAKBm5p7ZUg+lcP8TU3aY59DXZWJCNtHpXK/EVN2lzD2p9B0/iR4xJ1qB6nk6moXriPSIjQaXvSUAFJS0lABSUtFACUUUUAFFFFABS0lKKALZpppx6000AIaSlNJQAlLSd6KAHp1qZKgWpkoAuwHpWlbHkGsuE9K0bduRTRDPUvhieLoe611+p8y/lXFfDF8G699v8AWu11H/WcV0R2OKfxF6wObDHoTXHann+0Js+tdfpvNo4PrXIarxqUw7Zpsk7LwP8A8eJ5z8xrqpj+6HrXLeB/+PDPqxrqLg/IKaEZ02M5qm/PTpVq46dKqspycUxCLwDTRz+VOzzxTPu9+aAHx/e9x0q7kNA1VEwCB+dWoSCrDsRQI8P+JcOzWi3Tcn9a4C4HJGK9R+K0O28hfHBBGa8vuByelYVNztou6M+XrVZ6sy9aryVkbogNJSnrRQMB1rsfhf4hXw/4mRrhttpdL5Mp/u85Dfgf51xo607NNO2pMoqSsz0X4u+GZLDWZdXtEL2F429mUZCOeoPseufevOjXpHgb4hrY2g0rxFEbvTtuxXI3FB6EHqK2rrQPh/q7Gay1JLVm52JMFH/fLdKtpS1RjGo4e7M8dALEAAknoBSOpRirAhgcEGvWHg8GeGP31vcJeXafdJfzTn2A4FeV3svn3U0oGA7s35mpcbGsJ82yITSUtFSWJS0lFAC0+PrTKenUUAbdh/qxXfaSS2np/u1wFj9wV3egndp6/wC7WlPc5q+xo2Zw3vUHiEZtQR6ipLX7wNJrwzZE1t0OeK1ObU1IOmahB56VIuKzNmb/AIYP79813MRxDXDeF/8AWue2a7fdtgx2rSOxhLcrzEZNVJPTPFTy8896rykdqokjBy2AcUucYOeaZkfT1pu8FsHr2NAzUspOcZrJ8cJv02YY/hNW7NyJBz15FR+KEMumyd8rQgjozwiXhjUDVZuhtlYehNVWrjPSRHQaKKBhSUUUAFFFJQAtJRRQAUUUlAC0opKUUAW2ppp5phoAQ8UhpTSGgBO9LRSUAOXrUqVEvWpVoAtRHkVoW+OKzoq0LY+lNEM9K+GJ+a55/u/1rvLojzffFef/AAzPzTj1Irvbo5l/Ct47HHP4i/pwBtpPrXIat/yEpseorrtMP+jyDHeuR1cY1OXv0qmQdt4JX/iXD3Jro7kfIPWsDwYMabGemcn9a6C5+6AO1NCM2bGartg5Gc1YlHWoG9vTpTERH71Iww2cU9uKa38OKAGjPzEd6tWhzVUkFePXk1LbuFOPagR5/wDFm3/0aOQD7r8145dDDGveviZAJtEmbuBu6V4TeDk1jUR1UHoZco61Vk71cmqnJ0rE6kQGilNJQMB1FFJ3pTQAA0Z9aKKACmmlpKACiiigAooooAWnx9RTBT06igDZsf8AViu48NHdZAe5FcNZ/cFdp4WObYj0arhuc9bY1bcEH05p2tDNgee1NQlX/GpdT+awbjsa3RzLc5PNSLxUQp46dKyNzo/CoJlbHrXZuf3IFcb4UHzPj1rsZMCMZrWOxzz3Kkhwaru3PPcVYl56VSc8nmqJGgkH3ppOeaTdg8cmk+p59KBk9q/74cdqs6wN2nt3G2s+Btkoya0J28yxcHsKEHU8L1NNl7Mp7MaoNWv4ij8vU5x75rIauWW7PSi7oiopaSpGFJS0lABRRRQAlFLRQAlFL3ooASlFA60ooAuNTDT2phoAbRS4pO9ACUZoooAUdakSoqlSgCxH17Vft6oR1dgPSglno/w3YCSYZ7iu9uSfN/CvPPh0375+2TXfynMp9q6I7HHU+I19K/49pC3WuP1v/kLS/hXX6SR5Ulcj4gG3WH9wDVGZ3/hFdumQ+61tTnIrK8NLt02H/dFaUxytMRTYYbtUEg+Y+lTyjnB71E4IOTQBA4wPamHP6VKehzTCMjA9KYiMY6eopY+v0xQ6kdwcU2LJY9qBFPxdbi40iZeuUP8AKvni/TDEHtX0tqCCWxkXrgYr528QQ+RqFzH/AHXIrOpsdFBnNz9aqSirs45qlJXOdiIDSUtIaBiUUtJQAUUUUAFJS0lABRRRQAUUUUALT06imU9OtAGxZ/cFdl4Tb5JFPrXG2f3BXXeEj88o+lXDcwq7Gy3Ejc96tXXz2RA9KrS/8fDCrJ5t2HtW6OU44gZPNOpsvyysPelXp1rJm51XhIfeOO9dbOQEHrXLeDx8jH3rp7g/dz6VrHY55blSU8HFVX6dBU78kj1qBjnIqhFfgk+ue1IxGVz09qUEB/rUcn3ifyoGHmfvCw6dOa04XEkDqfSsQt1xWlYHBx6ikDPLPGUezVX461zjV2Xj+LbfBsY6iuNauep8R303eKIjSUppDUFhRRRQAUlLRQAlFLSUAFBoooAKcOlNpwoAusKjNSGmGgQ3tSGlNIaBje9FLRQAgqRaZT0oAsR9auQnkVSSrkHUUEs7/wCHzfvj7mvQSf3hrzvwGcTZ967/ADiRvfpW8djjqfEbmjEYkXjpmuW8Rqf7aA9QP511Gh8yNx2rA8TR/wDE6t8dWAH61ZmjvdDAWxjHotXH5B9qq6cAlmg9BVhjwc9jTEV365PSoyBUpGciogOTzQIhbkkd+tIRgfXrUm3kgelIcHnoAMUxEH+TUQ+UcnqM1MwwVz3qGTAB/CgZOp3o6/3hXhPj+18jXp+MB8NXuMDYfOeK8s+LNoY7+KYDhsqamaujSk7SPLLiqEvetG5HJqhL3rlZ3IqmilNJ2oKEooooASiig0AJRS0lAAKKKKACjtRRQAVJH1FMp8fUUAbFp9wV1nhE/v5e/ArkrT7gzXV+ET/pMmf7oq4bmFXY3J+Lpue9Wov9Uw9qqT83DfWrMB9T1FbHKzlLwbbuQf7VRVb1Vdl647nmqmc1D3N1sdj4NGYWJ9a6S6649q57wSP9GPc5rfujya0jsc8t2VCe+KryYyKmJ+aq8nKnmmKxEx5qOQ5/hyR+VOYjgDnFMZsKe9IZE/AGCMk1Zt5NrA9uuaoyMN5x0FTxP1AoG9TnfiHDlRIPWvPX716l4wjE+mMwHIFeXy1jV3uddF3iV2pKc1NrM2EoNLRQAlFLSUAFFFFABRRRQAUoxSUooAvHrTKkamGgQw0lONIeKBjaSlooASnpTaelAE8dWoeoqolWoaCWd54EbEnTPNegsAWU1554F5kH1r0EjDLzxtreOxx1PiNjRW23Kc8NxVTxFDnWrI+pxU2mMElU9hVzWoQ+oWTgZw+f0qzN7m/bDbbr6YqYZO7iolOI1HtUi/eI9aYhjZ3EkdKiH3Tj17VM+c++KRVzn0oERYIJ9KRkGOT0qRu/rTGGfagCsV6nGcCqsoxvPcCrT8E85BHSoLnABHY/pTEQxtjb7H865L4qWnnaOJwMmMg5rq87GXrjJxWZr0AvdFuoTydppMqLs7nz1djBNZknetjUEKuynqDismUVys9COxUPWkpzdTTaRYnaiiigBKKWigBKSlooASiig0AFFFFACinp1plSR9aANa1+4K6rwn/r5PoK5W1+6K6rwnxNJ9KqG5hV+E2pcee31qzEfmHvVNyTcMT61YiPPTpW5zMxdeUrdhsdRWd2rZ8RrzEwrFU+nSoluaxeh3Xg1NtnnHvWvctuPrzWf4RXGnBsVbmPzNg9D6VpHY53uQsfmPHFQOcqenBqeT7xPbriq8hByPemCIWA3kjnntTH4x245qWTHPPPtUT8AHrikUinKPmIJp6nBGcZzSSH97yMGnY+UnA60hjNSXztOkT2PWvK7pCkrqeoNepF90eG7jvXnOuxeXfyjGMnNRU1R0UHbQyGFMqVhUdYnQJRS0lABR2oo7UAJS0UUAFJS0UAJTxTR704DIoAvGmGpGpjUAMIptONJQA2jFOxSUAJTlpKVKAJkq1D1FVkqxD1AoEzvPAf3/xrv924474rgvAakua7cvsnTnIPWt47HFU+JmrYE/KSDx3rdlj8wwN/drn7JjuGfWuptk8y3BI6CrRmyfOBweatYAbJGAeKz423S5Jq/wBDj36UxCPnjmkAKn260rjnpSDnAPPFADGGCcGkbv06VKV+cD86Y4HP1piKsiYb5ev8qqzEEk4wAOauTff9/WqdxjJIx0oEU5sCQYPygf0qn5gw4z1wDVm6OWyvHU1mO5WT5h14/GkM8d8Z2X2PWblMfKW3D6GuSmBya9Q+JlpnyLxR94bGPv2rzOcfNXPNWZ30neJQfg02pJBzTKg1EpKU0UAJRQaKACkpaSgApKWkoAWiikoAWpI+tRipI+tAGtbfcFdT4V/1kmK5a2+4K6nwv8vmE1UNzGrsarH96T71PGcdDnNVeCM981OhAUetbHMyDXxm1Rh2IrAFdFq4Daf71zi/lUyLhsek+GBt0dT6jNOkJ8w46ZPWjQPk0GFiOq5qOQjzM59TWi2MeoxjnHHamOAXJpSQTge9Jk5yOhpiICMZJ6UjAnGRnvUsgXnPrSSH92cZyeKBlGbG7caj3cN15qe4C8cHvmq/VWJzjOKRRWLcdfauR8VR/wCkLIBwRXUSnG70FYXiFBJbZHVeazlsbU9JHJOKiNTOKibrWJ1DaKWkoASilooASig0UALSUUvFACCnCkpw6UAXjTD1qQ80wjmgQw0hp1JQMbSGnUlACd6ctJSr1oAmSrMPWqycVahHIoJO+8CZCk/WuzwWbjqK5DwSuLNjn2rqFbDKM9fet47HHP4mbVjyCD36muv0sYsGOcgniuP04cDjjPNdnar5WlqvPXNWjNlW2P70ZPrWoo5GMZ61lWzEy/LxzWrENyEng4piEkzuGacB09c00jOOufenp1BxxQIQ/eJxzUZGMY4zU2DjvTHG1iRz9aYFOYEEEjPU1TmUldyg59D+VaMqZHI74qnNgKVx6nrQBkXC5Lbe/asm6IIGOvWte44dtoPQcVjXoZQmR2x+NJjRi+JrZNR0S4gT76Auv1FeMXS4Yg17S0xjuMkcc8Hv3ry3xdY/Y9VmVR+7f50+hrKotLnTQdtGczIOaiqeUVDisTqEpOlKaQ0AFJSmigBKSlooASkpTRQAUlLij60AHepE61GKkj6igDWt/uCuo8OcQTMe1cvbfdFdRony2T+5qo7mNXY0UOScDrU2chfXPNVojgCpc4B5PWtTnZNeru0x/UZrml/CunlJOnyg8YrmrcbpkX1NKRUNEz0uwXy9Ctl/2BVZwCSR2GauS/u9Ot19EA5qipG1cqeDWq2MBCuGHOacv3gDgCkXqBnqc0mAckDjOKBjXHJ9cnpTHzsJHp3qaQdCCeegNIYwVOCckdaAKDjOW6k1Vk+42B+VXpxtBx74xzVRsHdnpSKRmXDDLA55NZF+N0Zz05zWrcA845NZd30YHGazZtA5KddkjD0quwq/qC4lyOhqi1YnShlJS0UDEpKWigAopKWgBKKWigApyjim08dO9AF89aYakYUw96BDCKbTjSGgBuKMUppDQAlOWkpy9aAJUq1AOarpVu2GXXjvQJnoPhgeXYJ710MWSVyOa5/Rx5cKx46KMZroBlih9hkCt1scUtzodKTLqoGctXZSALZAY6Vy2ioQFl45rqc5sTk8561ZBQtR+9bJ71rxDMY5rItQC52nuetbUIAiI6UxAcEdKRBz2IHNSAblztoTvx7UCGtk4JpjKSwLe1WCoOMHpURGRk9e1MCGRWI9MVQfJyeeprSZeM9x1qi/KsOfWgDEuAqy/MMg9qx9R6BuDjI+lb17GQQQMHrWJqH+rA2jqRn9aTGjlrzcJQckDNct4yg+02QkXloDgn2NdZqZYOV4AFYd6BKGRvuMCpqGjSDs7nmEoqvWhqEJguJI26qcVQYYNc53IbSUtIaBiUUGigBKDSmkoASiiigANFFFABUkfWmCpI+tAGtb/dFdJp522qe9c3bn5BXR23FpF7CrgY1C/G3yjmrK5NUrds/Wr0Zz2rRGDJ3GLGcHnjrWFo8RkvU44Brf5e2nXH8Jqj4eh/0lPUnND6CWkWdhqBG2JCMgKKrR/d6dqlvDvnIyPlpg9ck5rQyGEdD0IOKVBjq3ftT9hIORlaCq+lACOvygDPX0pACVKE4GKkxhcEHrSchj/KgCjLHhFJJ71SlUYYAZPetKZWPPb3qhKpVSSMk84pMtGTcLyRnrzWVdLxzWvdDBC9AKzLlc5IHFZyNYnNakhweOhrMYVuajH8rcdqxGrJnTHYhIoNK1J25pFCUGlNFACUUUUAFGKKKACnr0ptPHSgC+RTTTuvU0w0CGmkpxppoASkpaQ0AJT06001veBvDV74w8T2OhaY0SXd4WCNKSEG1C5JIBOMKe1AGUnXir+nJuuYl/2hXT+Lfhd4w8Il31bRpzar/y9W486LHqWXO3/gWKw9Bj8zUIuOnNNEy2O2sD/pJ46YUVuWo8xuuTjIrA0z/j7fjj71dLYf6xMYAB7VsjjZ1+mp/o6gVugYhIPdeaxtOxtHcDjHvW2i7lC8AEYqzMzbL72RW7Bjyvmz+NZljCdxztHbrWzbxkx4OOKYDVHGAeB2oHPfkelWRBnPrxSfZ2J4/OgCEAc9/amMuen5Va+ztkGhLZj1GeaYinKvy5HOeapyx9Op45GPetk2pH3iKrTwALgYzQBhXcQ3gMe3PvWDfRHysFR3OfWuovIsbXAzhDXP37OkI4bAGSPegEcjqcGSeO3Wucu4wqOc8DrXZamg8sAHDbR1FczqMe0kcEEVDLTPP/ABVBtuhKP4xz9a5txzXca7b+bauuPmA3KfcVxUq4NYSWp203dEJptONJUmg00UtFACUlKaQ0AFJQaKACiiigBRUkf3hUYqSPrQBrQfcFdDAf3CL3xXPW4yqiugg4AA6VUTGZbiyJB9Kvxj5cg1njjDDtXQeHNV/sjUIr37FZXoTnybyPzIzz3FaIxZqeF/DWs+IJGj0jTri5VgQZFTCA+7HgfiaytOsZrHVprW5Ty57eVoZF67WU4I/MV9CeD/jdo1zHFa6vp8mllQFDwDzIR+AAK/TBryzUfEWm3njDV5o/DukyJLdyyrM0l0GkBckMQJgMnqcAD2oTb6BJRUdGY83M8nbmmIePl4HvWjqN9BeBVg0mysmByZIGmJb2O+Rhj6DNUUjJb6cVqYDsljyTjtSjGwEj5vUUqqccA8+vrTgpCMecZxQFxoxty3TrTRzzn8ak+baRimFD6fpTEVLjO3HVeaoyAncR9OfStU28knQcYps1soBG4EjrikykznbmLLDg5NZ00ZGeOK6W7jWNUDoSM9jWRe+W8m1BwOvvUtGkWcxfR5RuPeublXDkV2V1HuQkD6Vy2ox7LhuODzWMkdNNlBqZUrCoqg1EpaBRQAUUUUAJS0UCgBacvSmipF6UAXjTDT24phoENNJSmmnpQAlXNJ1KbSrwXNqlo8gBXF1aRXKYP+xIrLn3xmqZooA6f/hOdW/59PDv/hPaf/8AGK6n4Z/FKfw94003U9Xs9LawhLiYWOi2cExDRsvyukasOSOjDPQ8V5dUkY70AfRXi39pnWr4vD4W02DTITwLi4/fS/UD7o/ENXlGnXlzqur3WoX8vm3UvzO+0LknjoABXKR9q6fw+u2Fm/vH+VVHczqPQ6G1BW5LdMiuo08g4A7nvXPWkQchsncK3tPZkHzgbhWyOWTO10thJEGUYHfFba8xEjgg1y2jTL5uOQGGMZ71043GBOOvpVIhklgyq5GF5bHXvWxaEbSMDqQfWsa2QeaeOM54rdt025wOOtNEslHB5HNKpOD0FTBQR7UhA9M0wI/mz3zinHJpcdcelAP8qBDSmR1NQm2HJOQBVvOaac465oAxLm03AY3fKK5/VLQntnPG4jFdo6q2RuFZd9DlMEcDsaBnmWrROfNyD6DFcver5YIbJAHUj1r0XVrLhijkDoBjNcVrkBRhlR06VLGmcjdwk7lGeB8ua4fVYfLuWwMA84r0O7XDetcn4otgp8xRweaymjqpS1OYPWmGpH60w1kdI2ilNIaAENIaUmkoASilpKACiiigBaki+9UdSxdRQBsWg5QVtwHPFY9iMsta1vjeKqJjM0YV+XmrMfyjHOO1VoOvB71djwcgitUYMtWh+YZPetGGMpfeYOQwBNZlsCHA7VrQsTCGPDIQKpEM10g/eBTj/wCtUqRxhlw/WoYGLyqfbircdtu77QD0qjMd+6DKu7ke1SKIyCME9+lPFuOCDj3qYQgEYBNMBqx25BBQn0pVgh3EJFz6mpREP7owD3qWMJGeAeaYrlN7cupxHgemKo3MHluWkjYAjJwK6DOR94gVHIqOe/uaAucFf7ixwPcDNc7O370569q9Dv8AT4XZyow5HWuU1Sx2TYMeB3I61Mkaxkc7MAVJAzmud1qDncO1dhdQoisck57Y4rD1OAuhJHUVlJG9ORx7iom61ZmXaxHpUDD0rE6RmKKWkoAKKKWgAoo7UUAL9akA4pgqVeBQBaamE04000CENNpTSUAJQaKO9ACVIlR96lTtQBYj6iuu0dMQovHauTthmRR712ejoGCDocVcTKpsb+mjoOcnoa6CzQnG4dBnNZekrgdgAccV0FqjSAgde+K1RysvWkJLgj866aOTNsDJnIH51l2EQIVW4xW7FbmSExgc9RVEFSDUBbSAcE+hrobPUYpFBAArCh0mJ5iX3MR3zWlBpcKcqGX6E0xG3HMjDineYuP/AK9U4YAo78+9SiNcYywpiJd600zKvUCk8tP9rn3qNoVbsfzoDQbLehVOBzWbNdTvnaGP0FaiwIvRFz7808rgcDH0oA5K5urmFt7KwGe4qxYaqLgeXJ1963Z4g6lXAIPqK888TxS6LqEc9ux8hz9309RQB0WqQgo3Gc8/hXFa5a8MMA9+mK7O3uheafDMpHTBrH1a1WRGJBBzQNM8uvYyCVI5BrA12DfYsCORmu31Gz+duO+feuS1hCkEuRxyOtZyNoPU87kGDURqeb7xqE1znchtIaU0UAN7UlONIaAENFFFABR9aKBQAo96ki6io6lhHzUAblgMDPtWpb53ZNZtkPkWta3XIGKtGMy5FgfjV2Dk4P1qpEK0rdDxgAitEc8iZFwVIFbUcatArgZB6iqAXCe3SpYrowLtPzKe3pVIzeptWs8Ua/Nzj9K0Y5onAxIPSuYg3XUn7psL/tVpR6dIg+WUZ9MVSJNsGNufMXntUwC/31wR61zxt7tSdroR+NCJdj+NfpzTuFjotyZBaRcCm/aYU6tuxWF5d22SGTPQdadHazniSUAewouBrtqUQHRQPSq0+tKsZbAAqIWELLhncke+KgudFjkHyyMuPfIp3CyIm1pZl2uoGT1Haq91icHacj361VutKmtlLZ3LnqKLTdgj1pDMu6i284BXkHP86xL+LcGx0GMV1N/HvzxgViXsBQHjjHFTJGkGee6kgS5cAd6ouK0tTO66lI9aznrme53LYiopSOTSUhhRS0UAJS0UtAAvWpl6VGKlXpQBNTTSmkNAhDyaSikoADRR3ooATvUqdRUXepUxQBds+ZV9q7bRIyyBh/CrH9K4mz/1legeHIt8BPJBH9KuBjVOn0iMBkO3Ebd/Q101jaMSHP3aw9Ni/wBFQFQhTnPXNdhpOACMjaQOvNbI5WX9PslzuYgA98VtWcRDD29KjtYwI8hQF7HPWplmQK2zPpVEiWiZdue5q+qgLVeyU4zV9RQIai5A9qftHSlx1x6U7FMBm3g4pCuD2qTHWlxmgRGVprDipsUwigCuy5/+vXGfEeAf2fFgDO7NdwfvYrnPG9r9o03IH3aBp6nF+E9RVLR7eYZCnj6VuyfZ5kH70euG4NefpK1jdbucdCPar9xqClAS4ApXHY2b6ztVQyO44HXNeT+NbyziDxW7AsewNaXinWlERihkJPsa83vWZ5GZjkms5y6G9KnfVmdL1qE1NJUNYHWJSdqWkNAxKSlpO1ABSYoooAKBQKWgAFSxfeFRegqeAfMKAN61+6grUi6fjWbaj5VrWs0LLVxMJmhZRl2PHati0gwgOT0qrpsJJJI+X1rQjlVG2Acg8GtUc0nctRxDyzkc4zzVeeLecAZJ7VajkDADI/2j2pyYa44Ucd6skks4Fi2IAPT8a2IAMDNZ8KlnBx071p2yHABoJuTrHuzTzAueRUyKMgYFThR3OaoVykLcDnFI0ZBq64IGece1QMOwHX1oArtF6E4HpRHKA21uKlkB2EkGoGXjgYxQBaMIlUgYINZV5pbRtujUBSenSpizIp2MR6VWl1KYKY5W9s0BqVriwYpnI2iuV19/IhfJHANa17qMxyrthR6cZrh/Et+ZcoG6mok7I2pxbZzFwdzsTzmqb1ak71Xk61ynciBhSU80ygYUUUo5oAKBS0uKAAVKvSoxUy9KAHmmnFBpCaBBSUGkoAKKM0UAFSpUVSJzQBfsvv16R4VGViTGCePrxXm1njzVzwDXpXhg5jjBOMYINaQMKux3NtGfLAjO7+8MdDW/oqbiPmGfQdKp6UqSoCvGetdBDbJFB8gwp6VscpaEmEwnSqcd2DeeSnfg4qpql8LaMQwnMrdfal8L2by3gnk+4uSSe5pgdhbLtQdqtKM0xFwRxUqLTJBRg4xT9vFKF6U8DpQBHt9BQUwDUwHFIRQBCVxTG471ORxUEnf2oEREjd71XvoluLdkPIYYNSnqKa3KMM9KAPHvFmmPaXDkL8ua4rUJHCFQxr2vxTbxyW7s6ZC9favIfEFqIZnVSCOopSNInF34zkmsC6HJrpL5MA1z92vXiueR1U2ZctQmpphyaiNQbDaSlooGNNJTu1JQAlJS0UAFAoNAoAWp7cfOKgFT2/8ArBQB0VoPlWtuyXGB2PNYtr0X6VvaYQ2Ae1aROaZsRMI4gFJ55qHJyWBP9asxqGTOPYU4RKDmtLHOPhZsD+70NaljGWcN6ntVC1TzWOFIUd62LaNkwVX5R6VSJZq21ooXLc1cUKoAVcYqvZ3HAVqvlFIyDkVSJIwwB6j2p0b5x3qNlPbqaXAXBxk4xTAmfJ56VAee3I704v1yaaT15+tACFSQQTn0qC4BKqDxg1aUbsnv/Wop0yDkHJ4waAKJwV+lUNUj3Rl1HIrTa3ZMMQenzVSuFfYWYYKgcdiKQzgtbeXBH5GuNvA29t/Jr0HXLYNvx2JrjdUg2qDjnHNZVEdVJownqFxViQdagcVgdJA1MqRhzTDQMSlHWkpaAClFJinCgBRUq9KiWpl6UAIaQ0GkJ5oEFJmij60DCiiigQVJHUdSR0AW4c7hXf8AhS7RhGGxnOOa4CGtrSbhoHBHSqi7GdRXR75oY4UY4/nWprOrJZqkERDT4yR/dz615dpHiW8SBYYWAPQOwyR9K6TQrZ7yUNI5YscsSck1umcbVjc0i1kv59z5OT8zHvXf6fAsMSqqgAVmaZbw2sSgDP0rZhIyCKpEst+3SpI1pqDI6VMg46UxCqKdilUU7FAxhop2KQigQwjio3FTEUxqAZTdDgDsKp3OV+7WlJ35qhdTKkbNj9KYjG1wqNNmaboVwB6mvIfFMeLgEdCoIr0/xCzy2qsxyG+bHpXnuvQ+dCHHVDj8KTKTPPtQjyp9a5y8XrXXajHgGuXv161hJHVTZgzjBquatXA5NVjWR0DaDS0hoGNNJTjSUAJSUpooASilPSgUAA61YtR+8FQDrVqxXdMv1oA6qxiDKuFya6TTLLu2F4qlpcCLGm0AkiugtEbAwOMc8VtFHFUkSx20S4zIzf7IFTqidBHz6VIkchGABj16Gr1raqgEjksx6DNaWMbkVtatLgsCsa9gK17eJQvyjJpIYXk5YkD0q9FCqj61SJIjbKcdm9qaHkt256H8qu8cd+aR0DqVIBHfNMLjIpY3HPDU8r3PSqc9swOYzx6GmpLPGTwdvvQFi20fJGMgjINOSLcCOpFRR3hGA0dTzyhY8RgLK3Y9QKAIxEVbnIp8q9CVz6UtqMsMkljztqcqHBU4IJx+NMBqKvl4ZcqeDms6+tgQcAfMuD6cVqxxEJsOfb1qtcLhuR0POKARwWtW3mB5FOCTz+VcdqSBlMb+mc16Xq0CnzQygZ7iuH1y02O7rluPTpUSRtB6nBXCFXYVVcVrX8fzZFZsgwa5Wdidyq4phFTOKiI9aRQyilNAoGFKKSnUAKOtSjp0NRLUy9KAGGkNBpKACkNBooEFLSCl7UAAp6dabTk+9QBch9q1rJeRWZarlq3LKPpVIzm9DodHXkZ6V6H4al2MoYYB4rhNHjIYcV3WkJtCk1tE5ZM73TizAZOQK6GzQkDFcxojlgg4z/OuytU2x5I5NWZkigcfpUoFNUAVKKAAClxRRQAfypDS0hpgNNNYZp5ppoEQSR5HHWs+5g3IVxWsajkXIoEchrNmWhGzHAxg964jUbYKCu3HXIr1W/thIuQM1wniC3Ec7nHUUAeUa3BskcDpXI6mmCa7/X0DTPgcVxGqLy1ZSR0U2cpdDk1UNX70fMfSqJFYHYhlIadSUDEpDS0hoAQ0lLRQACigUCgBRV3Thm4T61THNX9LH+kJ9aBPY9L0qLdEnB6V0FpGB8oP4YrF0508pOAuB1rbtmLADP410pHnSNGELgAg81oQIgA+Xn3qjCD1Bq9C2RyMn61aJLSZPsKnXOOBxVeLB6HirCnrTJF5IzjjFJ05wfpinZIGTjFMZuvb3zTAN+1c5H4io3myOlMkJIGCfwqndSsqkDaRSHYsT6jBajKrvk64HSo7eeLUW2vlJD0rIMbSNuPJJrSsIBC8bEfMDmkDN23t/KfDqC4HU9asLEDk7Qfb1qeF0mAbvjFBC+u4mqEhjx87uvGOarXiglWC5XODVmXO/A4yOtRoecMAFoA5/VbPej7OX7D1FcDrkMqhgQSo6Yr1ie23A/JuQdB6H1rGvNLjfMhGR64/nQ1cpSseJ3cBYEFMMfTvWDPGVJB617Zc6DDKSQo/AV514p8PzWNzIyIWizwQOlYTg9zqpVU9Dj2HWoWGDVqRSCagcVgdJARRinMKb9KBhSikFKKAHLUqjiol61Mn3aBEJpOlKaTtQMKSjNFAC0opKcKBAKcnUUgpyDLCgDTsVyRXTafDuArB05MsK6/SYdxAq4owqM6DRLXO2uxsodqgAVlaFbADP5V2miWHnuC33e3vWyOZst+Gona6VVztHJrsw+Dt9Kh06zS1j+VQGPpVoR5P9KokcnPOKkWhVAFOxQFgooxRQAUhoopiEpDTj703tQA00xhUhpjUCK0ozXN65DHJvLoDiulmO1ST1rnr8ebkn7o60AjzDXtJJSR4iT3wa811aLbuB7V7Vq8JDMVHA5BrzDxja+TdyMq4VhuAqJLQ1g9Tzm+X5jWY3U1sagvzGshxgmudndHYYaTFKaKRQ2mmnGkoASgUtJQAUUtFAAKv6Z/x8pj1qiK0NKGblPrQJ7Ho1izFFzzxW5aHOOmaw7FR5a59K2bUkAEfrXSjz5GzBkjBI47VegGPx/Ws62PzD39a0IycjjNWiGW42YdAM9qnjdsDB5z1xUEW4tgdOtWlTJ4PSmJis54B5pkjgY+WpGT8/WoZI8kjJz7UCRDNIDwOg96pu5b0H61b8rLFVGSO56VWmgcMM5J9hQMYJMPg/wD6quwMGcEnjtxWa8LRnnOf5VctSw5x+JoA3bOXYwzyD61YI2OfXNZ1s5eRQcEZ4rUCjeXB4piILkneAOCBkGnoA6ZB59x3qnNLvkJJ71PbPuPsaALy4ZOfvLxVO5i+9jIPJFXFwp56Y6+tNkj6g/WgDnpU27iAOOfSql5ZRXFszTxjBHIIree2MkgVRg9T6VU1f5I8IpIx0A5FMaPHfFnhF1V7rT1Eijl41HIHrXBSIVyCMEdq9ymZrTdID8p5/wA+1eb+NNNSO6a6t1xHKckdhWFSF9UddKp0ZxzioyOasOtQkVznSMpRRiigYoqZcYqEdamXOKAIabS96SgAooooAUdadSClFAhwp8YywpgqeBcsKAN7SY8la7nQ4cleK5PRY/u8V6F4et8lcitoo5aj1Ou0e1yI1x9a9B0S2CqG7DgVyWixYkUd8V3Omj90McVqjBmgp7AVIBTEHepB0oEFOpKKAFpKBRTAKSlpKAA0nalpDQIaaY3Ap7UxuaAKVyS2R2rJvUwMAfWtqZayrxc5piOU1KLksB06f4V5/wCMLTz7R5EG5lHIHavSdRjIBLYGeuK47UkJEysOqkGkxp2Z4bqS4YisWUfNXR61GEnkA/vGudmGGrlluehDYipKcaKk0GGkIpxpKAEopaSgBKKWkoAUVoaV/wAfKfWs8da0NL/4+E+tAnsejWL/ALsZ6Y/Ste1kB69KwrNv3ZGe1almTwDyRzXRE4JG/bsuA3bpV2Jy+MHJrLtXz8ueD2q/A+D0qzM2LZgwAI9qvRxqyccVl2h+YZ6H9a04XwMk1SEy3FCBgt3pTbws2SOajD8ccU7cwLH070xEqrDHwsQ/xpZUhJwyDmkDB4s9DSOQRzSAry6bBKeGP0qF9MZEJibPtWgiZYEGp5MpESx7daB3OeybeQbwVI69qvx3SXCBYHB9ayvEFyr2rf31+6e9ZWibgRvJBz2PNGwWOiMDbicDPQVdtoiAcjBxg02237AT8w9TVkMQMBaYhwJC4x+FBYlsDO4/pUcHmvK6t8o/WraxrEM9PUmmA6OFYUIJOe5NZ9/DHLwasyT7jjHHb3qN1z05x/KgDmNS01WBZCSBziuC8RxfI8EiZRhx7V6tdQlc7eg6jNchrulm5mfy1yKTRcXY8PvITFMyHqDVJxzXY+LdEuLOYysmUI5I5xXKSLiuScbM74S5lcqminMtJUFgKlXpwaiFTKOKAK9FFJQMKUUlLQAopw60lKBQIeBzVyyjLOKqRjJArb0qAs68GmhSdkdLoMGWHHFekaHBtVSBXIeH7Tc656V6LpluAq4GBW8UcU2bmmDa8frkcV3dlHthTPWuY0G182YOfup/PtXXRgKMVZmSAYpaBS0DCjvQDS5FAhKKKKYBSUtJQIKSgnFBoAaelMNOPSmmmBDIPyqhcpkHitFzVScDnNAjmtUi+U+/pXD+JJVtrGaRz85GABXd6/cxwxY7+1eT+KLh592ThB0BpMpI8x1oZlY8Zzmucm++a6fWF+YmuZn/ANYa5Z7ndT2ITSGnYppqTQQ0hHNONIRQMaaO1LRigBDRS0negAq/pf8Ax8p9aoir2mcXCfWgT2O6tWwVK+lbFqc8jjIxWHbMflI61s2h+XJ6dq3RwyNm2+4MYz2rTt1bhsYJrMtDnnFa8LngVoZWL0BAb6dKuxtu/Cs6MEY9KuxdQD35FUhMsQOfMA7VIZNvyk5Dd/Sq0LYkVcZzmnEFgCOCDg4oEWY3wAvvj61PGhL4xzUcKArnvnpVtAODjgUwJYU5HTPSq+qy7U2jkntVyIcjFVWh865y3OKBnOtpkt7IWYED17U8aW9tJkcgV1GFUYUYqJyrId2PakIj01kaEAjmrTyomePxrNdDG+5T/wDXpftCSLgsAcd+9MCW5mKyB0AyOv0p7yGVQTzkflVKV1CHcyA9DzV5VxCoVs8daYFYcPnPH8qtxcjHNVfOijY4yW6fSrltjblsjNDAikg3ngYHrVE2ikyYHGe9bDyRgH2qpkSREqODQBw3iLT1ZXBXKEbTXkPiPSXsLk/L+7PQ17zrK742KjJXgj1FcL4h01b+zI4+T5Tnt71M4cyNqU+VnkDrUJ4NaeoWj2s7Rv1HQ+tZ7rg1xtWO9O40VKvSolqZelICvSUUYoGGPSlFFAoAUU4DikFPUZNAie0j3uK7DQrTO3IrA0q3LuuBXf6LaEKoxjIq4IxqysdDoNsFZdoruLFCBxxXPaPbBADXc+HrA3Eiu4+RefrW6ORnQaLb/Z7SMtnceT9TWrHVYLhgOgHSrKdKZJKv40ppoNOoKD8aKKKBAKSlopgJRRQaBCGkNKaSgENNNIzTjSGmIjYVWmTPFWjUUowpNAHFeKo8MR6CvM9ej4PHFeq+IUEm5iK841+P5GHHFJlI8s1leWrlJ+XNdlra4Zq4yX77fWuae520tiKkNPxTag1ENJTqQ0ANoNL2pKBgKSlpKAFxV7Tf9ev1qiKvab/r1+tAnsdrZjgH9K2rPBx6VjWaFwAOB3resY1yB5sefdq3icUjSs1O7Izj0Na1sARjrVKziA/jQ/8AAq1oI845ArRGRYhGUCnrVq3U7TweOlMhjQEEkH2q19/BHABqiWMjUhqmiX5WB9aVF2nrz7VIuCM4z2pisSRDaBj0qyhGzrzVdeoJOBipUxigCfOxCc0kZAJPc1UuZcAAdBTUkZlPzflQDLbPuJHekI45HBqKPgk9anJBB+gNAFK8J3cdRxk1nSrtxuI4rUkUk9+uOlZsoyzkZPzUwIdQRnsC8eTg5IFRaZfkDyHYg9jmtG0XaWDDIYc1z+oRLb3+5AdobHuKQI3YSCzFTk5xkVpwuxiBz1rHsyEuOOjVrKNrEflTAWfcuA38VVpJDCpUjg9f8atTN91s9Ky76QEn+9jOR3pjsR3QO3cecdCO47g1gXlpkyGM5Dj/APUa24Jt4KsckDOOxpyWyyYcAe3tQF7HlPivRVMUkkcZUj5gK8+mTBIPave/E+m+ajgEL8pYZ/UV4prFsYbyVSMc1z1odTsoSvoY5GDUidKHXNA6VznQVqO9LRQMKWkFOAoEAqxbpuaoV61qabAZJFGKBN2Oh8PWmcEiu90e3JIGM1iaDaBYwAK7jR7YIo4reKscc5XZs6RaF3RQOSa9E0yBbeEKOo4rn/DdoFQStyT0HoK6qJDtGK0RkyVVqQUiinUAOFKKTtSigYtFJRTELSUtIaAA0lGeaSgAoopKBCUhpTSGmIYagnPBqwwqpcn5fegDntYXdGxNeb+IP4x2r03VBmB68018H5xSZSPL/EPyrIfSuJbljXYeKpMBxnrXHtXNPc7aS0GGkp1IRzUGo2g0v8qQigBpop1JigBtB4paTFABVqzYrKpFVgKsW33xQDOihuZSB85x6VegnkzkGseFulaVucgVomYSRq291MDw2DWxaalcjGZCQKwoAavwnpWiZi0jqbDWGDAS5IroLO9imwY5Bn0JrhIugzWjBkEEHn1zVpmTR3sTb+B1HapQ2RiuSsr6eFx824D1rYh1QvncoB/SquSbi/N9KJJQudxAH1rLF47fdIApdxfO48jvTAkYsxz+Qogk5fJpqn5BntTVwH4wKBF6KUqwyKvoQVI64FZaYZevOa04uAvy4yKAE2huhrOkiKzYPSrt2DBynTriq0mZohJ1J60ABdFwFFYmqoGnZu+QDWsFZiBjCg9KzdcDRMshXgkZpggsyRtBJyK10lJxjnAwawVlAyQfpWhbXG4IwIye1JBY0ZnwAo6Hk1lXq7xtHU9DVxXJOSc9qgvIwYyQcZ5HtVAjGtZWZtufmU4B71vWzjbno38QrmopPLuJCeufxFadtK743g8cY9qSGx/iJ/MhG3DHH+TXjHiqwlF6zlTg17XOgaD6dK8+8V2jElx057UTXMrGlKVmeXtGVfBGKTyG7Dita6g3k5HzCnQQjy+RzXG4nbzaHMUUClFQWIKcBQKUCgCW3TcwFddoFllgSKw9JtTJIDiu/wBDs+VxVwRjVlY39GtDhcDNdzpGlyOFLDaKd4V0RVhEs4y3YdhXZWtsAQK3SOQk021NvGq+3WtZBxTIx7VKowAO9MQ9aKQU6gAoHSil7UDCikpaYgpCaXNNNABnmkpaSgQUlLSUAFIaWmmmAjVTueRVs1UuaBGLqnEDeuK8z8SuqRyHPavSdZbELD1rx3x5fCJWjU/MaTKitTzHxLcebcMB0BrANXdQkLykn1qkTzxXJJ3Z6EVZDTSUppKRQGm06koASijFGKAEoxS0UAIBU9v9+oqmt/vigGakPWtO1I6VkxVftX5xmrRlJGxCc4rQgxWZAx44rQgPPNaIwZoxdqvwMQtULfn3q5CeMDpVoyZehf5gcc1ooAMMOh6VlRggnjNa2nuDCUfHByppkstwkp82R9KvISWI7EZFVQucLxzVyKMluOtUIVcBfWnqvz5A4qUw4AxjJ6inIpLD1FMQ+OPI4rTt13bfX1qjCjYJJOK0YOF75oAh1FdsR44FZVnOoUoeM8ity9ZXtyrdeormLhdrkIeBTCxeDhW4pNQhW5snI5wKzXuBj5jgj9av6dcByyEggigOpztifMMkZ5Mf54q5bkrMB1UnmqtwDY6tv/gbg+4rWMAZFkhyQDnA7UrDbJF+QZwcDtU5CywblGR3HpVe8yoVkJAIp2mykMAx+VuKoRkSWeLok/d/nWjFGqLxjHatC9gCx54yOc1hS3ZkcxA4ycHPFHmMvN+++RThR1IrC1+1SePYRge3etD7WkIAJGAOQDyazdUmFwoMRIxzigaPP9QsfLnIUZGakTTSygjjPtW3NGsjkOOc8/41s2mngQLnj8M1k46mnOzwOiilFch3gKnt0LyADrUQFbugWRkcOw4ppXE3ZXN3QrHCqcV6H4SsPP1S3iA6tXOaZbhQvFek/Dqz83WUOPuIzH24x/Wt4qxxzlc7yytMKCBhRwtakKYGBSlQoCqMVKi1ZkOjGCQOlPoQc0uKADoadmm06gYUUUjHFAgzS00U6mAlB60UhoEFLSUZoAKSiimAhpDS000gGmqlz945q0TWbrN1HZ2zTTNhQPzpiOY8W6gllayO7cgYA9TXz/4ovnubiSRz1Nd74y1iS9kdm4UcKvoK8p1qcs5FZzeh0Uo6mFcNlzUNPk5bmmVzHYNNJTu1JQAlFFFACUAUvegdaAENBpaKAEqeD7wqEVLCcNQBoxVahaqUTCrMZwapGbNW1l6A1p27+9YULVeglweTVpmMkdBbvwK0IGz0rEtJenNa1u+44A5rRGTRfjOOlaFmSciobe2yo3nJNXoYwnCjmrMy9audwDjPvWrDGxwVIPFZlvywzWnFxHxyfamhE8asz4PFW1hVV5PJNZckhVgwPTtV2OTzI/vDn3pgy4oRf4uKlWVE7jNY8shXOTxUX2rAGCDQBpX251JB/KsB3Pm4fqDgj1rZhnEg5P4VheJQ1rcxzIPlYAGmAmpwmOMlfu9sVT065aOYD0PXFbFhJHeWQzyCMH2rJu4fspc55+lLcDS122FzZiaPGcdBWFoOrmKbypjyOOe9bOkXazQG3c/SuR8RWjWeoyFchWOVND2GlfRneXOyWFSo+X27VFAqRDIOT2rA8K62C32e6POMDPcV0s8IRg0Y3RnkEU07ktFib/SLcfTBrkdbBgbMY69e9dLC5DbSflNZ+s2peNgMnjsKY0zk2ncKuW5PI9vamGfAP+119qZcIYyUx83cmqoOeCSakouKvmSgnkngHsa6iyjb7OtcvYsAxDHlegB611tg5e3U4P19aRLPmgClApwQ+lWrSykuJAkakmuI9Ruwyzga4nVFBOTXoWi6WyRriM1q+C/AkkcCXFyuXfnGOleg2Ph549o2cfStYwOWpUT0Ry+m6ZIcZjYnsK9i8G6ONL04M64uJQC/t7VW8O6KiOJ5UwF+6D/OuqUYrZIwvcZs5qRRilpRTECj0pR1pAadSGGKOlFJQAtIaWkNMQlLRRQAUhooNAhKKKCaACikpaAEpppajkbAOOtMRDczJAhZzXHeNpTcaQZu0Zzj2ra1UsSck1j3MJu7G5gf+NeKBo8P166Ls2DgVw+pvukNdpr1o8M8sTg7kJBrjr+E7jxWEzqpGNJyabUkgw1MNYnQNIopcUYoGNpO9OIoxQAmKAKWloAaBxRTgKXFADMU5SQaX6UmKALMb1aies4ZBqeN6BNGnE+OtXIn9ayo5KsRy/lVpmbRt2k21sE10WkOpl5rjYpsYNb2iXW2cAkcgitIswnHqdtFLkgHpVlT34rKhlGAe1Wo5wTjPWtTCxrQSqGAyMj1rUtn3MMEc9s1zHn7MFe9aVnchMNk5HHsKaBo3Li1MsR2dayVuntpvKckE9P8K2bG8jfAc4PSoPFOmmewFxAP30fzcdxTEtSq8/nRK4OR3qvvC4zisTSNRcXYjblW4IrZmhI+6Dt7fSlcCzb3hUgkDHoK09Rtk1LS2UH5sZB9DXORnY3pz0rc0i4+YRseG4FMNjl9Hu2srx4ZThScEH1rob+3Nxbb4xk9axfFunm3vGnjHDHmp/Deq718iY/N796NmNrqVoXNvcqxHftU/iW2F1beYnUjI+tSavblJvMT7h/SnWcnnRNC/XGVo2Bdzz7zXhmBGQymu88N619qtxGzcjgiuS8R2Rt7nzAuFY1R066e0uFdScZ596nZltcx65EyTDJC5HB9qknh82EgY4rm7W78+BZoW5xz7itCy1RWYRyEA+9aJmdrHL6/a+TOXx8vesTdg57dxXfa7Y+fCxTGCMg1wsqESFTwRwaUilsJHjeuw4PtXZ6eAbVTnFchaofMHTGa62yXNuOKkUjwezsvOkCggZOK9S8D+FYDNDvKnnJoornpo6qzdj2zTrCKOJFAGOla8FsmegwKKK3OVl1VAGAMCniiikUKKDRRTAcOlHaiikAUZoopiQtJRRSAKDRRTDoJ2pKKKACiiigXUQmjNFFMBp5pjjIoooEZmoRApk/WsyBB5gP4UUUMDzf4h6QkV8ZkIxIMke9eXapaKGOKKKymbQbOVvIwkpFVyPWiisGdq2ExSYoopDAikIoooAPSlHSiigBQKXFFFABgUEUUUCAikzRRQMmjbgVOpoopiZOkh4q7a3LROrL1HNFFUjOSOx029aVEOOtaeGRs5ye1FFbxOSSLqIJcNyP8aljcxx7hwB2ooqiOpLDdODnJznNdhot4biy2SDJHGaKKYmzjvE+nrp12Lm3IAZs7fQ1t6RML20BYEEjrRRR1G9hl1aiNsk59agjmKSDaSMdKKKbEbV0q6hYkyDkjBrz24V7G8YRtyh4Iooo6FROs0u7+32QEq8ng1nyhra5YKeVPWiijoQP1y2S7sSx4LLkexrgSuCQaKKUjWm9DZ8Oag8NwITkq3T2rpLqIcMvGeaKKFsS9y1p145haN8sF9ax9UgjknLoNu7miiqWwkVLeLa4Gc811NlFut1IooqUNn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This nondisplaced, oblique fracture of the lateral malleolus (white arrow) was stable and managed nonoperatively, once the absence of a medial injury was confirmed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5520=[""].join("\n");
var outline_f5_25_5520=null;
var title_f5_25_5521="Three-chamber view of classic MVP";
var content_f5_25_5521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1156px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83604/Three_chamb_class_MVP_video.mp4?title=Three-chamber+view+of+classic+MVP\" style=\"width:512px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apical three chamber echocardiographic view of classic mitral valve prolapse with bileaflet prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5521=[""].join("\n");
var outline_f5_25_5521=null;
var title_f5_25_5522="Pathophysiology of aortic regurgitation with VSD";
var content_f5_25_5522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of aortic regurgitation with VSD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathophysiology of aortic regurgitation. In early systole (A), ejected blood from the left ventricle (LV) will be shunted through the ventricular septal defect. As a result, the anatomically unsupported coronary cusp and aortic sinus are driven into the right ventricle (RV) (B) (Venturi effect). In diastole (C), the intra-aortic pressure forces the aortic valve leaflet to close, but the unsupported cusp (right or noncoronary) is pushed down into the left ventricular outflow tract away from the opposed coronary cusp, resulting in regurgitation.",
"    <div class=\"footnotes\">",
"     AR: aortic regurgitation; IVS: interventricular septum; PA: pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tatsuno K, Konno S, Ando M, et al. Pathogenetic mechanisms of prolapsing aortic valve and aortic regurgitation associated with ventricular septal defect. Anatomical, angiographic, and surgical considerations. Circulation 1973; 48:1028. Copyright &copy; 1973 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5522=[""].join("\n");
var outline_f5_25_5522=null;
var title_f5_25_5523="Ankle foot orthosis1";
var content_f5_25_5523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Ankle-foot orthosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 369px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFxAhIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5u8MaBL4gupoIJ4oWij8wmTODyBjgH1rek+Hl1G0Yk1XTYvMO1WldkXOM8krxSfCtguq35P8Az7f+zrXWeKGWWCOOSwfUUcnNtGWDMcHBG3njrj2rKUmpWOmFOLp8zR59Z+FLq8EHkXNpvmiaVUeTaQFJDBs/dYY4U8kHIroY/hdqDqGGo2IBHH3/AP4mrTzGZSbyRr+GSUSlYi+6edQQt4Bt/wBUB8hGcZHSu+iu1x8zHgZyOgqZzkloOlSjJ6nni/CfUm6anYfk/wD8TT0+Eept01PT/wDx/wD+Jr0pb7oBnmtGydMhB8vcg1n7Wfc19jT6o8fk+E+rICft9gfxf/4mue1bwXrGlEm6gBi7SRZdT+Qr6TVEccYzQbZT8uBzTjXknqrlPC05L3dD5bj0h5B8k8JA478fpUi6HKf+W8X6/wCFfRGp+EtKv5C1zZRbz/Eg2n8xXOXnw1t33GxvLiHPOxwHX/GuyniaEviVjkqYSrHWOqPHV8Pyt0uYc/j/AIVIPDNwcf6RBk/73+Fd/d+Btcsxuhjhu0X/AJ4ttYj6GsSeK5s5dl5bTQP6SIV/+tXdCGGn8LOWaqR3Rzn/AAjFx/z82+fTn/Cnf8ItPuA+1W/PQ/N/hXRI+5iM8j04qUZOMFce5reOFpMz55HNf8Ipc9TdWwHr83+FKPCVyePtVuD1/i/wrqk4A6Hnp608c5zuHf0H/wBemsLS7fiT7WRyY8I3JOBd23t97/Cl/wCEQuef9Mtv/Hv8K61SDxz0x060uCMdT+ORT+qUe34i9rI5H/hELj/n8tv/AB7/AApf+EOuuou7bHr83+Fdjg4Oeh9sEUi47E8d8cflTjg6L6C9tI5AeDbo/wDL3bf+Pf4Uo8GXRBxeWv8A49/hXXYPqfpT0yBjv15p/UqPYXtpnH/8IXdf8/lr/wCPf4Uh8GXQzm8tsf8AAv8ACuywMjOM/Sl4z3GT9c0/qVHt+IvbzON/4Qu6/wCfy1/8e/wo/wCELusf8flt+Tf4V2g6ZUkYowc45FH1Kj2D28zjP+EKusZ+22n/AI9/hSf8IVd/8/lt7fe5/Su1PUdM0gyDle/Xmj6lR7B7efc4weC7ojJvbUY/3v8ACj/hCrnGft1rj1w/+FdmVOST/wDrpR93Hf16mj6lRtt+IOvPucYfBF0Oft1rj6P/AIUf8ITc/wDP9a49cP8A4V2h6g8g/wA6aM5OKPqVHsL28+5w954RuLWyuLlry3dIULkKGyf0rnoYGlBKkYFen63kaFqOMYMDZrzexGUYe/WuPEYeEKkYxW6OilOUk2xgs3JwGWnCxfPLoKuKualRMc1n7CJfMzPGnyH+JP1p/wDZknH7yP8AWtJI8HOffrUwTociq9hDsJyaMpdHlIJ82Mfn/hTxokp/5bRfr/hWyoJHOakAxVKhDsL2jMT+w5sn9/Dx7n/ClGgzn/ltD+v+FdAqdeBUsaYGBgU/q0OxHtJXOb/sCfOPOi/X/CmnQpx1liH5/wCFdQEAAzigx5z0INJ4eC6D9ozmBoM3/PaL9f8ACmtoU4JxNCce5/wrpWTAwOp70BRzwOnpS+rw7D52cpJpcqZy6YHUjPFV3tZFOMqe/BrrJoA3IxiqU1sNp2qMetZyoJFc76nNtGQea29P8OSX9kLiC8t+mWQ7sr+lU7i22jJqzoV8bC72McQycEHsa5qkHHY2ptN2Zs6J4AutWRjDqNkhHVW35/QV0OkfBfUdTLrDrelqyHDKwk4P/fNN8L35stbCB8Rzfdr1Xw/dJbajmLOZhuY9q5J1Jp6HZCjCS2OD/wCGetYH3vEOiD6mX/4ikk/Z61xF3HXNIK9iPNOf/Ha+idNdb2IEwmZcfe28fhWTr6TaXIJbIkI/WFzlW9vY1Mq0oo2jhafU+YvHHwwvPB+jxahfarYTLJMIVjhD5JwTnlRwMVc8NfCa48QaUby21uzil+UC1mgmErZ7gbenv0r1PxFq+n6stpDJBC9yJSIluF3eS/c49cV6D4djttPs0jt1yQPnkbl2b1Jpe2lJ2Q3g4JnhEf7O/iNomkfVNJQA9C0mfy205f2edaZcjXdI+mJc/wDoNfQsl828BSetBkxJlhtY8Htmr9pLuP6pT7HzrL+z9rcYONa0pyBnCiXP/oNZ1/8ABPWrOymuW1PTnEa7ii+Zkjvj5a+ir6aSK4OScgjCD/PWnN80Ls6AnHzD270lWlfUbwlPl0Wp8nr4Bu2XIv7LHtv/AMKX/hX96f8Al+s/x3/4V6f4g04aXqssI4if54j7E9PwqgOCOc179PD0akVNLRnztSdSnJwb1R5//wAK/vec39mMf7/+FKPh9ek4F/Z5/wCB/wCFd++O5FPGRxjj61f1Ol2Idefc89/4V9e44vrM9v4/8Koa54Sn0fS2vbi7t3AdUVEDZbOfUY4xXqbfPyvYdq5j4hrjwvkcj7QnP4NWdbC040247lwrSc0mzy7FFFFeWdh13w3k8vUrw5/5Yf8Asy10uuybkhla4mtokkDNNBy8Q/vAd64zwbP5F7ctgnMWP/HhXRXuqILcldyOrblYDO056471hP4jspK9MVS0GXEv9nFUBLR5ZbeNlYrEPmwUlzuyPutXQrdSbIm5ClAxArmhdQxXiBbiL5ZuJSu6MyuQWk245hx/D1U81uWU0Jt0R5kDKNhJ9jjNKeoUHbc0LfVQr4Le1bulXaSMTu5xwTzXHXMUbruiZXPfFVY767sH+TJTOeTWLR0aM9gspTt65HY1oRHd8xHPSvPPDXiaO4Kwyna3v/Su8sp1lQMp4HvxU+pat0NFOOozUwjDrwADTY8MowamB4HHP86odmQNag9Dz3qG404XEZWZY5U/uyKGFXt2W4IpC3YdfSknbYfLzaHHah4F0q73H7EIG67oG2/jjpXN3nw8nTJsL9GJPCTpt/UV6TPem3kCSxMqNyHHKj6+lS+ZDMnVc9evWt6eNqw+FmU8JTlujw2/0fUtLJ+22cqKn8a/Mv13Cq0bhiCGwfY5z9a93iVCuxwGX0IrA1nwLpmoOZYUaznP8UPAP4dK9Glmt9Ki+44q2W2X7tnlYYnJOfY46VInLY5IP+ea6fUfAGqWkTTWUyXiKRug/wBXIU7kZ4J9qr3XhO9toTPaSi6jIG2LYUlyei7fWuxY/D3tfc4ZYWqvsmOIyRkH6seSajBA68n37fhVrUre80xvK1C1ntN3d1xn8ehqh5qux+cE9yp5NdtOSkrxdznlGS3Q75R0IVewp455BwSMHnNNUq3JYjscDkU7IAGDgD/ZqyGrDucjGfwoZsHGDmkA2kEE7vSnqMH1/GmIAMc9RigDDZzil6mgjHQk9ueKBCH1AxRjJx0GePalYHbg9u9A4wfT8c0+gMVeKQk44/8Ar0HoepoGT9cUrABwcFf1pMZPzDk9acSeTgAmjtjHNIClrf8AyAtRB/54NivOtP8A9W4969F1zjQtRB/54NXnmm5MT/71cOK/ix9Dpo/Ay4qjaBUqKCfamqnHp9amjXmszS49VBB4qVEHYChV/OpAKZmOQA8HIqVVAx2pFXJH0qZF5HSqQmCqec9aljTByaRVzn7tPUcirSEPC8nJ/KhlzzwMcUqjkgU4fd7jPrVWBETKeP8ACmeWcZPFWACT2NHJ6n/Pt7UrCuVSnBA4FQvFz8o+bHWrxTnmmlM0OIcyMia3B+v0rKvLTqMc+tdQ0RIPTAqpcW28Hjj0rCdO5pGdjN0e8cFIJm/eod0LE9favWPAOqJe6gqTnoBuGe1eO3MBVuRgryPWuj8K6o8F9FNuCzREB+fvr7V5lejZXR6WGre8kz7E0TUYBbrCoURgYQLxmrOsaWmq6VPA2AzKdp6bW7GuC8NXiSrE8cnysAetekWEu+IbeeOK5YRU42Z3SdtUfIHirUv7J1ST+1FY6nbylPKHBO08E+g967DwL8R4NQia2uP3Nz1Cs2f1rq/j18OLTWWOvWkbJeIAs7RjJwOjEd8V84ajo+o6SUuJYy0anK3EJyPx9DVxpwa5W9SJ1Kqlz2uj6l0/WEncc5f0rpbALK2XJYn1r58+HnjiC4CW2qELdqPkkzgSD/Gvb9Fv4pIleKQNuHY9KycXB2kdMaqqxvE3tTsTPCGQL58Y4LDtVW1h/dkk5J4IPep0u97YLdPxptwpH7yMZ7kUpJN3Gm7HC+PNGdrKSWP52h+dMjkjutedA7sd8/hXuUyxX8UkTnKuNp9jXjGq2M2l6jPaTphkY7T/AHlzwR7V62V1rp0n8jxs2o2aqJepVHYfrStgkAcY70nU8gilxXsJ3PGE5znof51z/wARv+RV/wC3iP8Ak1dAQcYPIrnfiKf+KXIHIFxHz+DVlX/hy9CqXxo8sopaK8M9M0NGu47SWVpScMm0YHuKuz6tAwACM2PXvWDRUuKeppGo4qyNuxv4nAjmkS3CD5XZWbI7rgdCe571FdavLLcyzZVjIcsDnk+o+tZVJRyolSa2NNdavEPyOF+lW4/EU5wJ13Dvg1g0oNPlQ/aS7nUR6ksjLNavtkU5K9K9Q8KeIXmtUJII714QpIOVJBHQg10HhrXnsJxHM37pj970rKdPTQ2hW11Po+y1TdGDxg1pQ3qyYycGvL9K1pWVAj/nXR2mqqy8n8RXO00dsZHbNMnPP/1qZ5/I4B9a51NQG0MsnPSkGr7W2E8fyqWdEGmbxn+baoB9QfSo59MWc+ZYyfZpOrKeUb8O34VmWt6sjkn9av8A2kFRtNSlcp2uV/tNzp5P26A7V6unzKR9a1rTU7eVAwcEEZHOapC8IQ7TnHbrVaextrx1QpsuH+USxHaR3/IUXHyLqdCbqJ1+RgGHrzTS6cMxGfUVxGoaRrmnsDY3cd8meFf925H8jVKbxZNpsoh1SCSCQ/3xgH6HoaB2stGd/PHBeW7Qz7ZIyQdsgDL+RrMm8M6PNlZNOt2HYgbT+YrnF8WWpTKkZ6nmoLTxnt3FmxyeM1pGpOPwtmUqUJ7o2bvwBpM65tlubV+xR9w/I1z114C1CJ2+zXUU2OQWQqa2E8cRCMEthu9Rw+N45GcbifSuiGOrx6mDwFCetkcwnhPXXmeOOwyR/EXAB9+azbu3ubG4e3vI2jlU4OeR+ddT4j8eRae32fe73O0N5ZHOD0/Cucutdn1axijmUhUcyZbqSfT2r0cHj61Wqqco6Hn4zAUaVJ1Iy1Ko5PPX+VKMHIbOaRST1B+pp2MV7Z4ohyD8vr3NHIYZ6d8UrDqcHNJzjgAn0oAbjGcY560YIGRS9gcAfWg880CDPbsaXqeOmKaeDzSjI9PwNFuwynrZ/wCJFqOP+eLf0rz7Sv8AVSfWvQNcJ/sLUMDjySK4HSQDBIf9ofyrgxS/ex9DqofCy7F6d6soAME9ahQZU461ZjyQPTtUWLY9PfvUqAHFNUHPPWpVyFX60zMkVeuaeBx7U0dD2qRatCY4AAcd6kAHBGRTcdKk7AfzFUhMD1JY5+lLyOKUAEMB26+1OTJHUH8OaohgoGOe3U0nbOKdksOaVVAUBsc+9CGIRke/rRs6kfnUuCPSlGdvYn1NXyokr+Xxzzn0prQls+tW0jB6jOPxApwQOcuM0OI72Ob1C27gDNZRjaKVXTKshyD71195ACpIAzXP3cG0ngZrjq0/uNoTO4+GXjl7K9TT9T+5JxFL7+lfQOkayURTuLKe2a+NmyrhkYrIrAhgfTpXsPhbxbe29vbrqY+ZlzleAwrysTB03zR2PYwlZVPclue/3WpRzwney/MMY9favC/FHh/+y9Rne3G7T7ljlWGQpPb6V0a+Iw/7yPPzcYFbGnyW+p2k8V4gKuv3G4z9K4HJt3PR1hF2PEtR8LwTLuWIwzDlZoRjnt+FXPCnii/8NX6adrbfupP9VP8Awt7e1eqR6LpJXBtJoz6rIao6n4O0nUbcxPOXjJzsnTcAfYjmu+NCUlZvQ82WIj8UVZnS6RqsV2gkVx9a1Pt7pnawG31PSvNrHw7eeG1xZTi4ss/cLksg9s/yq8+pXcjKhU7f73YD2rkqp03ZnfQmqqudekpnkzGcAnnHFQ+JPDia1poClVvoeYXz/wCOn61i2l9M8witlZ5MZIUdB7+ldJo97NfxOjMtvLHwUK5LUqNRwleO5pVpqpFwlszxpo5InkjlBSSJirKeCCDyKQ4IHGDXffEDQ3aE6oqbbhAPOK9JV9T7iuCHIBOB+NfT4Wsq1Pm6nyeLw8sPU5Xt0FBK8r1PFc58RB/xSxPrcp+PDV0ZBzzj865v4iY/4Rcgf8/Ef8mrSv8Aw5ehhT+NHllFFFeEemFFFFABRRS0AFBFLxnmg+1AAKAKKM0CNTTNZnsSFJMkY6c4I+ldXpniq3ZdjTmEn/noOPzFef5oNS4Jmsaso6I9ftNYDqVS7t3U91lBq09/Kq75p4UAHUuBXkumaTdaiSYExEPvSvwo/GuhsvD9lD/r2kunH935U/xrN0onRDEz7Hb22vGSJpbWcTRq20tGcgH0qVfFTxFVkc57Z4xWbpVokelyCOFIk35CoMD/APXVPU4QkQahUYjeLmdtp/iKOQYZ8E9O9dFp1+huA+/LAYH49cV4sNyANExU+xq9Z67fWRG0q4Hc9azlh2tjeGOg9JaHv9hc2st2jXDhI0Qnn+JvSludP0rUrJoLyGG5jduI3GfwHpXiyeNpgoV7c47jd1qGfxvqSxSJpwFtv4Mn3mX6Z6VPsZ7WNHiqUY3TMvxvpFro/jbUdP0uZ3soGG1S2fLyMlc98E1DahCoBOfXnmqiKxdmd3d3JZmY5LE9z71bt0OVGO/Wu6MFseTKpJu7NKK2Q4IB+tdp4N0qGS7kuLgKLe3jMjkjgAcmuZsYmdkCjnNemeHtHFzoVzYyO8a3i+Szp94AjkiqUVfYXPJq1zyWfWYtav7i/ZF/eyZRSBkL/Cc/Sp45g5x93P05rndXs4fDviLUtHtbmSeC1l8tZXUAtxk5x9aWC5YADNevSrRstDiqQfVnSgYwQSyn1p2cnAUZ7Z4xUdqwkjB4JA5xUgxjBAP1rqTuc73sBwOuQT6igEetOOM5Jz2pD7H8qdhCHBBA70hyPejjB7e9LgEdaAQw9Tnv0FAPc8cUpOMDJB7Z9KQ4OTQMp67/AMgK/IPWE1wmicI+Tj5v6V3OuZ/sO/z/AM8Wrh9EybeXBx83p14rgxH8aPodND4GaSDOR1x1qYL0A6UxASSMc49KkXrjpUsuTJEA71LGopiAjnH51IAQcjnPUUyGSL1x+FPQYxTQM59MdalVferRI9V4Hr796k+YnJwc9CP5UwdDT4yOf5U1uSP2Y64oAUE5ySfQ0g5JA5FPyeBkj3AqmrAIuCxHOKAuAAACPT1oGQ2efxFOwchvwz6VfQlBhf4cDFSYG3Pf09aRR7U8L93HT1qUgGjnHp7DFSIBjJFAByB/k1IPSrSJBxuTGc+1Yl9BknA/StwDJwc9arXMI5wCf6Upx5kVGVmcqtr5l1BGOjSBSPXmvRJLI3M0dqn3pJAi4/h965OwtvM12wUqcGdeleseHrHfrhcr8sMbODjv0rzasNbHVTm73XQyrS2fTNRSK4kDkNgHs3vXcWkkYVzcMoXHynpz7Uk+nK8YVoww9xmooLCOJ+FJPbcc15k8I76PQ9eOOVveWpqWfzxq3+TU7xqy5IH5UlinKjGSxCj6mt288N6tFZ+clpmTfsEJPJ4yWyOMDp713qyjY85vmbZyd3EoU7cqcdqwZXe0lAcAwE43f3TXVeQzyyJevHZiIEyearZQfTqaxCEnjDp/q2z96uetCNTQ2o1HTd0M0y4+yTSRocb/AJs+v41sTanb2yQ3MhWKXOwEnG76euKwhpSEmRZpYsDOB0/WuL1+XzdbmjkYvHFhFVj046isKGDnVfKnY7a2YwpRuonoXizxhaSaLcafAVub6dNh8ogrCvqT0LV50qjYADwBUcKqikIAo9AKlTP0r3sJhlQha92zw8ZivrM+a1gAGCByK5z4jc+Ff+3iP+TV0me27PsK5v4i/wDIqY/6eI/5NWtf+HL0Oan8aPKqKKK8I9MUU7bSwruY1YC8HPFawhdCbK20jnBpwjJqwseeO3WnmM8EcjpmmqMnuTzFbyiRz1oEZHaroj5z1pfLx/COvcVo6WlguU/L9qQxVf8ALBH3cUeVnHFEaWmqE5GaybRk12fhjwTcXdjHqmpxslpIMwQjh5v9r2X371N8NvCX/CS68XulP9l2WJLgkffP8Mf49/avoSHShc/vGUcDCqOir2ArKVN3sikzxKSwuQVWWERwqMLGgwq1JDAAu3H5ivcm8OQyLgRjB61zup+EkEjFE2/SspUmjZT6HE2Ft/xKZmA6OKztViDWBxzg84rtDpv2bS7qE84Oc1wNnb3CjUvMDKFkwC3Q+mKErNEt6MzDGSflAxURTpWosWBxxULxZPTNaqNzMztmckdaFi+UirphpfKOMDkU1ERUEeRj0q/YQlyoUck8ZFPitwx5HOKuNG0NhNIhZGUZLIuWVe5A9QOabXKtAvqdfoOkiFA7rmVvUdK9E0GLZ5K46Asa4P4X+bd+FLea4LuQ7qkjkkyLng816FbOLe1upjwIoWOfoCalfC2ylufKviK5N14q1m4B/wBZdyEfTOB/Ko7YOzdSSaqwMZp3l4zI7PgnHUk1rWkePmByDzXdRjojKbOh0onywpJHHbrV8gsN2ceue9UNPXaqjjOK0B0GRz716MdjiktRvzbTn8MCm9+aeeRxjPXrTTjt171ZIdAMdPpRjINGenbPvS/SkAhyByaax9qcccZzTGH3QegoAoa7zoeoE/8APE/0ritAOIJSem4V22vY/sLUOP8Alia4vw//AMe0w77x/KuHEfxo+h1UfgZpYBPue/rT9uTTQpPXpjNTJk4P86hlMcowPu/kalXgYGTnrmkUHHSnqDxkVRLHjnPapUUZzzUfQfhUqZwMCqSJY9V5ye9OUAN0J+tA5PPT0p4xjitUyRoGSRzkdjTxkDFIpGeT0qTluvXr0xQ9RAAMDnijAIHWjBBwf/1U5RyDVLXQQqgggipfuqcDIz2pvJdR3H6U7HQGqUbCFUenSlXJyX/D2oU5P04xSrkAgmnYQoXIyOh6mmSAEAJke9P+vWkbBHT9etKwhvh62EvirTRyT5hYkDrgGvYfDNri7unbI+UD9a8z8DxCfxlYJgZG9h78V7Po1uI3mOPmYiuKukp2OqjqixLEOfpVF4trHgVsSryaqSJgGsLGxFpyF9StIwM7pF/nXrl+SIYlBPT1ry/w/Fv8Q6eoH/LXP5CvTtTPzRj2rKe5UTmPFWjxalatcg+Xcwj/AFnqvoa8o0yGJLedISTFHcyKuTk4Br2XxBKINHncnGFP8q858OaH9u8KQXdn81yd82G48wFicfWsZblrYzdpVc44ryPUJ1bXL/kf65hn6V6/JgAlgQBkHPqK8Ltrjzry5kLE7pXJ/M12YP4mzmxCujchbjrzVhTuxyfzqhbyAkZ47Amr6MSMY+vFenHY4eo9srxgfiK5v4jgDwofX7TH/Jq6PBwK5v4jg/8ACLHPB+0x8fg1Z1/4cvQul8aPKaKKK8E9MsWa7nb6VdIGeuf8aqWH+sb/AHavAdhXfQV4IhvUQLkjnoKcq7hjvUgHIpQOK0sSNx2p2Bn1oC5YcVIFIPFJQ6iuIFyMA8jrT4YJrqeK1tIjLczsI40A+8xpyqcDHTvmu9+EGki41a41WVci3HlW/s5HLD3A/nTkrRuJO7PTPCmhQeHtAttNthuZfnmk/wCesh6n+n4V3GjRjavT3rItosgcD34rodNTGOOKwRojXgtATgdD0qlqdkmMkVt2wKqG9Kr6oB9mZuBj1oauUeW65AFjuVH3c88Vxesw5098V3utqfJuy6ld2GGRgketcNrMyvGsEZ+pHesGrkvY5VoBsznmojFzz0IrSaLgjtUbx5rTlsRexmNGR1FIkZxwKuPF6fUUJFkYNC3DmEt4uSTxW3pcZBRxjIPQ96oW8eW6Vv6XCNgzWiWliW9Tt9NWP7HGYlCoRwAMYqTxFN9k8Ha9PnGy0lIP/AcVW0QEIUJ+UHIqt8S5Db/C3xBJ0LxiP06sBWU10NoPQ+atOT9ynTkCugtVBUA8fhWRYriPpyK37JMjNehRic82aVsNoHHGMHiri52gjcQB1qCBcAY6gVOrAZOAMc8HrXalY5nuNHJwCMflSY6kZ/EU8tuAzwfYU0ewxj86ZLGkHABxwaDnjFOAye5/Gk56H8RmiwIb7mkOO/B7U88U08N8oxQCZQ107tBvzj/lif6VxXh4D7NMe+8fyrtteGNC1D/ria4vw6M203++P5Vw4j+NH0Oqj8DNRRkNzyeakQAEH1pq9OnHTjtUqrt4PQd6lobY5BnjtUq9hTVB5pyjvVRRLJMgA+mKkXAI7juKYBjI4PapeMjNaEscoAA55pwByKFJK4wMUq00JggI60/ng02lXkgVaEOGP7p+nWpR7Z/CmY6g8U9Q3GBVJaiHqox0wffrSqOMHI98UDJbB9Kf/vE9Ksl3Ez8uAfwoz2Pp2pCTtOQAM0xjjJHI9qNb2Adz2HJ4xnj8al06yu9V1GKw0u3a5uZSMIo4UerHsKteGtA1HxRqS2mlRbgCPNuGHyRD3/wr6Q8C+DNP8K6cIbJN9w/M1y/35T9ew9BWFeqoaLc0p0+f0Oe8GfDy28MaVLd3JF1rEwCPOw4Qd1T2961I4fLkIHc12OroE09FB6sK5mRAJlP6V5/M5O7OtRUdEVpE5NVZQK0Zh/KqTjnmqAteEIhJ4ktz/dRmFd/qJ/f/AEFcd4Fj3a9I3ZYsfma6+/5uW+lYVPiKic342fy/DtySSPkY8fSvDrr40WvhCz0vTdL08aj9mjjF9IZNirkZKp6t1r1z4r3a23he5XdhpYzEv1bgfzr5qu/g74rvPFclhb2ezTZJMm/Yjy0j7k98j0rmm3zaGkdj2jxNdQSQ3F/aH/Rp7b7THnrhlz/WvnPTn+QE9+a9y8cNDYeE9RitMi3trT7PET12qoUH+v414PZHYiAjoAK7qGmqOepqdPZtlRg49+1akRypydo9utYVk42juD2rXgb8PSvRjscc00y2Rn+I9K5v4jk/8Ipg4/4+U/k1dIvKkrg8dDwa5v4kAjwsc9ftMf8AJqmv/Dl6Cp/GjynFFJRXhHplvTv9Y/8Au/1q+BhjVLTMeZJkfw/1rQH1r0KH8NGctxQOmacMdT0FAGSB0NOVSRgnIrUm4oAAIHU08DFKAM04+9V0IuRSH5GI7c4+le7/AA40wWOhWMQ+8U81zjqzcmvD4ofPmigTJaWRVAHfJr6R8M2+2JEHRQF/IVhXeyKhqzpbCHIGQa3NOi9f/wBVVrGLZGCegHJNcn8RfiJpvg7TmDSebfuP3Nsp+Z/c+i+5rNu25qd7rviHTvD+mSXepXUVvboM7pDjP0HevDvF37Q0UZlt/Culi4YfKLu7zt+oUdfxxXiHirxPq3i7UDdazdvIM/u4QcJGPYf161lxphccYrPmuwPePAHifVvFfhjW73Xbs3N0lyET5QoRNoO0ADpmobhAZhjjNZXwTbd4Z8RxZGVmV/0/+tW9KmQM9ataWuSyi6cnHUmoTDnHOav+WNuCAT60iw/OQTwB19a0gtNTLRmW9v2xTxb8DjitHyOevGamW3yMHp9KfKrk3S0KVrD82MVu2MXAyKghgAbgZrVtYug6U7Ia3NnRwsIlkYfKiFz+ArwLVvF2t63pn9nXd/KdODNvibB84hyVLHHbsPavdNWm+xeFdYuO8dq+MeuMCvnC3XEEYYDOBke9KMYy3NL2LFogGMVuWKZ/PFZVqvIP6Vt2iDaCOP55rvpIwnoX41GOOtSAYxjtSR49O3Sl9citzC40ijB4pR+VIOOe9BIcdDg0nvtNLj06/TNBwMbhye5oCw3HbuaTJxwOQacQexwDSDPIFAijr/8AyAdQz/zxP9K4nw7/AMes3T74/lXba9/yANQPrCf6VxXhwE2s2OocfyrhxH8aPoddDWDNZQMt9KlTJHTimJ6EfhUo7cUimOA96kGM9aaBzTx1rRCZJheq84qQDIBHWo064qRc1SRJJg4xwCaVQBmmZbPTj1pfQKdxpkjhTx0FNAz7VIvIHFUhMci81KF+X5Qc01VPOO1S4PGBxWiRIBQAWHUnt1obA5JJ+tOwQTt6mm96HuDIpGAUk9O5roPDvg+91poLu+c2WlO2C7f6yVe+wf1NVvB+mLq/iGKGVd1rB++m9Co6D8TXqF7M8jYAAVeAAOAOwFcuKxPslyrc2o0ufc1tN1nTPDllHY6LYpFbxdgcsx9Se596mk+IMyZENih93Jrk2Q+1ROn05ryXVk2dfK1sd9p/jM6tHJFPZCHysHerkhh6Yq7FMl06vHuCY/i7GuM8Ox4W5PqVFdZpKkQKT6muinrG5Jadc5qnKPm6Vfbmq0y8CtANz4fxA3t1J6ACt+6Obh/rWX4BjxFdSY43Yz+FXppR5rsegyST0Arnn8Q0ee/FpfPi0y23YMl7AmPX5wSPyWpNZ1xnt2srIkRHiWTOC3+yPb1rC8dXa6n4i0XymYxLdM4OeoRDk/mRT9ntioirtlN9jivipN5Hg27Ax+9dI8fjXjcOAAPTg16n8ZJh/Y1nbj/lpOGI+gzXlict168jjrXVTVloZSNWykwAPyrbtnyOeorm7Z8MMdq2rOTjiuuEjkqI2YjuGTkn0Nc/8SNv/CJnb/z8p9Bw1bcDdOCKxPiRj/hFGI/5+Y+nTo1XW/hS9CKafOjyeiiivCPTLulDMsn+7/UVo8elZ2lAmV8f3f61pV6WHt7NGUtx6ruAOTUigAUxByAMZPt2qbnbgfWtbGbY1cfjRyT9KMjGaBwM44o7COi8BWP2vxEkpX5LRTI3PfoK+hvDcGy1DtwAM5NeR/Caw3aVcXe3m7n2Kcfwrx/Oug+Kfjc+GdHjsdNb/iZzrhGx/q16bvr6VzVZXmaRVkXPit8UYfDsb6bpDLNqhHblYD6t6n2r501G8vdUvXvdTuZLi5f70khycent9Kgy0krSzO8kznLMxySfXNSgADgGsWm9S7iKm09Of5VKowOg5pSBwe+Keg49/Q1dtLvcVz0/4GNmHxNCcfcib+ddVInSuP8AgQxGta/F132it+Rrt5F24yO9HUTK2z2HuKVY/mOcmpNuTUgHH0rWJk9yNY8HkA+9WPK46Usa5qwqcVpyk9RkMPNalvEOOKrRL83QVq2aYAqZIpbmH8SJfs3w81TacNMUhH4kV4Qi42gAAV7L8apvK8I2NsTzcXYPHcKCa8ejAG0c5xj6VVOOly5Fu0XJWtu2HyDgVl2YG7oc1sQDgV201Y5qjLKjAHSlwC3IP4UcAYOaOp4IxWpkxpznrnNCglc470HnGO9Jg5wOvagSAAg80h75p5PPPHbNMx70hiUh56DBFOpG4AwQfoeRTJKGvf8AIC1HP/PE/wBK4vw2P9Gm5x84/lXa69/yANR648k1xXhv/j0m93A/SuGv/Gj6HVR+BmwAdo9alXnHp71GudmMKTUqYAppLqU9iRRUgA+Ug8GmcHJ/SnqeR196pCHKMHOM4p/ce/NIOSR0FKcAg+vb0qxDu/SnDk4zSDue9PVSeg5piY4DkjqPrUsfApqipEzgccetVYhkiDsBg+gp45HX9aaOvHB9R1p6Y288n3prcQ5AAM7sn3qKbKqQo59alIG3I6+lRzDCk8cetWI7/wCEFgZNP1G7AH7yVYh+Heu9Gk5yxBx9KxPgzbFfCMUrqwEs7uufTOM/pXoCrwQBXkVlzTbZ3U9Io5KfSOM4K56etZ82muCQRXfmAkcrx61FLYIeqjNYukjTY5LSLdoYJd2cllHSuk01CsKemKhurYQFVAxnJq7aLtgGa2guWNiWPNVZhyc1bPeoJFyc4poCu+vazo1ug0WOzmTfmZLhDkr6rg9RWRrPjCS4aW3kLeRn70cLJ5nscjIFa8sfHTmqzxtn5h+lZTg27oaMA28V1qsN5bStLaxRsVdoym53wCADzwBjPc1cYYXrV6VeOnSqc/Q0KNgPHfjJOTqmm2+SQkbSEfU4rheM8gZrp/idObjxhOFP+pjWMe1czj2reGxiySLGRnrmti0bjKjBrHiByOMVqWjfw/rW0DOSubNueARWP8RST4SP/XzH/Jq07Y5XrWT8QznwofT7TH/Jq1q/wpehjTXvo8rooorwz0i/pOfPfH93+orUB45+prL0jiaTn+H+taoOFxxjOa9PDK9NGU9x6dAD0p5X1FNUA7cnFBboM1rs7GTEc7uT19TQwdgqxnLN8q4Hf/JpueecYrpfh3pn9r+LrSMrmG3P2iU9gF6frSbsrsVj1vTYbbwz4WhluWEcVnANxPrjJ4+tfO+vanNrutXOoXBYmVjtBOdq9gK9F+M3iWSe4j0m2fbGv+tx3B6CvMo0+T6VxrV3ZttohAOR0p3I6EGnbQFJyTSgY7VQCqM09eQKYpIJ96miU5BPGKpK4XR33wNk2eMrmLvNYuPyavQ7hSspwMfMQa81+ETCLx/YeksUkZP4ZH8q9UvoyLqRTjhzSceV2Fe5R2/NipFQnPYUoGWNTKlXHYzuJEnHHWrQT5aZEvNWVHFa30uT1EjT5q2LZcItZ8Y4GK17ZMqPyqW7lx3PLvjpcEXWh2gJ+WJ5iO3PFeaxqMLjIJ612fxkuDP46kgBO22t0j+hIya42Hlgfwq6asgbNKxXp6mteEYHWs+xAAFacS5Uiu2mc0tWSZpP4gKd09QPY0nDEnbxjr1rSRA3aM85HuKQ5xz+IoOTxnPvSgflUguw0kYABPFBB64PTrTiAM5JAHPFNOcEnp1oBoQ8nk5oAx2opCCQeuKBJXKWvf8AIv6j6+S1cV4Zx9knz/fH8q7bXiP7A1HqT5J/DpXFeFxm0n6/fH8q4cR/Gj6HTR+BmwAANv45FSL94elMToRjI96lXHHH4U0UPHJp4xx7U1cZ6ZqT0AXmrRIbgT1x2qTsKYORxjFSKOlUgFUc/wCcVKqkY4pVA7Cn9lqkiWxUXjrUijGc55NNXvUow23gDtVEXFCjPXinRDKn0zSAcZpw5II4HpQtyWx+McDqfxqtckrGWIPAzVnr7VW1H/UOCDytU1dgnc9/+Flr5PgXSUPG6MsR9TXXpGAcc+1Y/gKIxeE9IUknFsmfyrp4157YFeRJ3dz0YK0URJHxycY59aUQ7sEnmrAUH8aeo/GpuUc/rEeLqJf9gmiIfLjNWNYGdQX2QVEnCdK0RI3tUeKkPTOKQj2oAiZciq8iHpVzGB0qJx7UAZsyYB5rOmGSAehPWta7HNc/rlwLTTby4bpFEzfpUSBux89+ILn7Z4i1K4/vztjnsDj+lU1pkJMi7z1Yljn1NSKOa3SMSSMcir9qCp4zVWJec1egUZ6HNaxM5Oxo2+ABWR8QDnwmeMf6Sn8mrWgBKj2rI+IRz4V5z/x8Jx+DVVZ/u5LyM6fxo8uooorxT0TQ0b/Xyf7n9RWqnvWXovNxJ/uf1FaYwPzr1cL/AAl8zGe44tjsaR2wSSBimsRjNMc9cnjBNV1sTYecsVjiUvKxCoqjlmPQCva/C+g/8If4adpl36veYaYj1x8qD2HT3NYXwu8NR2EKeJNcXbK4P2CBhyF/56Y7Z7V2NzM13cGdlKIv+qQnO33rlrVbqyKirI+d9VmurrW7yTUEaO58w7426pz0pEAAPXmuh+J+mtZ+JFvVB8m9G4n/AGxww/kfxrADAL14pQldFA/Qimqcg08gd6WNCc4p8t9BXFRM4GOKuW8Q470sMW0D1NXYo9vWumlB7GUpGz4Eb7N420SUttH2jYfxBFe06xEVv5RjHOa8L0uX7PrWmOuS4uYyFUZJ+Ydq+idatDLcs69wPxqa8bNFU3zJnMOuDzmnqKklQqxBNNXINTHYlksa8irAHTNQRcfWraDIBqkIlhA3AVuafFuZM9Mism3TLjity2IhtpJnyFijZyfoDUmkEfNXjm7+2eNtcn+8DdMgOem3isu3GDwOtVhci6muLgkMZZXfPXqxNW7UbmX0raDuTLRGvZLgLmtSLlRWfaLjGOlaSH1xXajlbVxfwprbfU/40ozg8fTmjAHrTE9RBwR0xQWAA7UE45pOo/HvQLXoAbPAzn+dNPofXinAYPI59c0Hlf5GgfqMOC1IfbI+gp/s2c9qb+FAropa/n/hH9RyT/qT/SuL8Lf8ec/++P5V2evgDQNQ6/6lv6Vxnhb/AI9Lj/fH8q4a/wDGj6HTS+Bm0q8U9eCKRelSDgjjk1QxU4qQc4pinGfpT0GAD71RI8DLHmplUDvj9c1HGOckVMvY461pFXE2OGAfTNTKoPLdKjUA5zkVIMYGcfWtbEDgCAQQKcg4HFA4OSacpOMnmiwhQOn+NPTGDTAPmJPQ9qkU8dKjqJi4HoDVXUCfIbB5OFH1q3jPHIHtTWi8x4l9ZE4/EU29NBH094fCQaLYxABdkKLjOccDjNa6uoHX8a47TrzEQXP3QBtrVju8qPmHPbvXjt3Z6S00OgRgehz6gVKpHXpWHFdkfdJqZbsnI5pWAZqxzqBPoq1EozHSXL77gt1yAKeBhR2rVCIuRRjjrTwOTkUEdsUwIyKYwqRulRt0pMDOvc7jiuB+Kd39k8GX4Bw822Ef8CPP6V3t4ct6V5B8brz9zpWnqeZJGmb6AYFK12KWx5ag2qoHAAqVBlhzUan16dqmTBxxW6RmWY15FXYRjsfrVWHng1eiGeMVqjGRajx0FY/xBGPCpx/z8R/yatqJQB2zWN8Qv+RWPH/Lwn8mpVU/Zv0Jp/Gjy6iiivGPQNDRv9dJg87P6itM8ng1l6PzLLxn5P6itInBzXqYZ2pIyluJwwIzjHWmSruRgMZIwKcDuPPHNKc96u1yT6A8DtZ+KPCVnfMTHdWyCCVOuWXj9etS3kTI5AHA6Yryv4XeKZPDevRWtwVbTL+QJMT/AMs2PAYfyNez6pEFllQjnP6VxVYcsi000ea/E2x+2eF5pB/rLVhMuPyP6V5RbtuiBHftXvurWiz21xCwG2RGQg+hFeA2sLRNLDJkPG5Rh7g0qe9gexaRARyKswwjBwKI489R9M1u+FPDer+KdV/s7w7ZtdXAwZGPyxQj+9I3QD26muuNNLWRlvojMJEQDE4J6AD+Vd94R+GPiPxII55YP7L00gEXN0PmYf7KdT9TgV7T8PvhTonhDy7q8xrGtqObiRQUiPpGp4H1PNd/NHvBMjbj2UdBRKqlpFFxpfzHBeE/AuieF4g2m2yzXxBVr+4G6T8PQfSrOqxiKPJ6Zxmulm+9jjFYXiKMtpzMAThxn6Zrnm9Ls1StscTqUYW4JqmOpxXbQeFJtTED3V4ViVADIY8SSn1x0Wty0+HmjBf3v2yb3aXH8qVOppqZyp66HmURyw5q9DyBXp6eAvD44+yS/XzjmobrwFpRU/ZmurduxD7h+RrT2iJdNnMaJZxOvmXDAAnaik9TVvXlhi0bUBID5PkssmOpUjBxT9R8M31okDRzs6QyCQSRjB46qy+h9RVbxW+fDl3zzIm3P1rKctzSMbHzj8RLCw0rWNOstJthb240+JyP4nJz8zf7WKx7IjIBrb+LDY8eyQjpDZwRj/vmsSzGWz+ldWGvZMzqdUblouOo5q8vIOKqWwIXJ5q4AdvGK9FHE9w6dh+dH44ppz3UUMOmDxQK9hSw3dMmmnJ5B70DvQMDsaYXFORgU0ggAY/OlJ+Yc8U05BHT6Z6UFaB070ZJ6nj2owe4oOe68e3NBCRR14n/AIR/URnGYT+PSuN8LD/Q5/8AfH8q7HXSP7A1Hn/lif6Vx3hb/jzn/wCug/lXDX/jR9DqpfAzbXpTwOnXIpg6GnjpkmqHckUZGQalUYAqKPrUy9uvPNWiSQDk1Kqnjnj0qOM5YgKR2qZeMHrzW0NiZKw5fvf0PepBjP8AT0qMfezT+vTrVED8ClHSlAGSccUhBCgMMc5Hek3YBw6U9TkDmmjncPWnDpipkJjxnNWdIga98QaVaIQGmuUXJ9M5NVS2VyOPXPaun+Edp9u+IunlsGO2R52+oGB/OolK0W+w4q7sfRcui20+zdEoZRjKcVA3h6NQTGzA+9aCTnqvT0NSrcNjkc/WvK1PRMV9GnC/IwP1PNVpLC5TgpkV0n2nnpxQbpdwYgGhCOZCsrbXG1vSrBHAzUl9+8vZJB0JpG+lapgMApD1qTbTSBmmIhYcHmoX4FWHAANV5OBSYGVekFz2FfP/AMVb37X40kjBytrEseB2Y8mve719odmI2jJY+wr5g1S7Ooa3qF43PmzuwPtnApJ6ilsVwMnI4xU8QyarjkVahHOe1bRMi3bjH3sVoRDocgVThXI4OKvRDHPc10JaXMW7k8fXnrWL8Qf+RUPr9pj7+zVuIOuRkisP4hj/AIpT/t4j/k1Kr/Cl6Ch8aPLKKKK8Q9Av6R/rZM/3P6itA9qztK/1sn+7/UVo16eHv7NGUtwB2nPYU78MfWkHSnAjJLdSa0IbsNcMYzg4ZeVI7H1r6J0DVV17whpuqjb5jx+VMAc7XXgg/lmvnvbkFTXpvwVvibLXNJY5A23cfOcdm/pWVaN43CMjqrx/mP0zivFNYthb+KtTiwAGk8xR/vc17JeSBQS3fnHrXC3Phe88U+PdPstMOz7TEVnnK8Qxqclz+HT3rlpSXNdltXVh/wAN/A97431WRIma20i2YC6vOwPZE7Fj+lfVfhbQ9P8ADukRaZolqtpZxjnA+eVu7Oe5qh4b0mx0LSbXStJiEVharhB3c93b1YnnNdJa5Ixit5yuOEbIeygA7QB9KiPB571ZK9e4qtcEBcVBZTvFx8wqrZqk5GQGXdkA+1WrrL2buSqRopZnY4AHrzWH4D1iw1uxW50mYz2nnSxrJ2YqcEj1GelN7B1OttI+efXNa8C/KeKz4B0rUg+6K5my2rEiJ6ih0HpUqihhSuSZ1wgHYYrzXx3hdOuFUKAZcY6V6hOvH0rx34uX40vw/fXjNEPIk3KJDgM2OF/E1TfusNj54+KT7vibq6DonlJ+SCqOnZ3DGM981m6pq1xr2uXmrXyxpdXbB3WMYReAMAfQCtXTwCRXfhtEc9V7s2rfpk+lWVIBwc1XgGFqfJOB2r0UcT3HE9hRxg7s0Y6479aYCQcA80xt2FH40hPvn3pTnAOeD6UDnvQKwnrik6cjOaQdCc8Cg8cg89aBWAkZJ/lSDrn/AOtS5GDge9J6YIzQUUdd50DUev8AqW61yHhUZs5/98fyrrtdP/Ei1H/rif6VyPhUZs7g4z84/lXFX/jx9DopfAzaHepABUag45qUCqSuDJEGCR0+vepl4xgkDHWokOR7VMvUVpDcl7Ei56ng9akXrTV5pwx2FaogeDwc5NSLgjNRryDmpFOMA0yRwPXPBpVGOM8GkVRg8cUY+UYqJgSJwOKVcHGf/wBVIvGRSjk0gEkHy+9ejfAGz36zrN+QQscKQqccZJz/AErzaUkqQP1r2j4GW7W/hCedhtN1dMy57gcZrKu7QNKK989QVsHA4pxlxwaq+YF6VG03XvXnncW3l9c1ZtYi+NwqvZQF8Mw69M1tW0Q4wOaTdhGHfIBK3HftUJWrmoczsO+41Bt/E+nrVJjIgppjCpiMjgGo2HWncCCQcVTuDhTVyUcVRuiQhoYjkfG16NP8M6ndZxshb8yCB/OvmuDhFB6kcmvbvjZefZ/Cf2fODdTqn4D5j/KvElztBpx7mcmSrirUC8fWqicjHc1chXvitYEN6F+3GTjHJq+i44zkVVgHygdqtxKOQOldCOaTLCDkYrA+In/Iqn/r4j/k1b6AnpWF8RgR4UI7C5j4/BqVX+FL0Cm/fR5TRRRXiHpF/Sv9bJxn5f61ojn2rO0k4mkx/d/rWiF616eG/hIyluLjingDaDxmm5HGaXtWq3M2OAzxXVfC67Fn46sUL7Eu43t29DkZH6iuWXljU9lctp+oWt7GQHgkWQE+xolG6YkereI52ivWgU/MCBjvnPQV6b4B8Ptoelr9oA/tK6AknPUxr2Qf19axNA0RNS8TPrc6B7JFSSAHkSOwyPqB/OvRIkJJZid55zXBCFtWbo0LTqB0rZtRnGax7MYwT261euL220+xmvdQuo7OwhXdJPK20Af1/nWrGXmyXKLlm9PSuL8feP8Aw74JiI1i5a51IjKWFthpWPuP4R7mvJfiJ8cr7UfMsPBIbT9PGVN864mkHqgP3QfXrXh88haaWWWR5Z5CWklkbczk+pPJoUdLkufY634jfFHxF4zWWGab+zdJydthasQGH/TRur/Tp7V7f+zvELTwtplr0yzufqea+Ur1zsbHXGa+sfgQ4ex0wf7BP/jtQ7bAr3PY4ugrQtyaoqMVetiDXNc2ZcTGKDQtKaRJUuRxxXh/7QlkLzwhrEBUEgRyr9RXuNx0NeSfGiPOlaiCMhrUHHvWsNdBM+PbJt4HHbium0/pweccVzFhkYAAwCa6nTAcf1xXo4bY5qpswjgDvUvA9c1HFwAcdKkOAK7lscgZPvQ23GB1o/melN6kZOKYIc3A5pv4cdKCeaaemKAe4ueo/Okz3z14pOe1A+mfagBS3GMdKQnp9OtBPSm5Bx7UDKevD/iRX/H/ACwNcl4V/wCPOf8A66D+VdZrmRoWoZz/AKk/0rkvC3Fpcf74/lXDX/jx9DopfAzcWpUI3DA5HaoVqVcZ9q2iDJUB554zmpgckVEBnG3FTA54bpVQIZKM4FScKwwD+IqNc8mpFJPArREjlBGc/pTkywyaapz68U/qQc0xDl6H6U5cbRmk6AEd6BkfQ1MhWHDBJIp+e9MC46U7p1qSSvdNiE+gr6H8CWZ07whpNsy7XEIdx7tzXz/b27Xmq2NrGu95ZkXaO4zzX0sF2bVAO1VC/lXLi5WsjqoLVsnklAByas6ZbmdhI/CZ+UHv71hahqEFjhrhSwB4Ud6op8SkgOwaSGQdPnwa4nNLc6T0+3jUADiranbnA5rzW2+K2m8C40m6TPUoQ2DVmX4t+Dre4tYL+7uLOa4cJEskLHJP0qOZMG7HTXkMiOryADzCSOa5XxHrt3Y+J/Duj6ciNPfNJPKzjIEMeMr7ZJHNdxrnMtsP9gmvN9WTzPjLoox/qtHnYf8AApVH9KfNoM37m11K+1AeRfx2glcfIkW5F/OuhTRphE4vbiBJNxEflgkMvYnPc1DpqZvIvbmtbU3xOq+i0m2noM5y8sZ4clkLp/eTkfj6Vi3LA5HPHWuwmuoreCW4nlSGCIZklY4VR7n+lZdwlpq+mtc2TxycEpNH3x2NHOKx84fHi8J1HR7EMBsRp2A7nOBXmaenPHrXXfGK4Mvj+ZGBAit0VR+tcgnU10R1Ri9WWIhnFX7dev19KowDDCtK2XcxNb0zORehyAOnPHNXIwQM9c9h2qtCKtoBkZz+dbIwZNGe1YPxG/5FI8Yzcx/yaugj6e2eK5/4kH/ikyP+nmP+TUVf4UvQdNe+jyeiiivDPRL+lf62T/d/rWgeBWdpX+uf/d/rWgpPNenhv4aMZ7jwc4FOBweTTAT2pSe461q9DMl3AA13Hw9+G2qeNkN20y2GhqxRrlhlpMdRGvf0ya4cDcpxy1fRn7PGqm+8Fiwc82E7wgf7J+YH9TRNtLQcdWdxommQabp9tpdqGW2soxFEGOSQO5Na0SdBU0kISVXHQ8NVfULuDT7eWW5k8uFOS3f6D3rlNthmq6tZaJps1/qMyx2sYJ68uR2HrXzJ8RPHOpeN73N0xh0qBs21iD8q/wC03qT+lXfjR4kudcaC43PHYwXCiOAcDGDyfU157LKCo28Dqa0oyjJOTM5t3sLNJtBwQO9Z00u4E9vSiWU59qgkOe/Ws6s22OK0Irg5jIPTHFfWH7Pu4w6Yp7Qnn/gNfJ0oLIVPJz1r69+BMHlCz4PyxEfoKwu2y0eyEYFW7Y9KruMVNb/erI16GgnQUrd6SMcUrUiSncn5a8t+NPGmT4/is3r1K4HFeYfGtCdJ3DvayCtae4PY+MtNPbrya6rSycHB4rldLOCc9/55rqdOODj7uexr0cNsctU2U6CpKiU8Dmn967Vscgds5/Kg8HHagdTj0z700/rVBYXPYUZz9abzkEdfagELmgAPGKaSf8mlJyelNJy2MjH0oGLkj0/KkB+9nrSFhuINNxwOMUAVNc/5AV+f+mJ/pXKeFSfslx/vj+VdTrR/4kd/3/dH+lcr4XGbOf8A3x/KuGv/AB4+h0U/gZuZHQVIKjjB9qkHQVrFiJUAI4/WpxgqAB0qGPjNToD+lWiWTDvUiD0qIY9qmU5IPbFWiRwGOKcoyMjkjt603HzcfiaeBjn1pO5I5Rz8xz6YpwBPB6DpSAA9MfiKVRgYPWi+grijJNGevT8e9L2prnAOevQUtw2N74b2n2zx1YDHywK0zAew4r3ojqeea8m+CFgZdT1bUGX/AFMawK3uTkivXQMAdK4cU7zsuh2UV7tzmPEVs02QT8ua5efSzl8BsduK73VEzycGqMsaEHIGT0HpXBUjdm6PP5LVo26HjuK4j4gWJOq+GLkAjbfRxHHbLAj+VeyXFiMHcoGfzrk/F2mR3Nvp6j7yajbsuOxEgzURXKxN6H0bq6F7qMcnEYFefXMZPxjQ8ny9FXH4yH/CvTJl3Ss3HQCuEdA/xguc/wAGjwgf9/GrS+iQzqdKixeDI7d6s6h812474xU9mv8ApA+lRTYa6kJ9abeozzr4oabc6o1lZTSSrpRHmNGvSSQHjOPTtW34cszonhWZpEKGT/Vo3B6YH411V1cw2sIabBJ+6mMkmuY1W5mvHDSjbGv3UHb/AOvUcurYz5T+LLq3xG1IHqiRrkfSuXjIz7f1roPie+74j63kZKuo/wDHRXPwjJJOM9a7IbHO+pag+8K1LYAN+FZsIGRk85rVtwNxHNdEDKZdhHb1q1CpGN2Paq0YGeeKtRrkDPWt4mDZKvrWB8RwR4TbP/PzH/Jq6Fcceh/nXPfEj/kU+B/y8x/yalW/hS9Cqfxo8nooorwj0S7pZAlc/wCz/Wr5I255HvVDTMeZJn+7/UVdd/m46V6eH/hoxnuLvxk05OlQ5yeDUiDPXNaN3IZaTr04r179mzUDB4l1XT3OEnhSdf8AeU4P6GvIU4HGfxrrvhZqA03x5p8hJAmV4M54BYcZpyV4hF6n1P4n8QaXoOnvcapew2ygfL5h5J+leNar4r/4SmN54JnNiGKxxsMZ9yP5VxXxTtpl1+38+aadQrBRIxYKc9R71iaJrD6F5qmEzW8pyVDYKn1FcrpSnT5olOetmT/EqTy9JtIyfnkm3AewFcW0pKD5uRUviPVLjWNSe4uMIo+WKIHiNfQVQVs4B6CsFJxVkaWTJXYtikCngkk0g6k461NGuSAMn2pqOl2J6BEhaaFcZBkUfrX2Z8GYdsSP3ER/DmvkCyjzeWucf61f519mfBwf6C/qIh/OnJJBFnoRGSc1YgGKYF6VYjTGK5jYtR9BSv8ASiPpSsKVxMqXA4rzj4xx7tCTAyTDIP0r0yUZWvPvi0o/sCInjCyc/wDAa2pvUlnwzp5+bB7E/wA66uwOWB6nFcrZ/LK+MYDN/Oun085Bz6V6GFOeqbMfGMnGelSk4wOKjjbgAU7ccgHNeicjFB55A49aAD2GaDg/WkPDckigBc008Ak8ClPBHc00Z9PwHSgQH8PxpvQ/e5FBJGeM9jmm9B70DuLnJ65NIc7vwpc8HPamkZHf8KdhlLWx/wASO/P/AExNcr4YOLSf/fH8q6nW+dEvuB/qj0rlvDH/AB5zHuJB/KuDEL9/H0N6fwM2kJ47e1ToQMZqsvI+tTpx1qkInUnmpUPIPeokJ6cEGpVOCM8n1rZEky81YQYOKrrVgDdgZ4qkSyQfeP1p6gkj2pqc808e/WqexG2o48uR3p2DnJpqjnJ6mnYx3qBJAelRyg8fjUh6Cq90cRNg496E9Rns3wWtlh8HPcD793cscn0HGK7wjoTniuc+HVr9i8FaRAyhWaPzSOvLHNdMT6HHNeZN3k2z0IK0UjH1pljgLvwKyEuZrlgtun6da6h4obiVYrhQ6nsa2rXTIYR+5iAzyMDtWMo63KONt9Cup8NM20HsOtWbnwjDNBCZSSUmSUH3VgRXbpGE+8AMj602by/KIC5OR17UWQWNqMblLHrXHaravpvjw67KCbCWwFu+1SzK6MSBgeua7G34iH0qpqlzDaWkk05ARazSuxlK18QadHDJdSXCrGmPl/jJPYL1NQtqolYmBCGc8F+1cTrt3cXbGWF1ggHQKMZH1plkPKiLCaQk9yelacgXOyKFmLysXc9STVO/wF4AqhpuoTKwincSRn7rdx9auXT7gPrSaKTufI/xHYH4i69nP+uH/oIrFhJ4960/HUnm+P8AX5PW6I/IAVnQ10Q2RzvqXoAQRWrACeccgVn2wxtrRh+brniuuCRjNluIMSCOCKtJ7VWTpVqPGB/WtkrHP1JYxxkVzvxI/wCRUI6f6TH/ACauiXp/Sub+I3/IqH1+0x/yaor/AMOXoXT+NHlNFFFeEekW9OIEj5/u/wBassRgdaqWZwz844qdmPBz7V6FD+GjKS1JEODirERwOarIR61OhyK1TM2XEwQcVZtZ5bS6t7u3/wBdbuJkHqwPSqsI9Rx61aTpwea1tdWIlpsel/EWVNZ0HR9bij2LPGGIPO1u4/A15zecwk5GPQ132gv/AGh8NRbOc/Zrt48egbkfzrg7+JollhcHch2kVnh2vepjnrZs5a6++frTY8lcZ5pbxv3xFEWAOOTmvPa5qjRutixEufvYzV2GMY9+2KhhT5ccj0q9ChyDiupQ0sZyuPiXaySDh4yGX2xX158Abv8AtHw39o/iMK5+uTmvktF+Ujj15r6q/ZjQjwcxPTYP/QjSr00o8yHTep7DEmfpU4HNJCuEGaenLV550kyLxSOOakUYFKwyKRNynJ0rzT47XJsfAs90OsUMzD67eK9MmXBrzL9oRAfhXqrEci2l/lWsHqDPh/TsBU68jJrqdPOSOeCK5SyJ2R4OBgV01g20Anp616GFOaob8PPTIqXv8oNQQHI757VLuOec16hyPcN2T3x3x1o/h5z9DSZxnk0Z469aQheOuCcUhIB70nfgj3oPrnFAwyMnIP8ASk7UhwRgnANIzAHimhBn/Z49zxSMwA/lSE/MQaYzY5HahFFTWz/xJb4djEf6Vyvho4tZ8Akhhx+FdRrJ/wCJLfZ6mI1y/hs4tZ+SPnHT6Vw4jSvH0N6fwM2QMDGSKmUj1OarhjzmpEIB65FO9xFpCOm49PSp0IOM1VQ9M1PHwK1RLLS9vQ1OmMg5OarR9zU6H6A1RJYQEjI7VIp4FRKw59PSpA2TjjH8qpvQhkoBPSlNNXIBxnHqaVTxzUgL0FQXChkYHuMVI7cj3qJjjI600tQZ7b4J1uXU/D9nLF5aiJBCU6kEcc10ZuZxjOzNfPeh67d+Hr77TaEuh/1kJPDj+h967vTvi34WlZY9VN1p85+8ssRZR75FedVpOm9TtpTurHocl46zRPhWIYY5rtkuS0KlWwCowO1eL3/xG8FJCXXW4mTH3UQsfyrtvhv4psvFvhiO/wBNMnkxStARIMNkf4jFY2Rrc6/eScsSaVjkADuRUO+pIDumRffNJ7DN+NsQqPauI8b3TXGqWdhuxCoMz/XoK7MHEQ+leeaxIJfE15Kediqg9uOaimtRMx9eucARRjamQAPSo1n2RYzzVLUJPNvVHUA7qVnxgH61o2SXft7xsiqMl3Arp5G/dA9eMmuMsx5+qW8YGcHca67UH8qzkfsqM35CspO7NI7Hx/r9wLjxNrUxyd97Jz9DimwAHmqPmGWe4lxlpZnc/wDfRq9b9M10xMJdTVteSK0oAQ3AHNZlqNwwOeO9asGBlc8YrugjnkWkHAz0qdMgcAdKiQcY4P1qZT2rRGTJASAAe9c58R/+RVOev2mP+TV0n8Irm/iPx4VIz0uY/wCTVnX/AIcvQqn8aPKKKKK8I9Imtjhm6dKk3cjvUMRAJz6VagRtu5NoOfvGuqFSMYK7JauxyK4G8qQPep4nyMg5xSpbTzHls57/AP16U6Xc7sxcevNCxK5ttCeS5MsmO/8A9arCTBjgcDFQLp1+BwsTf8Cp4sbwH/U57cEGuyniKba1MpQkeifDmU3Xh/xDp0b7bjdHcpkZOOhIrB8YReVdK4HyyJzjuRTPAd5e6L4qtLqa3YWcn+j3B9I24J/Dg1s/ErTJYLmMQqDFEzEsTgbT0rHmjGvzJ6DcW4WPKLsn7Q/1pbdsfnT7mN5rhvKRmGccCpYdJv3OUt3/AErk5lGo2bW90u2zAkZPatCFgQOenFVIdH1TaP8ARl4/2uavwaTqan/j3HP+1XoU61O1mznlGW5IXCwszdBz+FfY3wDsfsPgGDK4LIvPrxn+tfH8GkalPc29u1sQZZUj6jgEgGvu3wTZLZeGbKFBgHmssVUjKPusqjFp6m8BtQD2p0Iy2aSQ1LbjCmvOOpk1FFFIgguB3ryH9pe+Fr8MNQj6mSFl/wC+iBXsFx90V89ftYXuzwRew7hlpYIh/wB9bj/KtIdxnyTZtgD6V0umNlMHBHfNcekmD0P5Vv6fdrkAh+O4Br0MNOK2Zz1EzrYG+UcgfjU4kwOfrWPDdHaMk7fQrUzXi5HINerGzV7nK0aG8Y9yafu5AwB61mfakOQCM9smnfbIweP59KfKKzNDII6D86azcc1SF4mNu4fSmtcrkYYfnRYLPoXw+B/9amlx/UVQN0pJJ+vBpftSnHp9aXIr3QWLRYmjdjgVUNyopr3K+34Giz6DDWGzo96DjPlnrXL+Hmxazf7w/lW5qkynSrsAnJjIrD8PnFrMP9sfyrgxP8aPob0/gZrH608NgDnvUAJPSpF4xxmmiZaltDnirEfQYFVIzk84/CrCnuOcVpHsJ7FtWzx0qcEde/eqqNkZ9anXGR/OrILKHjnpUqkAjJ4PFVQTg5NShwcAA091YllsGhiPWoA/zEn6fWkMnXmiwbCu1Ru/OKYzDoOgqJn69KtILEjN61Uu7WC5PzorZ9ak3cc0hY5zjjFKST3KTa2Mp9CsyxIjA+navY/2cb5bLUNW0RW2xSqLiNCcfOODXlpPNbfgTU/7H8aaTdk4TzvLc+qtxXPOjHlaSLjNpq59XBgeB1q3YD9+D6DNUsjggjnpzWlpK7xK/YcZ9/SvOnojtTNKUhIQT6ZrzF3x9suWbPmysc+2a9H1Z9llKemENecaiPLs0RRyeTUwWlxSOeY77liBjbxn0pHfDmlhPJJHUk81C7gZY+uabJTNXwuhk1OaTsg25rY8VyGDw/qDj+C2kYf98mqvgiLFk8p6yMTTvHxI8Kavjr9kl/8AQTWTNFoj49045t4yeTtzWra9ax9PObeP1Cite1OMcV2w1MJPU2LQjjNasAxgisqz6ZBA47jNasPKZrtgrI5ZstRDIx29DU6jPNQqM4x0qePIwDgn2q0ZDwcDAFc38SP+RU/7eY/5NXSn7uO/WuZ+I7f8UuR6XEf8mrOv/Dl6F0/jR5VRSUV4R6Y5FLMAOSa3tLtwmHdFf+6rdBWXpkYe457DNdNbRnbnHNJlJFm2hzjdtA/KrsdtgAAUkKdscVoQJwMjJFTcbRFHaZGdpzU4tf4u49quwR84HPrVtI88EcUMkydm3IAP4itDxvcrfeCowVL3duVQ5/ijHc+tWFgVj0/OpGhSRGR1ypGMdiKLgcX4W0oXMSzup2+uK6g2ccaAIo+uK0IYY4YwkKBEHGBRLGAnpSuG5npGO/NTooI+7+NOVeelPUADgkUrhY1vCVoLvxHYxgZ2kyH8BxX1jp0Qgs7WL+5GB+lfOnwf0/7Z4hkmKkhNqA+5OT+lfSLkLIR6cVsvgF1FkPNWYBhKqqC7VdQYUCpYDqKKY74HHWkIhum4PtXzB+1A7tp9ujA/PqCg+mAp4r6alztz1r5k/ahkJhsFwVT7cW3dgdlW9IOxUdzwuygWSRRtX+ld5pNjFtXMangcYrldBiMlxyvevRdMiKxg7c8VjsU0KtrCoX90pz7dKc1pCT/qYyP90VbKc88UEYPFVzPuTYpGytduTbx4x/dFMbTbQ5PkRfgtXxj0pCBninztbMOVdjO/syyPJtYh/wAAFRtpNietpD/3zWrt5HY1Gy/MRn60c8u4uSPYyTo+n5/49Iuf9mmNomncf6JF/wB81slRjA/GmMCeRQpy7hyR7GI+haad2bVPwFNbw/puV/0Zfrk1tMDg8cmoyuTyeR2qvaz/AJmHJHscr4j0Owg8PanLHBtkjhZlIPfivOdBP7iYZ/iz+leueK1/4pXVjn/l3b+leP6Nn7PJxn5h/Kt8NJymuZ3IqRSjoaoYc4PWpFaqu456VLGeBkc16PoczLqH5c1Yjbp61TiyTgVZTIx3zTWjuSy5G/HPWpkbtmqYbk1KrEcHrWsWSW1fJ6HinhuM9Kq7sHg9fanCTjg81aJLG/HSkLdeahWTPTFKW454pgweQADkCmSFlIxz3FKcFff6UwrkcnOe3rRfoAM+c7fypc8Z7AZqMOu8Rx5Zz0VRk10uheA/FOvlTpuj3AQ9JZh5aj35qZVIx3ZSTexzfJGexqvczbFwJFWT+H1J7cV7p4f/AGfL2ZVfxFrSW6n70VquW/76NeqeFvhf4P8ADQDWmmJc3Pee5/eMT689Pwrlni6cdI6mioye5i+AnfxT4Z0W+a3mF2IhlnUpsYcE/SvSIbdbW1SJTk55Pqe5qyrIi7Y1VFHQKMConO6VR6DNedKpzs6oqyM7xASLCQDvxXnWtlCCu4ggYFd/4jfEAUDq3Nec6rJvnYY71pHYUjKbCI3OcDFULiULA3OSRj86uXTHZjkE9ay7l1yFB6ndx6Ck3ck9E8LReXpUK4xxVXxnGZfDuqRgZLW0g/8AHTV/wywfSrcr021Lq0AmtZY2HDoVP4jFZ7mvQ+HNPcCGMe2K17QncM/hWTJE1re3dsRhoZnj/EEitGyY7Ru/Ou2D/QwlY6C0xx61rQHIPNYtqwyOhz6VsQZ2g4612wu0cky5HjILHirKEE8Y9KqxNg8/yqYMMEEAfjWiMyVjkiua+Ip/4pU8f8vKc/g1dEXAAyAT61zfxDYHwuQMf8fCfyas69vZy9Cqb99Hl1FFFeCeoanh9Q11Jnsn9RXVwKMDH41zXhVQ17Ln/nn/AFFdbEmRjvUvc0jsWII+efrWjAN3bFQW8f3fWtG3T5RnGalgyaKPn8OtWUT8qbGmanRcUrkpajQmCcd6eqYbHWpAOMkc07axRhHgv23DigqyGKlK65U8VMkZIGSCcc49adJH8hFAjPRM8nP+FBXbnB4qyoHHX6+lNdCzbAOWIA46knAoHoj2X4D6bsshcMudxaYn9BXqM0mXOO5rC+HunjTfDKEAAlRGPoB/jmtaIebOBXQ9LIzRq2q5AJqzyKSFdqAU81m2BGxpjZqRulMIpoCvNnafSvBP2nNK8zwxPcoufImiuR7DO0/zr36Vcqa4H4t6Suq+ELyLbuMlvJHj3xkfqKvo0Cep8n+GIwx3ZPbn1r0G0TbEOMDFee+C33QoDkHgEY716LAv7sY6VzX1NB23BOBSEZ7VIRwKaQfwpiGEenSk/iqQjqKaRzxRYQnWmkc9KewP6UmMAYoAj5prAAZqXGOlNI9KAIyM1DImfap243e5pmODnrTAw/FakeE9X9Ps7f0rxzSm228n+9/SvZ/Foz4S1f8A692/pXiVi4SB892rowztO7M6uqNBXZnwuc+nc1eSBlGZnEfoo5NUbIZ3HdsPZsVp29o8u0qXK5xkCuqWISM1TY1JBHLtbcV/vGrKyA9NvHrVuPRRJFl5SCTnAqWPw4XXidhmlHFJbilTbM5pMHHepVmBxzzWinhaXdkXLMPRlFOHhW4JGLjr6iuiOLpsydGSKAlFIZfmAxz71qx+E5d+GuuT1AFWU8JpjDzy8e1DxlNdQ9lIw0nHQfmTQ1wq8s3U4Hua6/Qvh9da9eC20mK4upScMw4Rfct0r6A+HPwR0Tww0d7qajUtVHIaXmOI+ij+tKWMg1dDVGV9Twbwn8MvF3ilUmtLH7BZNz9ovPlBHsvU16x4e/Z80u3CP4g1W5v2H3o4v3afT1r3YW/ygLwB0A4AoEBIPWuSeKnJmqoxW5y2h+DfDmgxqumaRaxMvG8oGY/ia3CzAAKAB0wKtmDnvSG3+tYSm3uzRJIqcnqc0vOKnMaL1YZqJXjdisZDsDzjtU2YwBAGT/8ArpIgdrM4wSf0qcRKvLHJ9KZKwq0BgeIGwFyeOa831FgJ2Oa9D8SEi2LDkg15rqkg3n1zitE7RFIzLybg8VnRfvL1hj5VXH51YuycgVXtS32YyKPnkbj+lTclHp/g9CdHgJHrWvcxfJnHSm+GbQwaXbIRzsBP1rQuof3Z70LRWNT4b+KdidG+JGuWxGFefzk+jDd/Wse0uVyF9e+a9X/aI0OB/HFjdSAj7Ta7TjjJU/8A164nTvDVo5HyP/30eauFdQ0ZnKDa0IbSdS4FbMFwAD83tz2+ladl4Vs+Nytk/wC0a2LfwtYA5KNkf7Rrqhj4LQ53h5M56K54PzYqbz1x1rpY/DWnrjMfH1NSf8I5px/5Y/qav6/T6EPCyZy32gZJBIrn/Hk4fw5tzybhP5NXpQ8O6eODD+prlPippNnZ+DjLbxhW+1RjIPqGqKmNhODiupUMNKMkzxmiiivNOw3fCAzez/8AXP8AqK7KBMGuQ8GDN9OP+mX/ALMK7e3TOKlmi2LVulaMCH0qvAnA7ir8anGfwqWwJVGOBUqg8U1BzUqcgcHJ6CkAqrkHJNSovYjr3pyrxyKeBQIUDpj0olBKtg808DpinMo2E0riKCrz71s+E7A33iC2Q/MFbef6fqazAMseK9J+C2mi41eW7ZQUj56elXDWQpM9fdBZ6db2qdUUZx61LpcJZvMOagnJuLjAzya2YIxFGAPStGxEtIaCaQmoADTcU7ik70wI5F4rH1q3E+mXCHBCkN+Hett+V4FU2QPI0Z6OpWrixHxJBZHSfFeraawI+z3T7Qf7pOR+hruLTJh54qj8WtNbTPiQLjbtjvYgT/vocH+lXbI5hye4FYyVpWNOiZNg0mDg+uakwVbpSGkBHj5utIRg+tPOc9RR0JyO1MCMrx1phHJwakOAQM/jTTxmkwI+9JT2pn0pCGN3pjH5cEU9s4OKaOTz1oVwMbxZ/wAilrHp9nb+leEwEkhQepr3jxfj/hE9Z/692/pXieiwebMWPQH9a0gJm3pFqFAdhnBzg101vumcM/GeoHArNsYjjkfWtq2TAHHH86Y2W4EXBGB+dXIE781BEvPHStLTrae7uVhsoHnmY42Rrk4/pUCdkSQxgH5s1aGxR7j+HrXceH/hte3AWXWrhbZOvlx8ufr2r0DRvB+iaWEaCzSSQfxzfOc/jWkabZLZ43pegatqhzZafM8eMbmG0fma9A8HfDESXIm8UsrRKPltoXPJ/wBo+ntXo8SgABBwOwFWohgitFTSC5paTp9hplqlvptvFbQKMBI1AFXwKzIZNtWPtIXg8nsBUOLC5bAHpUckscf32GfTvULys69cey/41QltxIcksD14P86FHuBfkncqTGmPc9ap75nmUPIu3uO9SKSqAdaaSM54z61SVgJiqlegxUaosQxGoUewxSb+OTTXlFADy3FVppMD3qKe5VASWAHqawdV1qOEtGGy2MnFNICj4t1HykEUZ5J5rzq8lMk7OTWlq94bu5d2Y7V4X61izNhGJHTk1elrEsq3O4gheSx2D8a1dI09rjVbG2TO0Hew9hVKziZrmJQpzGpc/U9K9J8D6Rtle9ZeCNiZ/WlYInX2kASFQPSorwAKa0QNq1m37ARk1K1NEfOn7RiqNT0BwMttkH8q5XRLfcqHBx1xW/8AHq7W68V6ZZqcm3hLsPQsf/rVV8O24MKHGDWE/iZZr21uBjA7VcWIcVLGm0DAqTbgUgSIlXaMYpCp3ZxU+3im4phYhK5NcV8ZFx4FPT/j8i/9Beu6xXE/GYY8Bt/1+Rf+gvTE1oeBUUUVRB0vgZc6jcdv3X/swru4F59Oa4bwEM6jc5/54/8AswrvYQOev4VMi1sXIhgirsYGO9VogO3WrSdKh7jRMg9uKspjHXJ9agTGe9WI15yAelAMco+XgcmpVTnmkTpmpEFBIbOlPCg9eaAORTwBj0OaQFFl4ftivbfgzbCDwtPddDIxANeM3MfzcHr+te6fCdFbwFp6R9Hkfdj2NaU+omdrpkGAZnHLdKvlqhzsAC9B2ppfJq7XJJi/NJu5qEMTS5osBKGpevSoc804NRYLj92RVeYlXVvQ1PnNQ3HKH2oQHz9+0pZrFc6feqBujuRz7OP8RXM6Rl7JCT6Gu5/aWwPDMEp27zJGBn1DVwugAnTYie4FZz+I0jsXwoycnHvTGHOO1SMo5z+FM29zUlDCOMjrk0hpT0prUEjMZP1pMc81J0x6VGeuaAGN16UzpUue1RmkA1vpTTjPTtSk9fSkIOfUY6UIRi+Lv+RT1f8A692/mK8k8LRh4pj3DD+VeueLz/xSWr/9ezfzFeWeDkzbTkjI8wfyrSIbs6S1jAQH8MVqQqcAGq0KAgYAq/EvSkxjwWBRI13SSEIgHPJ4FfRvgjw7beH9HhhjQG6dQ08v8TMR0z6V8+6KyR+JtNkmx5STKWz0619RIoZVZD1GeOlbUkrXIZKqipEQ54PFMjVs896tRDH0rQkdGu2pAaiZwvFS2yeZy3C0AWIdzj0X1NToirwv501WyMDpS7sCoGSk4HWonfB5NQyz4X2qjdXgXvxSsCRdknCiqz3IHU1i3eqKq8nAHf0ri9e+IugaQzLe6vao4/hD7m/IUNpFqLPR5L5AOtUptWjG5VYErXjN18bPC6sQt3O47bIGOarWnxU8OX0+xb9oGfoZ42QH8an2iBxZ6brGtcAb+pyR7Vy1zftKZJmOC/Qeg9KzXkOpt51vdRTxH7vluDgVBMXR9kylVHQnvT57kNMsSuzbV6k/zqOYeY8cS/xtjj070ls0k7MYI3lc/KAo/Wuq8P8AhqWSRJr4hAFwqDr781ad9ETykfhPR3v55ZGUqGcAt/sjsK9UsoI7aFEQYVRgCqWnww2kSxxqqqo4Aqy9yoHUCgpKxPNIBnmub8Q6pBp9lcXV1II4IULuxPapdV1aC0t5JriZIolBLOxAAFfPXxD8YXHjG5/s3SNw0lWy7gf68j+lTKSgi0jk7y+m8TeJbvVHU/v5Mxqf4UHQV3+j2nlQLkdBWb4a8PrbRo7Lg+ldUkYUAdq5i9CMDjpRggVMF44pGUnvTERAcdKAKlwQpFM6UwGEelcN8af+RCJx/wAvkX/oL13fqa4b41f8iCf+vyL/ANBemmD2Pn6iiirMzqfAAzqN1/1x/wDZhXfwjPOOf5VwPw+51K6H/TH/ANmFegQrjpUstbFuLoatRnjqaqxCrKED+VQ9xosxj5s1ZQbeM96qp146VajPrQJk64ORipBUUZ/OpRQIeB7U8AYyRzSJ2p4A9adhoZJGGTn869G+C+tCCe60W5bB/wBdBzwT/EB/OvPwvoaVXmtbmG7snMdxCwdCOx/wpxdncTR9Mby3elUnpzXMeB/E1v4k0vzEIjvIsLcQ55U+v0NdLmtyCQFgOlG725pu/tSg5xnpSsA/OOCaTeKT86aeGosBMG96bL8ynHpUZY96yvE3iCx8N6Ldapqkipb26lsZ5Zuyj3NKw0rniv7Reorf6loOg2x3zhjPMB1VQeM1kWsSwW6RjqABWZpn2vW9WvfE+soY7u+YtFC3/LKPsPyrZLc5xj3rGTu7mqSSGEjPPFMP3h6U5sMSRTSelIBpHekIxzQxGCM01jTYhGyT1pOMZ6UpNMJyKQDTjPNN4pW61GxIxikAjcZPWmMf5UrHBJ4xUbHJ5oEZXi4k+EtXznItm6/UV5p4GXdZXPp5g/lXpHi5seFNXB/592/pXnngEZsLr/rqP5VcNg6nV268AVeiTOBVeBeM+laECcr+dKQxstqzAFeCPzr1v4a+OElt4tL1qTbOgCpM3Rh2BNebwJ2Pfpiny2IcDg56gA04zcSWkfTcaZRXGCh6MOlPYhFJrwbw94313w+ojXN5bD+CTkj6V0dt8VNPuDi+nS0JPKy5XFbqpFktWPToT5znqEHU+tXhKFGBwK84X4jeHFXnWbJcdf3gqtN8U/C8RO7WrVsdlbJqm13HY9P88A9ahlvFHfj+VeQ3Xxh0Hn7G91dt2EMDHNYV98Stc1EMuiaFIm7pLcnGP+Ais5VIoLHseoatFBE0ksqJGOrM2AK8o8X/ABcsbWSS30RDqd6OP3efLU+7f4VyV1ofiHxEwfxBqLtH18hDtT8R3ra0vwnp9hGirEpI9BWUqrexaVjhdSuvF/i1yb++khtT/wAu9vlF/HuaWx+G8YAMyBiepIyT9TXqsdusQwigfQVJs5rLVjOAg8B2sYCsikfSp28D2TRkGJenpXcbOc0BeOlFhHm7/D9FJaymmt37GJyv6Cks/DvibSZQ9lq8sq5zsuT5i/rXpJ4+lKMMMUAc9pvivxPp+BdaLaXSr1MDmNvwFb8HxOaFf9K8P6rG3oihx+YNSCPvT0QAYIyKtSkuorDl+KlqY9y6TrBb+75FU7z4iazdJjSvD8yseA924VR+Aq6Ew3A6+lAUA1TnLuOyOK1HSte8TTK/iG+zDnIgj+WNfw7/AI1r6foVrYoFjQZFbpXOTTSnI4rPcZU24+XHAo21My9aYeOtUJjAuKQjNOY8Uh60riGn0prCnk/jTR1PXFMZGwFcJ8asf8IC3H/L7F/6C9d8eDXBfG3/AJEEj/p9i/8AQXpoT2Pn2iiitCDrPh5/yErv/rj/AOzCvQIuv415d4X1mPRrqeWWBpvMj2AK23ByD6H0rpE8e2y9dNlP/bYf/E0mWmrHbwnGamjxn1rh1+INqMf8SyX/AL/j/wCJp4+IlqP+YXNn188f/E1NmPmR3qcVZjavPV+JFqP+YXNn188f/E09fiXaA5OlTH/t4H/xNLlYXR6MpwcipUOTnivOU+KFqBzpMxP/AF8D/wCJpw+KVpn/AJBE+P8Ar5H/AMTQosV0elLk4xUg6HNear8VrNf+YPPj/r5H/wATTx8WbP8A6A0//gSP/iadmF0elpUgHA5Oa8zHxcsh/wAwW4/8CR/8TTh8XbHj/iS3H/gSP/iaLMakj0uyurvSb6PUNLk8q5Xrjo49GHcV7V4N8ZWPiGNYiRb6go+e3fg+5X1FfJg+L1hnJ0S4z/19D/4mopPizYGRZYtGuopkO5JEuwGU+oO2ri2tHsS7H3Dj86Rnwc18qeHv2oLmxiEGq6E+oRrwspugkhHv8mDW3/w1Vpf/AEKN3/4HL/8AEVd0TY+jg+TTlyT0r5wH7VmmDkeEbr/wOX/4isrXP2qrqeFk0bw1HauRxJNdbyPwCCi6A+ivFniTTfDOmvd6pcpAgHAJ5Y+wr5/13VL7x7qkd5qavb6JbtutrU9ZGHRmFeXyfFC31HUzqXiKxvtUvASUElyojT6LtrRPxgsMADQrjjp/pK//ABNZybeiLVkelyHcMAfgKj28Hg/nXm//AAuCwHI0S4z/ANfI/wDiab/wt6y/6Alxn/r5H/xNTylcyPSDmkZTkGvN/wDhb1ln/kCT4P8A08j/AOJpf+FvWPIGiXH/AIEj/wCJosxXR6Jjrmkb615z/wALcsh/zBZ//Akf/E0jfFqyPTRp/wDwJH/xNOwXR6KevtTPXPHtXnZ+LNmRj+xp/wDwJH/xNN/4WvZ4x/Y0/wD4Ej/4mp5WK6PQz2qFuoPeuBPxVsyf+QPP/wCBI/8Aiai/4Wjaf9Aib/wIH/xNCiwujv375qNz6964Jvihak5/smf/AMCB/wDE1GfiZakn/iVTf+BA/wDiaOVhdHU+LuPC+qg9fs7fzFcJ8PF3afdf9dR/KptX8f21/o97ZLpsqPPGYw5mBC59ttYXhfxFDotrNFLavMZHDAq4XHGPQ1SWgNq56XCuW6VoQqMrXBJ4/tVOTpkpP/XYf/E1Zj+JFomD/ZUxI/6bj/4mlZhdHo8CfKN3b0FWFFedp8UrJR/yB7j/AMCR/wDE1IvxXshj/iTXH/gSP/iaXKxXPRkXnnPWpDa20wImhRwf7yg15yvxasR/zBbj/wACR/8AE1IvxfsV/wCYJcZ/6+R/8TRysd0d4vh3SXO5rGE+2wVah0HTEYGOxgX/AIAK8/T4x2Ckf8SO5/8AApf/AImpB8aNPH/MBuf/AAKX/wCIpcrDQ9MhsLeL/VQxr9Fq2iYHQD6CvK1+Neng/wDIAuf/AAKX/wCIpw+Nun/9AC5/8Cl/+IocWF0erolSAV5MPjhp4/5gFz/4FL/8RS/8Lx0//oAXP/gWv/xFHIwuj1jAoAGMV5P/AMLw07/oX7n/AMC1/wDiKD8cNPI/5AF1/wCBa/8AxFHKwuj1jaM9OlGK8p/4Xlp3/Qv3X/gWv/xFJ/wvHTv+hfuf/Apf/iKfKwuj1QqOeKOh75ryk/HDT/8AoAXP/gUv/wARSf8AC79Pz/yALn/wKX/4inZhdHraMT2qQAYryEfG/Tgf+Rfuf/Apf/iKd/wvHTsf8i/df+Ba/wDxFFmF0evgdD2owC3GK8iHxz07/oX7r/wLX/4il/4Xpp3/AEL11/4Fr/8AEUWC6PXD0IqNuteTn46aef8AmX7n/wAC1/8AiKa3xy049PD91/4Fr/8AEUWYXR6sQCTUbAcV5Ufjfp3/AEL91/4Fr/8AEU3/AIXbp/8A0ALn/wACl/8AiKVmF0epkdaaRXl3/C7NO/6AF1/4Fr/8RTT8a9P/AOgDdf8AgUv/AMRRysLo9SxSV5b/AMLq0/8A6AN1/wCBS/8AxFJ/wumw/wCgFc/+BS//ABFFmF0epH0rgvjaMeAT/wBfkX/oL1lf8Lp07P8AyAbn/wACl/8AiK53x/8AEiz8UeGzpkGlz2snnpN5jzhxhQwxjaPWmkxNo8zoooqyRe9JRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFLRRQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5523=[""].join("\n");
var outline_f5_25_5523=null;
var title_f5_25_5524="Normal anatomy umbilicus";
var content_f5_25_5524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    The normal umbilicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cilley R. Disorders of the umbilicus. In: Pediatric Surgery, Grosfeld J, O'Neill J, Coran A, Fonkalsrud E (Eds), Mosby Inc., Philadelphia 2006. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5524=[""].join("\n");
var outline_f5_25_5524=null;
var title_f5_25_5525="Pseudoephedrine and dextromethorphan: Patient drug information";
var content_f5_25_5525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine and dextromethorphan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/10/7332?source=see_link\">",
"     see \"Pseudoephedrine and dextromethorphan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pedia Relief Cough and Cold [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Children's Cold &amp; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM D;",
"     </li>",
"     <li>",
"      Benylin&reg; DM-D;",
"     </li>",
"     <li>",
"      Koffex DM-D;",
"     </li>",
"     <li>",
"      Novahistex&reg; DM Decongestant;",
"     </li>",
"     <li>",
"      Novahistine&reg; DM Decongestant;",
"     </li>",
"     <li>",
"      Robitussin&reg; Childrens Cough &amp; Cold",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702821",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pseudoephedrine, dextromethorphan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12195 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5525=[""].join("\n");
var outline_f5_25_5525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215395\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215396\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017950\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017952\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017951\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017956\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017957\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017959\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017954\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017955\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017960\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017961\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/10/7332?source=related_link\">",
"      Pseudoephedrine and dextromethorphan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_25_5526="Sonogram abn ut bleeding2";
var content_f5_25_5526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63414%7EOBGYN%2F71802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63414%7EOBGYN%2F71802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long axis sonographic view of a patient with abnormal uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endometrial echo is not well visualized and there is an area of acoustic shadowing in the posterior portion of the myometrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonohysterogram of an endometrial polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An endometrial polyp measuring 1.9 x 1.2cm is clearly visible. The stalk of the polyp can be seen extending toward the fundus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5526=[""].join("\n");
var outline_f5_25_5526=null;
var title_f5_25_5527="Superficial veins of leg anterior view";
var content_f5_25_5527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55019%7EPC%2F52340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55019%7EPC%2F52340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial veins of leg, anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 682px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial veins of lower leg, posterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5527=[""].join("\n");
var outline_f5_25_5527=null;
var title_f5_25_5528="Diagnosis of seasonal influenza in adults";
var content_f5_25_5528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of seasonal influenza in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5528/contributors\">",
"     Raphael Dolin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5528/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5528/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/25/5528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1018261820\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is an acute respiratory illness caused by influenza A or B viruses that occurs in outbreaks and epidemics worldwide, mainly during the winter season. Signs and symptoms of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower respiratory tract involvement are present, along with indications of systemic illness such as fever, headache, myalgia, and weakness. Although acutely debilitating, influenza is a self-limited infection in the general population. However, it is associated with increased morbidity and mortality in certain high-risk populations.",
"   </p>",
"   <p>",
"    In certain circumstances, the diagnosis of influenza can be made clinically, such as during an outbreak. At other times, it is important to establish the diagnosis using laboratory testing quickly, such as in the hospitalized patient with acute onset of severe pulmonary disease.",
"   </p>",
"   <p>",
"    The diagnosis of seasonal influenza in adults will be reviewed here. The diagnosis of this infection in children is discussed separately. The epidemiology, clinical manifestations, prevention, and treatment of seasonal influenza infection, as well as the diagnosis of pandemic H1N1 influenza (\"swine influenza\") and avian influenza, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262442\">",
"    <span class=\"h1\">",
"     CLINICAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64165495\">",
"    <span class=\"h2\">",
"     During outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an influenza outbreak, acute febrile respiratory illnesses brought to the attention of clinicians can be diagnosed as influenza with a high degree of certainty by clinical criteria.",
"    <strong>",
"    </strong>",
"    This was demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective pooled analysis of signs and symptoms in 3744 adolescents and adults with an influenza-like illness who participated in phase 2 and 3 trials of neuraminidase inhibitors during outbreaks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/1\">",
"       1",
"      </a>",
"      ]. The best multivariate predictor was the combination of fever and cough within 48 hours of the development of symptoms, which had a positive predictive value of 79 percent for documented influenza.",
"     </li>",
"     <li>",
"      In a study of 100 children and adults with an influenza-like illness of &lt;72 hours duration in whom there was a prevalence of laboratory-confirmed influenza infection of 72 percent based upon viral culture and 79 percent based upon reverse-transcriptase polymerase chain reaction (RT-PCR), cough (odds ratio [OR] 6.7, 95% CI 1.4-34.1) and fever (OR 3.1, 95% CI 1.4-8.0) were the only clinical factors associated with a positive RT-PCR result [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64165502\">",
"    <span class=\"h2\">",
"     Sporadic cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the utility of clinical criteria for the diagnosis of influenza during outbreaks, sporadic cases of influenza cannot be differentiated from infections caused by other respiratory viruses on clinical grounds alone and influenza virus infection may account for only a small number of such cases. In a review of 497 episodes of upper respiratory infection in elderly patients living in the community during the winters of 1992 to 1994, a pathogen was identified in 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common pathogens were rhinoviruses (52 percent) and coronaviruses (26 percent); influenza A or B viruses accounted for only 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64165488\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the use of clinical criteria for predicting the presence of influenza in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In a systematic review, 16 studies that met inclusion criteria were selected to determine the precision and accuracy of symptoms and signs of influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/4\">",
"     4",
"    </a>",
"    ]. Among patients aged 60 years or older, fever (likelihood ratio [LR] 3.8, 95% CI 2.8-5.0), malaise (LR 2.6, 95% CI 2.2-3.1), or chills (LR 2.6, 95% CI 2.0-3.3) was the strongest univariate indicator of influenza. The combination of fever, cough, and acute onset (LR 5.4, 95% CI 3.8-7.7) or both fever and cough (LR 5.0, 95% CI 3.5-6.9) also increased the likelihood of influenza in the older age group. In contrast, the presence of sneezing made influenza less likely. The authors concluded that clinical findings are helpful, but do not confirm or exclude the diagnosis of influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262449\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral diagnostic tests employing immunological and molecular techniques are becoming increasingly available. Options include rapid antigen tests, immunofluorescence assays, and reverse-transcriptase polymerase chain reaction (RT-PCR)-based testing (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ]. All are relatively rapid (range 15 minutes to 2 days), although some require considerable laboratory expertise and equipment to perform. Among these, RT-PCR is the most sensitive and specific. Rapid antigen and immunofluorescence testing are useful screening tests, but have limited sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262456\">",
"    <span class=\"h2\">",
"     Rapid antigen tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid influenza antigen tests are immunoassays that can identify influenza A and B viral nucleoprotein antigens in respiratory specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ]. The results of these tests are qualitative (positive or negative). Commercially available rapid antigen tests for influenza virus yield results in approximately 15 minutes or less, but have much lower sensitivity than RT-PCR and viral culture (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61718 \" href=\"UTD.htm?29/55/30589\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In a meta-analysis of 159 studies that evaluated rapid influenza antigen tests, the pooled sensitivity was 62.3 percent (95% CI 57.9-66.6 percent) and the pooled specificity was 98.2 percent (95% CI 97.5-98.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/11\">",
"     11",
"    </a>",
"    ]. The sensitivity was lower in adults than in children (53.9 versus 66.6 percent), and was higher for influenza A than for influenza B (64.6 versus 52.2 percent).",
"   </p>",
"   <p>",
"    Another factor that influences sensitivity is the timing of the test in relationship to clinical symptoms. Viral shedding peaks at 24 to 48 hours of illness and then rapidly declines; little or no detectable viral replication occurs in the respiratory tract after 5 to 10 days in immunocompetent hosts. Longer periods of shedding can occur in children, elderly adults, patients with chronic illnesses, and immunocompromised hosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a 2012 study that compared the 11 rapid influenza antigen tests available in the United States using a panel of 23 recently circulating influenza viruses, most tests detected viral antigen at the highest concentrations, but at lower concentrations, detection varied by test as well as by virus type and subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/12\">",
"     12",
"    </a>",
"    ]. These results suggest that rapid influenza antigen tests are likely to be most reliable early during the course of illness, when viral shedding is at its peak.",
"   </p>",
"   <p>",
"    A decision analysis performed before the availability of PCR-based testing assessed the value of rapid diagnostic testing prior to the use of neuraminidase inhibitors versus empiric use of these antiviral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/13\">",
"     13",
"    </a>",
"    ]. This analysis concluded that rapid diagnostic testing was appropriate first except during influenza epidemics. When the probability of a case being due to influenza reached 42 percent, the two strategies were equivalent. Conservative estimates for sensitivity and specificity of the available tests at the time of the analysis were used. In the previously cited meta-analysis, rapid diagnostic testing did not add to the overall cost-effectiveness of treatment if the probability of influenza was greater than 25 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/54/19303?source=see_link\">",
"     live attenuated influenza vaccine",
"    </a>",
"    (LAIV) can cause a false positive result on a rapid influenza diagnostic test, since these tests cannot differentiate between live attenuated and wild-type influenza viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, a positive test in an individual who received LAIV within the previous seven days and who also has an influenza-like illness could be caused by either LAIV or influenza virus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262463\">",
"    <span class=\"h2\">",
"     Immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct and indirect immunofluorescence antibody staining for influenza antigen detection are screening tests that have slightly lower sensitivity and specificity than viral culture, but have the benefit of yielding results within hours (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. The performance of these tests depends upon laboratory expertise as well as the quality of the specimen, since respiratory epithelial cells are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262470\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse-transcriptase polymerase chain reaction (RT-PCR) is the most sensitive and specific modality for diagnosing influenza infection, yields relatively rapid results, and differentiates between influenza types and subtypes (including pandemic H1N1 influenza and avian H5N1 influenza) (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8,15-17\">",
"     8,15-17",
"    </a>",
"    ]. Although RT-PCR takes only four to six hours to perform, it often takes longer than this for results to be available since it may not be performed in-house and may be batched with other samples. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCR-based testing can detect low quantities of viral RNA in specimens such as nasopharyngeal aspirates, bronchoalveolar lavage fluid, nasal, and throat swabs (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ]. The United States Centers for Disease Control and Prevention (CDC) has developed a test kit that can identify influenza types and subtypes, including avian influenza A (H5N1), on upper and lower respiratory tract specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A summary of available RT-PCR assays and other molecular assays for influenza viruses can be found on the CDC&rsquo;s web site (",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/pdf/professionals/diagnosis/table1-molecular-assays.pdf\">",
"     file://www.cdc.gov/flu/pdf/professionals/diagnosis/table1-molecular-assays.pdf",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262477\">",
"    <span class=\"h2\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza virus can be cultured from nasal washes, throat swabs, sputum, or bronchoalveolar lavage specimens (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    ). In one study, sputum and nasal washes were superior to throat swabs for the isolation of influenza virus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/19\">",
"     19",
"    </a>",
"    ]. Although viral culture has been the gold standard for laboratory diagnosis, it may take 48 to 72 hours or longer to see the cytopathic effects of the virus in tissue culture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since viral culture does not yield timely results, it is",
"    <strong>",
"     not",
"    </strong>",
"    used for initial clinical management [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ]. Rather, it is used for confirming screening tests and for public health surveillance. It can be used during periods of low influenza activity, especially in individuals who are epidemiologically linked to an influenza outbreak. During influenza season, cultures (or reverse-transcriptase polymerase chain reaction testing) should be performed using specimens from a subset of patients for surveillance purposes and to confirm some negative test results from immunofluorescence and rapid antigen testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262484\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is not useful for the diagnosis of acute illness since paired acute and convalescent are required to determine antibody titers (",
"    <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic testing can be used to establish the diagnosis of influenza retrospectively, using hemagglutination-inhibition, enzyme-linked immunosorbent assay (ELISA), or complement fixation. A four-fold or greater rise in antibody titers demonstrated between serum specimens obtained during acute illness and convalescent specimens obtained 10 to 14 days later is considered diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Serologic testing is useful primarily for research purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262491\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During influenza outbreaks, most patients can be diagnosed clinically as having influenza.",
"   </p>",
"   <p>",
"    For sporadic cases of influenza-like illness, there is more urgency to make a specific viral diagnosis, especially with the emergence of new viral pathogens, such as the severe acute respiratory syndrome (SARS) coronavirus. In this situation, rapid diagnostic tests such as reverse transcriptase polymerase chain reaction (RT-PCR) or enzyme immunoassay are appropriate. Viral cultures are used mainly for epidemiologic purposes to track which viruses are circulating during a given season, or for confirmatory testing.",
"   </p>",
"   <p>",
"    Detection of influenza virus can reduce inappropriate antibiotic use, guide antiviral therapy, and decrease length of emergency department visits, use of other laboratory studies, and healthcare costs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262498\">",
"    <span class=\"h2\">",
"     Whom to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the 2009 Infectious Diseases Society of America (IDSA) guidelines for the management of seasonal influenza, certain individuals should be tested for influenza if the result will influence management decisions such as initiating antiviral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibacterial therapy, performing other diagnostic tests,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    implementing infection control measures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ]. The United States Centers for Disease Control and Prevention (CDC) has also issued guidelines for the diagnosis of seasonal influenza, which are similar to the recommendations of the IDSA",
"    <span class=\"nowrap\">",
"     (file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During influenza season, influenza testing should be obtained in the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompetent outpatients who are at high risk for influenza complications who have an acute febrile respiratory illness and present within five days of illness onset. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of seasonal influenza in adults\", section on 'Definition of high risk'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunocompromised outpatients with an acute febrile respiratory illness, regardless of time since illness onset",
"     </li>",
"     <li>",
"      Inpatients with an acute febrile respiratory illness, including those with a diagnosis of community-acquired pneumonia, regardless of time since illness onset",
"     </li>",
"     <li>",
"      Individuals who develop fever and respiratory symptoms after hospital admission, regardless of time since illness onset",
"     </li>",
"     <li>",
"      If the results would be helpful for providing local surveillance data, immunocompetent individuals with an acute febrile respiratory illness who are not at high risk of complications may be tested",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that treatment, when indicated, should",
"    <strong>",
"     not",
"    </strong>",
"    be withheld while awaiting the results of diagnostic testing. Furthermore, antiviral therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be stopped based upon negative rapid influenza testing given its limited sensitivity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During any time of year, influenza testing should be performed in the following individuals if they present within five days of illness onset:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthcare workers, residents, or visitors in an institution experiencing an influenza outbreak who present with an acute febrile respiratory illness.",
"     </li>",
"     <li>",
"      Individuals who are epidemiologically linked to an influenza outbreak (eg, household and close contacts of individuals with suspected influenza, returned travelers from regions where influenza viruses may be circulating, participants in international mass gatherings, and cruise ship passengers).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once influenza activity has been documented in the region, influenza testing is",
"    <strong>",
"     not",
"    </strong>",
"    needed for otherwise healthy outpatients with signs and symptoms consistent with influenza, especially during the peak of influenza activity in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ]. In such patients, treatment decisions can be made based upon the clinical diagnosis.",
"   </p>",
"   <p>",
"    The CDC has developed algorithms for determining whether influenza diagnostic testing is indicated for individual patients when influenza viruses are circulating in the community and for investigating outbreaks in institutional or other closed settings, respectively (",
"    <a class=\"graphic graphic_algorithm graphicRef74504 \" href=\"UTD.htm?28/25/29086\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80044 \" href=\"UTD.htm?36/50/37678\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248871061\">",
"    <span class=\"h3\">",
"     H3N2 variant viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since July 2011, the CDC has reported cases of H3N2 variant (H3N2v) influenza A infection caused by reassortment of swine-origin H3N2 influenza A viruses and 2009 pandemic H1N1 influenza A viruses, most of which have occurred since July 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. H3N2v virus infection should be suspected in individuals with a febrile respiratory illness who have been exposed to swine and in individuals with a febrile respiratory illness who live in regions where H3N2v influenza cases have been detected. Clinicians who suspect H3N2v influenza infection should obtain a nasopharyngeal swab, place it in viral transport media, and contact their state or local health department to have the sample sent for influenza testing by real-time reverse-transcriptase polymerase chain reaction. The ability of rapid antigen tests to detect H3N2v influenza appears to vary substantially among the available tests. Thus, a negative rapid antigen test should not be considered conclusive evidence for lack of H3N2v influenza infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H104949276#H104949276\">",
"     \"Epidemiology of influenza\", section on 'H3N2 variant influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262505\">",
"    <span class=\"h2\">",
"     Type and handling of specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal specimens for influenza testing are nasopharyngeal aspirates, washings, and swabs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. Nasopharyngeal washings are more sensitive than nasopharyngeal swabs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/25\">",
"     25",
"    </a>",
"    ]. In immunocompetent individuals, the specimen should be obtained as soon as possible following onset of symptoms, but no later than five days after illness onset. Since immunocompromised patients may shed influenza virus for longer than five days, testing more than five days after illness onset may still be useful.",
"   </p>",
"   <p>",
"    In hospitalized patients with suspected influenza infection, specimens can be collected from different respiratory sites and on more than one day to increase the likelihood of influenza detection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ]. In particular, in mechanically ventilated patients, upper (nasopharyngeal aspirates and swabs) and lower (endotracheal aspirates and washes, bronchoalveolar lavage fluid) respiratory tract samples should be obtained if influenza infection is suspected but not yet confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specimens for influenza testing should be transported on ice and then refrigerated.",
"   </p>",
"   <p>",
"    A video showing the proper technique for nasopharyngeal specimen collection can be found at:",
"    <a class=\"external\" href=\"file://content.nejm.org/cgi/content/full/NEJMe0903992/DC1\">",
"     file://content.nejm.org/cgi/content/full/NEJMe0903992/DC1",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262512\">",
"    <span class=\"h2\">",
"     Choice of diagnostic test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations should be used for choosing the appropriate diagnostic test(s) for patients suspected to have influenza virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since reverse transcriptase polymerase chain reaction (RT-PCR) is the most sensitive and specific test for influenza viruses, it is the preferred test. It also has the benefits of yielding relatively rapid results and differentiating between influenza types and subtypes (including pandemic H1N1 influenza and H5N1 avian influenza). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"       \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=see_link\">",
"       \"Clinical manifestations and diagnosis of avian influenza\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid antigen testing or direct or indirect immunofluorescent antibody staining may be used as screening tests, but follow-up testing with RT-PCR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      viral culture should be considered in the following situations [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"       7",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A patient has a negative screening test when community influenza activity is high and laboratory confirmation of influenza infection is desired.",
"     </li>",
"     <li>",
"      A patient has a positive screening test when the community prevalence of influenza is low, making a false positive result more likely.",
"     </li>",
"     <li>",
"      A patient has had recent exposure to pigs or poultry and infection with a novel influenza A virus is a consideration.",
"     </li>",
"     <li>",
"      The likelihood of a false positive or false negative screening test result depends upon the prevalence of the disease. This is discussed below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral culture is",
"      <strong>",
"       not",
"      </strong>",
"      used for initial clinical management, but may be used for confirming screening tests and for public health surveillance.",
"     </li>",
"     <li>",
"      Serologic testing is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for the diagnosis and management of acute illness since paired acute and convalescent are required, but it may be used to establish the diagnosis of influenza retrospectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018262519\">",
"    <span class=\"h2\">",
"     Interpretation of results",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to interpret influenza test results, it is important to understand the limitations of the screening tests for influenza (rapid antigen and immunofluorescent antibody testing) and the level of influenza activity in the population being tested [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The following principles should be considered when interpreting influenza test results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive screening test result is most likely to represent a true positive result during periods of peak influenza activity in the population tested (",
"      <a class=\"graphic graphic_algorithm graphicRef59181 \" href=\"UTD.htm?26/5/26704\">",
"       algorithm 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A positive screening test result is most likely to represent a false positive result during periods of low influenza activity in the population tested, including early and late in the influenza season. A confirmatory test should be considered (RT-PCR or viral culture) in such situations (",
"      <a class=\"graphic graphic_algorithm graphicRef72005 \" href=\"UTD.htm?26/49/27408\">",
"       algorithm 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A negative screening test result is most likely to represent a true negative result during periods of low influenza activity in the population tested (",
"      <a class=\"graphic graphic_algorithm graphicRef72005 \" href=\"UTD.htm?26/49/27408\">",
"       algorithm 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A negative screening test result is most likely to represent a false negative result during periods of peak influenza activity in the population tested. A confirmatory test should be considered (RT-PCR or viral culture) in such situations (",
"      <a class=\"graphic graphic_algorithm graphicRef59181 \" href=\"UTD.htm?26/5/26704\">",
"       algorithm 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, given the limited sensitivity of the rapid antigen tests for influenza, a negative result should be interpreted with caution given the potential for a false negative result, particularly during periods of high influenza activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5528/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, treatment should",
"    <strong>",
"     not",
"    </strong>",
"    be delayed while awaiting the results of diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64165438\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization (WHO) and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and to predict the appropriate components for the annual influenza vaccine. Information is updated weekly and is available at",
"    <span class=\"nowrap\">",
"     www.cdc.gov/flu/weekly/.",
"    </span>",
"    In addition, FluNet, a database for global influenza virus surveillance, is available via the WHO web site (",
"    <a class=\"external\" href=\"file://www.who.int/influenza/gisrs_laboratory/flunet/en/\">",
"     file://www.who.int/influenza/gisrs_laboratory/flunet/en/",
"    </a>",
"    ). The typical trends of influenza activity in the United States are shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef60877 \" href=\"UTD.htm?12/3/12349\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1421049\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza is an acute respiratory illness caused by influenza A or B viruses that occurs in outbreaks and epidemics worldwide, mainly in the winter season. (See",
"      <a class=\"local\" href=\"#H1018261820\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During an influenza outbreak, acute febrile respiratory illnesses can be diagnosed as influenza with a high degree of certainty by clinical criteria.",
"      <strong>",
"      </strong>",
"      In comparison, sporadic cases of influenza cannot be differentiated from infections caused by other respiratory viruses on clinical grounds alone. (See",
"      <a class=\"local\" href=\"#H1018262442\">",
"       'Clinical diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Influenza diagnostic tests include immunofluorescence assays, rapid antigen immunoassays, and reverse transcriptase polymerase chain reaction (RT-PCR)-based testing (",
"      <a class=\"graphic graphic_table graphicRef69655 \" href=\"UTD.htm?31/2/31789\">",
"       table 1",
"      </a>",
"      ). Among these, RT-PCR is the most sensitive and specific. Rapid antigen and immunofluorescence testing are useful screening tests, but have limited sensitivity (",
"      <a class=\"graphic graphic_table graphicRef61718 \" href=\"UTD.htm?29/55/30589\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1018262449\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that individuals be tested for influenza if the result will influence management decisions such as initiating antiviral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibacterial therapy, performing other diagnostic tests,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      implementing infection control measures. Individuals who should undergo diagnostic testing include inpatients with an acute febrile respiratory illness, all immunocompromised patients with an acute febrile respiratory illness, and certain others. (See",
"      <a class=\"local\" href=\"#H1018262498\">",
"       'Whom to test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the limited sensitivity of the rapid antigen tests for influenza, a negative result should be interpreted with caution given the potential for a false negative result. Furthermore, treatment, when indicated, should",
"      <strong>",
"       not",
"      </strong>",
"      be delayed while awaiting the results of diagnostic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of seasonal influenza in adults\", section on 'Indications for treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once influenza activity has been documented in the region, influenza testing is",
"      <strong>",
"       not",
"      </strong>",
"      needed for otherwise healthy outpatients with signs and symptoms consistent with influenza, especially during the peak of influenza activity in the community. (See",
"      <a class=\"local\" href=\"#H1018262498\">",
"       'Whom to test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal specimens for influenza testing are nasopharyngeal aspirates, washings, and swabs. (See",
"      <a class=\"local\" href=\"#H1018262505\">",
"       'Type and handling of specimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since RT-PCR is the most sensitive and specific test for influenza viruses, it is the preferred test. It also has the benefits of yielding relatively rapid results and differentiating between influenza types and subtypes. (See",
"      <a class=\"local\" href=\"#H1018262512\">",
"       'Choice of diagnostic test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid antigen testing or immunofluorescence antibody staining may be used as screening tests, but follow-up testing with RT-PCR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      viral culture should be considered in certain situations, particularly if the result of the screening test is negative. (See",
"      <a class=\"local\" href=\"#H1018262512\">",
"       'Choice of diagnostic test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to interpret influenza test results, it is important to understand the limitations of the screening tests for influenza (rapid antigen and immunofluorescent antibody testing) and the level of influenza activity in the population being tested (",
"      <a class=\"graphic graphic_algorithm graphicRef59181 \" href=\"UTD.htm?26/5/26704\">",
"       algorithm 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef72005 \" href=\"UTD.htm?26/49/27408\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1018262519\">",
"       'Interpretation of results'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/1\">",
"      Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/2\">",
"      Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000; 31:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/3\">",
"      Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997; 315:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/4\">",
"      Call SA, Vollenweider MA, Hornung CA, et al. Does this patient have influenza? JAMA 2005; 293:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/5\">",
"      Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998; 15:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/6\">",
"      Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002; 50:1498.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Guidance for clinicians on the use of rapid influenza diagnostic tests. file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm (Accessed on April 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/8\">",
"      Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/9\">",
"      Hurt AC, Alexander R, Hibbert J, et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol 2007; 39:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/10\">",
"      Ikenaga M, Kosowska-Shick K, Gotoh K, et al. Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones. Diagn Microbiol Infect Dis 2008; 62:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/11\">",
"      Chartrand C, Leeflang MM, Minion J, et al. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012; 156:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/12\">",
"      Centers for Disease Control and Prevention. Evaluation of 11 commercially available rapid influenza diagnostic tests--United States, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/13\">",
"      Sintchenko V, Gilbert GL, Coiera E, Dwyer D. Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results. J Clin Virol 2002; 25:15.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. H1N1 clinicians questions and answers. file://www.cdc.gov/h1n1flu/vaccination/clinicians_qa.htm (Accessed on April 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/15\">",
"      Landry ML, Cohen S, Ferguson D. Real-time PCR compared to Binax NOW and cytospin-immunofluorescence for detection of influenza in hospitalized patients. J Clin Virol 2008; 43:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/16\">",
"      McGeer AJ. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do? Clin Infect Dis 2009; 48 Suppl 1:S14.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Diease Control and Prevention. Guidance for clinicians on the use of RT-PCR and other molecular assays for diagnosis of influenza virus infection. file://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm (Accessed on April 04, 2012).",
"    </li>",
"    <li>",
"     New CDC-developed diagnostic lab test for flu approved. file://www.cdc.gov/media/releases/2011/p0902_diag_lab.html?s_cid=2011_p0902_diag_lab.htm (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/19\">",
"      Covalciuc KA, Webb KH, Carlson CA. Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods. J Clin Microbiol 1999; 37:3971.",
"     </a>",
"    </li>",
"    <li>",
"     Treanor JJ. Influenza virus. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2060.",
"    </li>",
"    <li>",
"     Dowdle WN, Kendal AP, Noble GR. Influenza viruses. In: Diagnostic procedures for viral, rickettsial, and chlamydial infections, Lenette EH, Schmidt NJ (Eds), American Public Health Association, Washington, D.C 1979. p.603.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/22\">",
"      Centers for Disease Control and Prevention. Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count &mdash; United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61 (Early Release):1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Information on influenza A (H3N2) variant viruses (&ldquo;H3N2v&rdquo;). file://www.cdc.gov/flu/swineflu/influenza-variant-viruses-h3n2v.htm#table (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Case count: detected U.S. human infections with H3N2v by state since August 2011 file://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5528/abstract/25\">",
"      Lieberman D, Lieberman D, Shimoni A, et al. Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling. J Clin Microbiol 2009; 47:3439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15871 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-053DC9DE2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5528=[""].join("\n");
var outline_f5_25_5528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1421049\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1018261820\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262442\">",
"      CLINICAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64165495\">",
"      During outbreaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64165502\">",
"      Sporadic cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64165488\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262449\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262456\">",
"      Rapid antigen tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262463\">",
"      Immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262470\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262477\">",
"      Viral culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262484\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262491\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262498\">",
"      Whom to test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H248871061\">",
"      - H3N2 variant viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262505\">",
"      Type and handling of specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262512\">",
"      Choice of diagnostic test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018262519\">",
"      Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64165438\">",
"      INFLUENZA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1421049\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15871|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/25/29086\" title=\"algorithm 1\">",
"      Influenza testing when virus is circulating in the community",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/50/37678\" title=\"algorithm 2\">",
"      Influenza testing in institutional or closed settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/5/26704\" title=\"algorithm 3\">",
"      RIDTs during periods of high influenza activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/49/27408\" title=\"algorithm 4\">",
"      RIDTs during periods of low influenza activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15871|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12349\" title=\"figure 1\">",
"      Peak influenza activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/2/31789\" title=\"table 1\">",
"      Influenza testing methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/55/30589\" title=\"table 2\">",
"      Rapid influenza diagnostic tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_25_5529="Efficacy of hematopoietic cell transplantation in beta thalassemia major";
var content_f5_25_5529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5529/contributors\">",
"     Emanuele Angelucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5529/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5529/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/25/5529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H801568\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first successful hematopoietic cell transplantations (HCT) in beta thalassemia major (BTM) were reported in 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Since that time, almost 3000 such transplants have been performed worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/3\">",
"     3",
"    </a>",
"    ]. HCT has since become an accepted worldwide-applied curative option for those with BTM.",
"   </p>",
"   <p>",
"    The efficacy of HCT in BTM will be reviewed here. Other issues related to transplantation in this disorder, including the pre-transplant evaluation, conditioning regimens, recurrence of thalassemia, degree of replacement of the thalassemic stem cell with a normal stem cell, and long term follow-up are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=see_link\">",
"     \"Specific issues related to hematopoietic cell transplantation in beta thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16348402\">",
"    <span class=\"h1\">",
"     DEFINITION OF TERMS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This review deals with the treatment of subjects with homozygous beta thalassemia (beta thalassemia major, BTM). When the general term &ldquo;thalassemia&rdquo; is used, it will refer only to those with BTM.",
"     </li>",
"     <li>",
"      The term \"hematopoietic cell transplantation (HCT)\" will be used throughout this review as a general term to cover transplantation of hematopoietic progenitor (stem) cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"       \"Sources of hematopoietic stem cells\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801575\">",
"    <span class=\"h1\">",
"     OVERVIEW OF HCT IN THALASSEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6056166\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for performing hematopoietic cell transplantation (HCT) in beta thalassemia major is that it substitutes the high degree of ineffective erythropoiesis associated with beta thalassemia major with an allogeneic stem cell capable of effective erythropoiesis, while avoiding transfusion requirements and their attendant complications. HCT in thalassemia is therefore a form of cellular replacement therapy and serves as a model of HCT for nonmalignant diseases.",
"   </p>",
"   <p>",
"    The transplantation approach for a nonmalignant disease is different from transplantation in malignancies. In the nonmalignant disease setting, the detrimental immunologic effects (ie, graft-versus-host disease, GVHD) of the engrafted stem cells are not balanced by a beneficial graft-versus-tumor effect. This characteristic must be always considered in determining",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio and therapeutic decisions, such as the intensity of conditioning regimens, GVHD prophylaxis, stem cell source, and the use of post-transplant adoptive immunologic therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801582\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT in beta thalassemia major (BTM) was developed and grew into accepted routine clinical practice mostly following the Pesaro group experience during the 1980s and 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/2,4-9\">",
"     2,4-9",
"    </a>",
"    ]. During that period, more than 1000 unselected BTM patients were transplanted in Pesaro, with an overall 20-year survival free of thalassemic recurrence of 73 percent calculated on results in 900 consecutive patients who received HCT from an HLA-identical sibling (",
"    <a class=\"graphic graphic_figure graphicRef77686 \" href=\"UTD.htm?13/4/13391\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/10\">",
"     10",
"    </a>",
"    ]. These results have been confirmed by the Pescara group, which conducted similar studies in over 100 selected patients during the same period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3335368\">",
"    <span class=\"h3\">",
"     Prognostic system",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the end of the 1980s, the Pesaro group had developed a prognostic system to predict transplant outcome in patients younger than 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/6\">",
"     6",
"    </a>",
"    ]. This prognostic system included only three variables, all related to transfusional iron burden:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quality of chelation therapy received during the patient&rsquo;s lifetime before transplantation (regular versus not regular)",
"     </li>",
"     <li>",
"      Presence of hepatomegaly (liver edge palpable more than 2 cm below the costal margin)",
"     </li>",
"     <li>",
"      Presence of any degree of liver fibrosis at pre-transplant hepatic biopsy examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These variables stratified patients aged less than 17 years into three groups based on their having zero (Class I), one or two (Class II), or all three (Class III) of these risk factors (",
"    <a class=\"graphic graphic_table graphicRef67387 \" href=\"UTD.htm?17/2/17451\">",
"     table 1",
"    </a>",
"    ). This risk classification for pediatric patients was not applicable to adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/9\">",
"     9",
"    </a>",
"    ], most likely due to the fact that very few adult patients could have received complete and regular iron chelation therapy during their childhood years before the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    era.",
"   </p>",
"   <p>",
"    This prognostic system identified as low risk those patients who had optimal control of iron overload for their entire lives, while the high risk patients were those who had poor control of transfusion-related iron overload and resulting iron-related tissue damage to the liver. Results were impressively different in the three groups. The table reports detailed Pesaro results (",
"    <a class=\"graphic graphic_table graphicRef76537 \" href=\"UTD.htm?4/12/4300\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    From these results and from this prognostic scoring system, several conclusions could be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal medical therapy (transfusion plus regular chelation therapy) was the key to a successful transplant. Patients who had optimal long-life control of iron overload and had prevented iron related tissue damage (liver fibrosis) had overall and thalassemia-free (ie, freedom from thalassemic recurrence) survivals exceeding 90 and 80 percent, respectively.",
"     </li>",
"     <li>",
"      Patients who did not have this degree of control of iron overload had an unacceptably high transplant-related mortality approaching 50 percent.",
"     </li>",
"     <li>",
"      In the high risk group, after reduction of the intensity of the conditioning regimen by reducing the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      dose from 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to 120",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      transplant-related mortality was reduced to 18 percent, but the risk of thalassemia recurrence was increased to 30 percent.",
"     </li>",
"     <li>",
"      Adult patients had high transplant related mortality (35 percent), although with a very limited risk of thalassemia recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3335375\">",
"    <span class=\"h3\">",
"     Link between medical therapy and successful transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clearly the most relevant aspect linking medical therapy to the results of HCT is that prevention of iron overload and iron overload-related tissue damage yielded a greater probability to overcome the toxic and immunologic insults that are required to obtain and sustain engraftment following HCT. As an example, in a large retrospective study, it was demonstrated that GVHD incidence and severity were similar in the three categories of patients, but the probability of surviving GVHD differed significantly. Mortality rates following acute grade III-IV GVHD were 27, 48, and 84 percent for low, intermediate, and high risk patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This link between the efficiency of medical therapy and the efficacy of HCT served as a clear demonstration that these two approaches are reciprocally related. Optimal medical therapy is essential for successful transplant, and the prospect of a potentially curative approach is important for assuring that medical therapy is optimally carried out. Moreover, optimization of chelation status up to the time of transplant (much more feasible today because of advances in understanding and treating iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/13\">",
"     13",
"    </a>",
"    ]) could at least partially reverse the deleterious effects of iron overload.",
"   </p>",
"   <p>",
"    The growing experiences in long term follow-up after transplant have further enhanced the link between medical therapy and transplantation. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801589\">",
"    <span class=\"h2\">",
"     Current results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several centers worldwide are now performing HCT in beta thalassemia major with excellent patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/14\">",
"     14",
"    </a>",
"    ]. The different regimens that have been developed for HCT preparation and conditioning have more or less yielded the same overall survival and thalassemia-free (ie, survival without thalassemic recurrence) survival, which are now greater than 90 and 80 percent, respectively, in patients without relevant iron related tissue damage (",
"    <a class=\"graphic graphic_table graphicRef52120 \" href=\"UTD.htm?14/3/14395\">",
"     table 3",
"    </a>",
"    ). Overall survival has increased in some cases to above 90 percent even in high risk pediatric patients, although survival free of thalassemic recurrence has only been in the range of 66 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This latter observation is probably due to the reduced intensity of the preparative regimens usually required in high risk patients, with a resulting increase in graft rejection and return to the thalassemic condition.",
"   </p>",
"   <p>",
"    There is only a single report on a limited number of adult patients (n = 15) transplanted after 1997, with modest improvements in results (67 percent overall survival and 27 percent transplant-related mortality) (",
"    <a class=\"graphic graphic_table graphicRef52120 \" href=\"UTD.htm?14/3/14395\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/17\">",
"     17",
"    </a>",
"    ]. These multicenter results demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A relevant improvement was reported in all risk categories of patients.",
"     </li>",
"     <li>",
"      The importance of optimal life-long control of iron overload and prevention of iron overload-related tissue damage was confirmed.",
"     </li>",
"     <li>",
"      Reduction of conditioning regimen intensity in high-risk patients had decreased transplant-related mortality, but the risk of graft rejection remained high.",
"     </li>",
"     <li>",
"      Adult patients still had high transplant-related mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801596\">",
"    <span class=\"h2\">",
"     The Hemoglobinopathy Registry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Hemoglobinopathy Registry has been established inside the European Group for Blood and Marrow Transplantation. As of the last analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/3\">",
"     3",
"    </a>",
"    ], 2854 thalassemia patients had been transplanted by 134 centers in 34 different countries. The median age of patients registered was seven years. Analyzing patients transplanted from an HLA-identical sibling after 1990 outside the Pesaro experience (1396 patients, median age seven years old) resulted in 89 and 79 percent overall and thalassemia-free survivals, respectively. After 2000, 30 percent of the transplants have been performed outside Europe and North America. The registry report demonstrates:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      World-wide diffusion of effective CTH effective HCT procedures",
"     </li>",
"     <li>",
"      The widely reproduced high success rate",
"     </li>",
"     <li>",
"      The majority of transplant centers worldwide have decided to transplant very young patients following the dictum &ldquo;transplant as soon as possible&rdquo; arising from the Pesaro experience.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801603\">",
"    <span class=\"h1\">",
"     OTHER TRANSPLANT TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussions refer to transplants performed using an HLA-identical sibling and bone marrow as the source of stem cells. However, not all patients have this opportunity, as the statistical chance that a sibling will be HLA-identical to a given patient is only 25 percent (",
"    <a class=\"graphic graphic_figure graphicRef72917 \" href=\"UTD.htm?42/10/43169\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H5#H5\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched related donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore, there have been efforts to extend transplant opportunities by exploring alternative sources of stem cells and alternative donors, as discussed below (",
"    <a class=\"graphic graphic_table graphicRef64890 \" href=\"UTD.htm?12/1/12315\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801610\">",
"    <span class=\"h2\">",
"     Alternative sources of hemopoietic stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large majority of transplant centers continue to use bone marrow-derived stem cells rather than peripheral blood-derived stem cells. The young age of the sibling donors and the lack of a requirement for a graft-versus-tumor effect are the two most likely reasons for the predominant use of bone marrow-derived stem cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H16#H16\">",
"     \"Sources of hematopoietic stem cells\", section on 'Relative efficacy of PBPC versus bone marrow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The feasibility of using HLA-identical sibling, cord blood-derived hemopoietic stem cells for HCT in thalassemia was first reported in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/18\">",
"     18",
"    </a>",
"    ], and was associated with a decreased risk of acute and chronic GVHD and transplant-related mortality. An ongoing large, international retrospective study showed comparable overall results in patients with thalassemia using cord blood or bone marrow stem cell sources, although there was less GVHD when cord blood was used as the stem cell source [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H63572418#H63572418\">",
"     \"Sources of hematopoietic stem cells\", section on 'Umbilical cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Development of pre-implantation diagnosis for a single-gene disease and of preimplantation HLA typing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/20\">",
"     20",
"    </a>",
"    ] have made it possible to select a non-thalassemic HLA-identical infant donor for an existing patient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/21\">",
"     21",
"    </a>",
"    ]. However, this procedure raises very important ethical, legal, and financial issues. In some countries, such as Italy, embryo selection on the basis of HLA matching is not allowed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link&amp;anchor=H11#H11\">",
"     \"Preimplantation genetic diagnosis\", section on 'Increase chances of giving birth to a child with a compatible HLA type for stem cell therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link&amp;anchor=H23#H23\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\", section on 'Ethical and legal issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801617\">",
"    <span class=\"h2\">",
"     Alternative donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical development of HCT from alternative donors has been challenging and includes three possible approaches: matched unrelated donors; mismatched related donors; unrelated cord blood donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801624\">",
"    <span class=\"h3\">",
"     Matched unrelated donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of unrelated donors for HCT in malignancies has considerably expanded with improving results. Crucial determinants of this success have been the technological improvement of molecular HLA typing and the improved capability of selecting the appropriate unrelated donor.",
"   </p>",
"   <p>",
"    A multicenter GITMO study has presented results in 68 thalassemic patients transplanted using a matched unrelated donor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/22\">",
"     22",
"    </a>",
"    ]. In this group of patients (median age 15 years, range 2 to 37), overall and thalassemia-free survivals were 79 and 66 percent, respectively. In the group of 30 pediatric patients in the two lower risk Pesaro categories, overall and thalassemia-free survivals were 97 and 80 percent, whereas in the high risk group they were 65 and 54 percent, respectively.",
"   </p>",
"   <p>",
"    If stringent criteria of immunogenetic compatibility based on high resolution molecular typing are respected, results using matched unrelated donors are similar to those obtained in the HLA-matched sibling setting. It is crucial to achieve extended haplotype identity (ie, identity for the HLA-A, -B, -C, -DRB1, and &ndash;DQ loci on the same chromosome). As an example, one study has demonstrated that the risk of thalassemia recurrence after unrelated bone marrow transplantation is associated with presence of non-permissive HLA-DPB1 mismatches in the host versus graft direction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike donor searches in the case of malignant disease, in which time is of the essence, in the setting of matched unrelated donor transplantation in nonmalignant disease, there is usually no time limit to searching for the best available unrelated donor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/24\">",
"     24",
"    </a>",
"    ]. However, in addition to cost, there are two major limitations to this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The stringent, high resolution molecular matching criteria outlined above strongly limit donor availability.",
"     </li>",
"     <li>",
"      Ethnic groups with a high incidence of thalassemia are not well represented in unrelated donor registries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801631\">",
"    <span class=\"h3\">",
"     Mismatched related donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience with mismatched related donors has been limited, with sub-optimal results. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a consecutive series of 29 patients at a median follow-up of seven years, the probability of overall and thalassemia-free survivals using a mismatched related donor were 65 and 21 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study reported on the use of a haploidentical maternal donor after positive selection of CD34 positive cells in a series of 22 thalassemia patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/26\">",
"       26",
"      </a>",
"      ]. There were two transplant-related deaths (9 percent) and six graft rejections (27 percent), with 14 patients (64 percent) having sustained engraftment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801638\">",
"    <span class=\"h3\">",
"     Unrelated cord blood donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrelated cord blood HCT in thalassemia has not been explored in systematic studies; only one single center study and several retrospective multicenter studies are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Taiwan on 32 low risk patients, 27 were alive (84 percent) and transfusion-independent after a median follow-up of 27 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a follow-up report on 35 patients from the same investigators, 5-year overall survivals and thalassemia-free survivals were 88 and 74 percent, respectively, with a cumulative incidence of treatment-related mortality of 11.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fifty-one such transplants have been reported in the registries at EBMT and CIBMTR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/29\">",
"     29",
"    </a>",
"    ]. Of the 51 patients, 13 have died (25 percent) and only 16 (31 percent) had sustained engraftment, with a two-year overall survival of 77 percent. Based on these results, this approach cannot be recommended unless part of a well-designed clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22807819\">",
"    <span class=\"h2\">",
"     Alternative myeloablative preparative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of alternative myeloablative preparative regimens have been employed in patients with thalassemia undergoing HCT.",
"   </p>",
"   <p>",
"    Results are available for 60 thalassemia patients (median age: seven years; range 1 to 37) who underwent allogeneic HCT (20 HLA-identical sibling donors and 40 matched unrelated donors) after a preparative regimen consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    , treosulfan, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/30\">",
"     30",
"    </a>",
"    ]. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The cumulative incidences of graft failure and transplant-related mortality were 9 and 7 percent, respectively.",
"     </li>",
"     <li>",
"      Grades II-IV acute GVHD and limited chronic GVHD were present in eight and one patient, respectively.",
"     </li>",
"     <li>",
"      The limited number of class III (four) and adult patients (12) limits these results to good risk patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second study from China, a preparative regimen of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and thio-tepa was used in 82 consecutive patients with beta thalassemia major (52 reasonably well-matched unrelated donors [61 percent were",
"    <span class=\"nowrap\">",
"     8/8",
"    </span>",
"    antigen matches] and 30 matched related donors). At a median follow-up time of 24 months, the following results were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated three-year overall and thalassemia-free survivals were 92 and 90 percent, respectively, in the unrelated donor group, and 90 and 83 percent, respectively, in the matched related donor group.",
"     </li>",
"     <li>",
"      The cumulative incidence of graft rejection and grades III-IV GVHD were 1.9 and 9.6 percent, respectively, in the unrelated donor group, and 6.9 and 3.6, respectively, in the matched related donor group.",
"     </li>",
"     <li>",
"      Transplant-related mortality was 7.7 and 10 percent in the unrelated donor and matched related donor groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that matched related siblings are less common in China because of the nation&rsquo;s one child policy, and that many of the thalassemic children had not received regular iron chelation therapy, these results indicate that this preparative regimen along with the use of matched unrelated donors is a viable alternative in this population of poorer-risk patients. Given the relatively homogenous Chinese population, larger trials, especially in non-Chinese thalassemic populations, are necessary before this regimen can be considered a suitable, widely applicable solution for those with only unrelated donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801645\">",
"    <span class=\"h2\">",
"     Nonmyeloablative conditioning regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmyeloablative HCT conditioning regimens have the theoretical advantage of obtaining allogeneic engraftment with very low rates of early transplant-related mortality. However, the delicate balance of immunological effects required to sustain engraftment and to prevent graft rejection requires a prudent approach to the wide use of this regimen, and very few cases have been reported so far. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The limited international experience in thalassemia and sickle cell disease using such regimens has been reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/14\">",
"     14",
"    </a>",
"    ] showing overall poor results and a markedly reduced rate of sustained engraftment (only one of 11 transplants). &nbsp;A successful trial has been published in a small cohort of 11 adult patients with sickle cell disease conditioned with 300cGy of total body irradiation and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/32\">",
"     32",
"    </a>",
"    ]. However, this study is not immediately applicable to thalassemia as there are several relevant differences between the two disorders, which affect HCT-based approaches, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thalassemia major is characterized by marked erythroid expansion, severe anemia, and a need for chronic transfusion, leading to marked iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/33\">",
"       33",
"      </a>",
"      ]. Thus, a conditioning regimen capable of eradicating an expanded bone marrow and providing adequate immunosuppression to sustain engraftment, with acceptable toxicity on iron-damaged tissues, is required.",
"     </li>",
"     <li>",
"      These challenges are not present in sickle cell disease, in which chronic transfusion is not universally required, the transfusion-related iron burden is less severe, and the erythroid bone marrow is relatively less expanded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801652\">",
"    <span class=\"h1\">",
"     MIXED CHIMERISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant group of patients (11 percent of the entire Pesaro experience) develop long-term stable mixed chimerism (MC, ie, incomplete eradication of the thalassemic hematopoietic clone) after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/34\">",
"     34",
"    </a>",
"    ]. This has been confirmed by other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/11\">",
"     11",
"    </a>",
"    ]. Mixed chimeric patients, despite a limited degree of engraftment, achieve a functioning graft status characterized by normal hemoglobin levels, absence of a red cell transfusion requirement, no increase in iron burden, and a limited, not clinically relevant, degree of erythroid hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/33,35,36\">",
"     33,35,36",
"    </a>",
"    ]. Thus, in these chimeric patients, the genetic disease is under a substantially complete clinical control, without requiring complete eradication of the thalassemic hematopoietic clone.",
"   </p>",
"   <p>",
"    Immunologically, mixed chimera patients have normal lymphoid subset distribution, normal response to mitogens stimulation, normal response to allogeneic antigens and normal cytotoxicity activity. Specific aspects of the MC phenomenon that require additional attention in this setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=see_link\">",
"     \"Specific issues related to hematopoietic cell transplantation in beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is a distinct possibility that if researchers were able to transfer an efficient beta globin gene inside the thalassemic stem cell, with this gene achieving an adequate level of expression, it would not be necessary to replace the entire diseased bone marrow to obtain clinical correction of the disease. In theory, with a 100 percent expression of the transfected-modified gene, a limited (20 percent) autologous gene modified engraftment could be sufficient to obtain the required clinical effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H15642553#H15642553\">",
"     \"Treatment of beta thalassemia\", section on 'Gene therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15077999\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION VERSUS MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801659\">",
"    <span class=\"h2\">",
"     Availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical therapy of beta thalassemia major (BTM) has transformed BTM from a lethal disease of childhood to a chronic disease of adulthood, while achieving prolonged survival with good quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/37\">",
"     37",
"    </a>",
"    ]. The development of effective and safe oral chelation regimens promises to further enhance these results. Availability of resources is a central issue for thalassemia treatment, since the majority of patients with BTM live in non-industrialized countries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/38\">",
"     38",
"    </a>",
"    ]. A modern complete transfusion&ndash;chelation regimen is a high technology therapeutic approach requiring unique expertise and resources [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/13,39\">",
"     13,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3335522\">",
"    <span class=\"h2\">",
"     Cost estimates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs for these treatment modalities have been estimated, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Italian study generated an estimated mean direct cost of medical therapy in 2006 (transfusion plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      chelation) of approximately 15,000 Euros per year per patient [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A GITMO study estimated a median cost of 93,350 Euros (including pre-HCT, HCT, and one-year follow-up costs) for a hematopoietic cell transplant for acute lymphoblastic leukemia in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the costs of HCT are much higher than with non-curative medical therapy at one year, the continuing costs for patients who have undergone successful HCT for BTM from an HLA-identical family donor are much lower. Thus, in the over 90 percent of patients who do well after curative HCT from an HLA-identical donor, the total cost of HCT becomes equivalent to noncurative",
"    <span class=\"nowrap\">",
"     transfusion/chelation",
"    </span>",
"    therapy at approximately five to six years and increasingly lower thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801666\">",
"    <span class=\"h2\">",
"     Making the decision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central role of HCT in the treatment of thalassemia has been fully established [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/42\">",
"     42",
"    </a>",
"    ]. However, no prospective randomized clinical trial can be easily carried out to provide a definitive answer to the challenge of choosing between transplant and medical therapy for an individual patient. Accordingly, the decision process is highly individualized and patient-specific, and includes the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient age",
"     </li>",
"     <li>",
"      Availability of an HLA-matched sibling or matched unrelated donor",
"     </li>",
"     <li>",
"      Willingness to undergo treatment and accept its morbidity and mortality",
"     </li>",
"     <li>",
"      Cost and availability of proposed treatment",
"     </li>",
"     <li>",
"      Pretransplant risk class (",
"      <a class=\"graphic graphic_table graphicRef76537 \" href=\"UTD.htm?4/12/4300\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H3335368\">",
"       'Prognostic system'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Quality of prior transfusion and iron chelation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, parents of a child with beta thalassemia major and an HLA-identical sibling or unrelated bone marrow donor are asked to choose between two entirely different scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hematopoietic cell transplantation",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the child has had rigorous medical therapy and has an HLA-identical sibling or unrelated bone marrow donor, the likelihood of cure of the disease is approximately 90 percent, the transplant-related mortality is approximately 3 percent, and the incidence of mild, moderate, or severe chronic graft-versus-host disease is 20, 8, and 2 percent, respectively. (See",
"      <a class=\"local\" href=\"#H801589\">",
"       'Current results'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link\">",
"       \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the child or adult has not had rigorous medical therapy, the likelihood of cure of the disease following an HLA-identical bone marrow transplantation is in the range of 67 to 80 percent, with an estimated transplant-related mortality in the range of 12 to 27 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medical therapy with red cell transfusion and iron chelation",
"      </strong>",
"      : Beta thalassemia major is incurable with medical therapy. There is a lifetime requirement of blood transfusions and intensive iron chelation with their attendant costs and risks, and there may be complications associated with such long-term issues as residual iron overload, osteoporosis, leg ulcers, hypogonadism, gallstones, and possible need for splenectomy. However, if the child or adult has undergone appropriate medical care with life-long transfusion and chelation protocols, the quality of life may be quite good. As an example, in North Cyprus where such treatment programs have been in effect since the early 1980s, most of the adults with BTM have jobs; 38 percent are married and have children [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5529/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taking all of these issues into account, we believe that the balance of risks and benefits favors HCT over medical therapy for children who have received rigorous medical therapy and have an HLA-matched sibling or unrelated donor, and recommend that HCT be performed as soon as is reasonably practical following rigorous medical therapy to minimize the effects of the disease.",
"   </p>",
"   <p>",
"    For children or adults who have not received rigorous medical therapy, the balance between risks and benefits is uncertain, and the decision to pursue transplantation or medical therapy will be highly individualized and patient-specific. (See",
"    <a class=\"local\" href=\"#H801589\">",
"     'Current results'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For adults who have successfully undergone life-long rigorous medical therapy for BTM, their quality of life is good. While their overall survival with medical therapy is not fully known, if they undergo HLA-matched HCT they might expect a transplant-related mortality as high as 27 percent with a thalassemia-free survival of about 67 percent. Accordingly, the balance of risks in such patients appears to favor continuation of medical therapy over HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=see_link\">",
"       \"Patient information: Thalassemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15078037\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15078094\">",
"    <span class=\"h2\">",
"     Treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two semi-independent treatment options for beta thalassemia major (BTM): medical therapy and hematopoietic cell transplantation (HCT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy (life-long regular red cell transfusions plus iron chelation therapy), while not curative, has transformed BTM from a lethal disease of childhood to a chronic disease of adulthood, at least in the industrialized countries. The situation is completely different in non-industrialized countries where the large majority of these patients are born, and where regular transfusion and chelation programs may not be available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of beta thalassemia\", section on 'Beta thalassemia major'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although HCT can be curative, it can be associated with transplant-related mortality, graft-versus-host disease, and graft failure with disease recurrence. (See",
"      <a class=\"local\" href=\"#H801575\">",
"       'Overview of HCT in thalassemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two treatment options are interrelated, in that successful HCT (eg, high overall survival, freedom from recurrence of thalassemia, low transplant-related mortality) requires that prior red cell transfusion plus iron chelation therapy be rigorously followed from an early age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link&amp;anchor=H22#H22\">",
"     \"Chelation therapy for iron overload states\", section on 'Transfusion-dependent thalassemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15078101\">",
"    <span class=\"h2\">",
"     Who should be transplanted",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that, in preparation for possible HCT, all children with BTM receive treatment with a regular transfusion protocol along with regular iron chelation therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such treatment should be instituted and rigorously followed as early as possible, once the stigmata of the disease become evident. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of beta thalassemia\", section on 'Beta thalassemia major'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For a child with BTM who has an HLA-matched sibling or HLA-well-matched unrelated donor and who has undergone rigorous medical therapy (ie, transfusion plus high-quality iron chelation therapy), we recommend that HCT be performed as soon as is reasonably practical (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such &ldquo;low risk&rdquo; children can expect thalassemia-free survivals of 86 to 91 percent and a transplant-related mortality of 3 percent (",
"      <a class=\"graphic graphic_table graphicRef52120 \" href=\"UTD.htm?14/3/14395\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For those without an HLA-matched donor, children with prior poorly-controlled chelation therapy, and adults, transplant-related mortality can be as high as 35 to 50 percent. The risks and benefits of undergoing either curative HCT (with its high incidence of transplant-related mortality), or continuing with non-curative medical therapy (life-long transfusions and chelation therapy) are very patient specific, and a decision favoring one over the other should be made on a case-by-case basis, depending upon the values and preferences of the",
"      <span class=\"nowrap\">",
"       patient/family.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H801603\">",
"       'Other transplant techniques'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H801666\">",
"       'Making the decision'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/1\">",
"      Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet 1982; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/2\">",
"      Lucarelli G, Polchi P, Izzi T, et al. Allogeneic marrow transplantation for thalassemia. Exp Hematol 1984; 12:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/3\">",
"      Baronciani D, Elauroci N, Dini G, Peters C. Spreading and outcome of hemopietic stem cell transplantation in beta thalassemia major. Data from EBMT registry. Bone Marrow Transplant 2011; 46:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/4\">",
"      Lucarelli G, Polchi P, Galimberti M, et al. Marrow transplantation for thalassaemia following busulphan and cyclophosphamide. Lancet 1985; 1:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/5\">",
"      Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with advanced thalassemia. N Engl J Med 1987; 316:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/6\">",
"      Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/7\">",
"      Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/8\">",
"      Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/9\">",
"      Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/10\">",
"      Angelucci E, Baronciani D. Allogeneic stem cell transplantation for thalassemia major. Haematologica 2008; 93:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/11\">",
"      Di Bartolomeo P, Santarone S, Di Bartolomeo E, et al. Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol 2008; 83:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/12\">",
"      Gaziev D, Polchi P, Galimberti M, et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997; 63:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/13\">",
"      Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/14\">",
"      Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/15\">",
"      Chiesa R, Cappelli B, Crocchiolo R, et al. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant 2010; 16:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/16\">",
"      Bertaina A, Bernardo ME, Mastronuzzi A, et al. The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation. Ann N Y Acad Sci 2010; 1202:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/17\">",
"      Gaziev J, Sodani P, Polchi P, et al. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Ann N Y Acad Sci 2005; 1054:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/18\">",
"      Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/19\">",
"      Nabbara K, Locatelli F, Rocha V, et al. A multicentric comparative analysis of outcomes of HLA identical related cord blood and bone marrow transplantation in patients with beta-thalassemia or sickle cell disease. Biol Blood Marrow Transplant 2008; S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/20\">",
"      Fiorentino F, Biricik A, Karadayi H, et al. Development and clinical application of a strategy for preimplantation genetic diagnosis of single gene disorders combined with HLA matching. Mol Hum Reprod 2004; 10:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/21\">",
"      Verlinsky Y, Rechitsky S, Sharapova T, et al. Preimplantation HLA testing. JAMA 2004; 291:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/22\">",
"      La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005; 1054:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/23\">",
"      Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006; 107:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/24\">",
"      La Nasa G, Littera R, Locatelli F, et al. Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients. Biol Blood Marrow Transplant 2007; 13:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/25\">",
"      Gaziev D, Galimberti M, Lucarelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplant 2000; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/26\">",
"      Sodani P, Isgr&ograve; A, Gaziev J, et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2010; 115:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/27\">",
"      Jaing TH, Chen SH, Tsai MH, et al. Transplantation of unrelated donor umbilical cord blood for nonmalignant diseases: a single institution's experience with 45 patients. Biol Blood Marrow Transplant 2010; 16:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/28\">",
"      Jaing TH, Hung IJ, Yang CP, et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant 2012; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/29\">",
"      Ruggeri A, Eapen M, Scaravadou A, et al. Survey of outcomes of unrelated cord blood transplant in patients with haemoglobinopathies: a retrospective study on behalf of CIBMTR, NYCB and EUROCORD. Bone Marrow Transplant 2010; 45:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/30\">",
"      Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012; 120:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/31\">",
"      Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in &beta;-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood 2012; 120:3875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/32\">",
"      Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/33\">",
"      Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000; 96:3624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/34\">",
"      Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87:3494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/35\">",
"      Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/36\">",
"      Alfred A, Vora AJ. What is the minimum level of donor chimerism necessary to sustain transfusion independence in thalassaemia? Bone Marrow Transplant 2011; 46:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/37\">",
"      Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/38\">",
"      Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/39\">",
"      Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/40\">",
"      Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008; 24:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/41\">",
"      Orsi C, Bartolozzi B, Messori A, Bosi A. Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant 2007; 40:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/42\">",
"      Lucarelli G, Weatherall DJ. For debate: bone marrow transplantation for severe thalassaemia (1). The view from Pesaro (2). To be or not to be. Br J Haematol 1991; 78:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5529/abstract/43\">",
"      Bozkurt G. Results from the north cyprus thalassemia prevention program. Hemoglobin 2007; 31:257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3554 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5529=[""].join("\n");
var outline_f5_25_5529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15078037\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801568\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16348402\">",
"      DEFINITION OF TERMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801575\">",
"      OVERVIEW OF HCT IN THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6056166\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801582\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3335368\">",
"      - Prognostic system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3335375\">",
"      - Link between medical therapy and successful transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801589\">",
"      Current results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801596\">",
"      The Hemoglobinopathy Registry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801603\">",
"      OTHER TRANSPLANT TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801610\">",
"      Alternative sources of hemopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801617\">",
"      Alternative donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H801624\">",
"      - Matched unrelated donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H801631\">",
"      - Mismatched related donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H801638\">",
"      - Unrelated cord blood donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22807819\">",
"      Alternative myeloablative preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801645\">",
"      Nonmyeloablative conditioning regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801652\">",
"      MIXED CHIMERISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15077999\">",
"      TRANSPLANTATION VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801659\">",
"      Availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3335522\">",
"      Cost estimates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801666\">",
"      Making the decision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15078037\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15078094\">",
"      Treatment options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15078101\">",
"      Who should be transplanted",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3554|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/4/13391\" title=\"figure 1\">",
"      Results of consecutive unselected HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/10/43169\" title=\"figure 2\">",
"      Donor selection HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17451\" title=\"table 1\">",
"      Pre BMT risk class in beta thal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/12/4300\" title=\"table 2\">",
"      Historical Pesaro results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/3/14395\" title=\"table 3\">",
"      Updated results of HCT in thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/1/12315\" title=\"table 4\">",
"      Transplantation approaches in thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=related_link\">",
"      Patient information: Thalassemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=related_link\">",
"      Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_25_5530="Rapidly growing mycobacterial infections in HIV-negative patients";
var content_f5_25_5530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapidly growing mycobacterial infections in HIV-negative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5530/contributors\">",
"     David E Griffith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5530/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/25/5530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/25/5530/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/25/5530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly growing mycobacteria (RGM) include three clinically relevant species, Mycobacterium fortuitum, M. chelonae, and M. abscessus (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). The RGM are environmental organisms found worldwide that usually grow in subculture within one week (eg, rapidly as compared to other mycobacteria). The most common of this group of organisms encountered in clinical practice or in the clinical microbiology laboratory is M. fortuitum.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of RGM infections in HIV-negative patients will be discussed here. The clinical manifestations and diagnosis of nontuberculous mycobacterial (NTM) pulmonary infection (other than those caused by RGM), microbiology of NTM infection, infection due to M. marinum, and M. ulcerans are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of nontuberculous mycobacterial (NTM) infections is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical disease spectrum caused by the most common clinically relevant rapidly growing mycobacteria (RGM) (M. fortuitum, M. chelonae, and M. abscessus) varies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M. fortuitum causes human infection primarily by direct inoculation, including primary skin and soft tissue infections [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/1\">",
"       1",
"      </a>",
"      ], surgical wound infections [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/2\">",
"       2",
"      </a>",
"      ], and catheter-related sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/3\">",
"       3",
"      </a>",
"      ]. Rarely, other infections occur such as keratitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/4\">",
"       4",
"      </a>",
"      ], prosthetic valve endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/5\">",
"       5",
"      </a>",
"      ], cervical lymphadenitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/5\">",
"       5",
"      </a>",
"      ], and pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/3\">",
"       3",
"      </a>",
"      ]. The majority of M. fortuitum respiratory isolates are found in individuals with other underlying pulmonary diseases, such as bronchiectasis, and represent colonization or transient infection [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      M. chelonae, in contrast, primarily causes human infection in immunosuppressed patients, including hematogenously disseminated disease. M. chelonae may also cause surgical wound infections and keratitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      M. abscessus is the most pathogenic of the RGM group and the RGM most likely to cause pulmonary infection, primarily in patients with underlying lung disease. M. abscessus pulmonary disease also occurs in patients with no known underlying lung disease in a manner similar to Mycobacterium avium complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary disease due to RGM is predominantly due to M. abscessus (80 percent of cases) and M. fortuitum (15 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Various series have emphasized associations of RGM pulmonary infection with esophageal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/8\">",
"     8",
"    </a>",
"    ], malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], underlying lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], and rheumatologic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report reviewed the epidemiology and clinical manifestations of 154 patients with RGM pulmonary disease, 82 percent of whom had M. abscessus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/7\">",
"     7",
"    </a>",
"    ]. The disease was diagnosed according to American Thoracic Society criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age at onset was 58 years (range 1 to 85 years).",
"     </li>",
"     <li>",
"      The majority of these patients were Caucasian (83 percent) and female (65 percent), while only 34 percent were current or former smokers.",
"     </li>",
"     <li>",
"      The diagnosis was usually not established until more than two years after the onset of symptoms.",
"     </li>",
"     <li>",
"      Cough was the most frequent symptom at presentation (71 percent), but fever, weight loss, hemoptysis, and dyspnea were also common.",
"     </li>",
"     <li>",
"      The chest radiograph showed involvement of three or more lobes in more than one-half of cases. An interstitial pattern, mixed interstitial and alveolar infiltrates, and a reticulonodular pattern were all seen with approximately equal frequency (36 to 40 percent), while cavitation was infrequent (16 percent). These findings are similar to findings in patients with",
"      <span class=\"nowrap\">",
"       nodular/bronchiectatic",
"      </span>",
"      (non-cavitary) M. avium complex (MAC) lung disease.",
"     </li>",
"     <li>",
"      Death was attributed directly to progressive RGM lung disease with respiratory failure in 21 cases (14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a case series and literature review that characterized RGM infections in 341 patients with cancer, pulmonary RGM infections occurred most frequently (47 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/10\">",
"     10",
"    </a>",
"    ]. The mean age of patients with pulmonary RGM infection was 55 and the most common type of malignancy was solid tumor (in 60 percent). Underlying lung disease was present in 70 percent of patients. The most common species involved were M. fortuitum, M. abscessus, and M. chelonae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lymphadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial lymphadenitis, especially cervical lymphadenitis, in children due to RGM is predominantly caused by M. abscessus and M. fortuitum. However, M. avium complex is responsible for 80 percent of all nontuberculous mycobacterial lymphadenitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link&amp;anchor=H2272512896#H2272512896\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated infection with M. chelonae and M. fortuitum is uncommon. A review of the literature from the early 1990s identified 54 cases over 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/15\">",
"     15",
"    </a>",
"    ]. The diseases occurred most commonly in patients who had profound immunosuppression and presented as multiple subcutaneous nodules (pseudo erythema nodosum) or abscesses that drained spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case series and literature review of cancer patients with RGM infections described above, 26 (8 percent) had disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/10\">",
"     10",
"    </a>",
"    ]. Disseminated infections occurred most commonly in patients with hematologic malignancy (83 percent of cases). Eighty-seven percent of patients had undergone recent chemotherapy. The most common species involved were M. abscessus (46 percent), M. chelonae (27 percent), and M. fortuitum (23 percent). Among the 22 patients in whom the outcome was reported, 15 (68 percent) died, including seven who died from RGM infection or with RGM infection as a contributing factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin and soft tissue infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;RGM are an uncommon cause of soft tissue infection. A high index of suspicion is necessary for diagnosis. Signs and symptoms include nodules (frequently with purple discoloration), recurrent abscesses, or chronic discharging sinuses.",
"   </p>",
"   <p>",
"    In a retrospective case series of 63 patients with skin and soft tissue infections due to RGM, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M. fortuitum infections were more likely to present as a single lesion (89 percent).",
"     </li>",
"     <li>",
"      M. chelonae and M. abscessus were more likely to present as multiple lesions (62 percent).",
"     </li>",
"     <li>",
"      Patients with multiple lesions were more likely to be immunosuppressed (67 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RGM cause severe skin and soft-tissue infections in association with nail salon whirlpool footbaths [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Suboptimal cleaning of footbaths appears to increase the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/20\">",
"     20",
"    </a>",
"    ]. An outbreak of furunculosis due to M. fortuitum was reported in patients using footbaths in a pedicure salon; the organism with the same pulsed field gel electrophoretic pattern observed in the patients was isolated from the footbaths [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/18\">",
"     18",
"    </a>",
"    ]. Over 100 pedicure customers had prolonged boils on the lower legs that left scars when healed.",
"   </p>",
"   <p>",
"    RGM have also been associated with skin infections after tattooing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In 2012, an outbreak of 19 cases of M. chelonae infections following receipt of a tattoo from a single parlor in New York was ultimately linked to unopened bottles of ink that had been pre-diluted by the manufacturer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/24\">",
"     24",
"    </a>",
"    ]. A subsequent investigation by the United States Centers for Disease Control and Prevention identified several other",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6133a3.htm?s_cid=mm6133a3_w\">",
"     clusters of post-tattoo RGM infections",
"    </a>",
"    in other states, some of which were also linked to contaminated ink [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients experienced an erythematous, papular rash along the inked areas of the skin that developed one to three weeks following receipt of the tattoo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Musculoskeletal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the musculoskeletal system with RGM usually involves tenosynovitis and occurs from either percutaneous inoculation (eg, trauma or surgery) or hematogenous seeding. The clinical course is indolent, slowly progressive, and destructive, in part because of a delay in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prosthetic device infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections related to prosthetic devices have been described with tympanostomy tubes, pacemakers, and prosthetic joints [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. As an example, a case series identified 21 cases of chronic otitis media after tympanostomy tube placement caused by M. abscessus; the authors noted that mycobacteria should be considered as a cause of refractory post-tympanostomy tube otorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36457?source=see_link\">",
"     \"Prevention and management of tympanostomy tube otorrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another case series with a review of the literature identified 18 cases of prosthetic joint infection, which included the knee, hip, and elbow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/30\">",
"     30",
"    </a>",
"    ]. The implicated organisms included M. fortuitum (n = 10), M. chelonae (n = 6), M. smegmatis (n = 1), and M. abscessus (n = 1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical site infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue infections due to RGM are often associated with treatment in health care facilities, both inpatient and outpatient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/31\">",
"     31",
"    </a>",
"    ]. Postoperative infections with RGM have occurred following cosmetic surgery procedures, augmentation mammoplasty, laser in situ keratomileusis (LASIK), and heart surgery, including reports from the northeastern, southeastern, and southern coastal United States and from more tropical countries, such as Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. Nonsterile water (or ice made from nonsterile water) is a frequent source of RGM in nosocomial infections. Avoidance of nonsterile tap water is the single most important factor for preventing nosocomial RGM infections.",
"   </p>",
"   <p>",
"    Infection is characterized by multiple recurrent abscesses around the surgical wound. Identification of the etiologic mycobacterium is often delayed because only routine cultures are obtained and the culture plates are discarded by the laboratory after failing to grow in a few days.",
"   </p>",
"   <p>",
"    Illustrative cases include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Illicit soft-tissue augmentation in New York City resulted in an outbreak of M. abscessus infection in 2002, due to contamination of the hyaluronic acid derivative used in the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      M. chelonae was responsible for surgical site infections in four patients undergoing facelifts in New Jersey in 2002 and 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/39\">",
"       39",
"      </a>",
"      ]. Infection was traced to preparations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      that were used to mark tissues in preparation for the surgery; molecular typing confirmed the identity of strains from the patients and from a number of sources of methylene blue used in the medical centers.",
"     </li>",
"     <li>",
"      Postoperative infection involving 10 patients after LASIK in Brazil was identified following the appearance of corneal infiltrates in the third postoperative week [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/36\">",
"       36",
"      </a>",
"      ]. Diagnostic workup identified M. chelonae by culture obtained by direct scraping of the cornea or by lifting the flap.",
"     </li>",
"     <li>",
"      Mycobacterium abscessus was responsible for an outbreak of wound infections among 20 Dominican Republic \"lipotourists\" due to this pathogen highlighted the risks of infection associated with surgical procedures performed in settings with inadequate infection control practices [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An epidemic of surgical site infections occurred following video-assisted surgeries occurred in Rio de Janeiro, Brazil [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/41\">",
"       41",
"      </a>",
"      ]. Of 1051 possible cases at 63 hospitals, 302 cases at 38 hospitals were found to be caused by M. abscessus subspecies bolletii (previously classified as M. massiliense [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/42\">",
"       42",
"      </a>",
"      ], 130 probable cases and 172 confirmed cases). A single clone of M. bolletii was detected in 74 of the 148 isolates that were sequenced, and five of five isolates tested were found to be tolerant to the glutaraldehyde solution that was used to sterilize surgical instruments. The epidemic ended after the use of glutaraldehyde was discontinued or following interruptions of surgeries.",
"     </li>",
"     <li>",
"      Sixteen patients under the care of a single physician developed skin nodules at the site of mesotherapy injections, most of which were caused by M. chelonae [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/33\">",
"       33",
"      </a>",
"      ]. Mesotherapy involves the subcutaneous injection of small quantities of substances, such as vitamins, silica, or lecithin, for the purpose of fat or wrinkle reduction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Catheter-related infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. fortuitum and M. chelonae may cause catheter-related bacteremia in patients with cancer. A case series from MD Anderson Cancer Center identified 15 patients with catheter-related bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients with either bacteremia or catheter site infection responded to catheter removal and antibiotic therapy. Tunnel infections, however, required surgical excision.",
"   </p>",
"   <p>",
"    In a case series and literature review of cancer patients with RGM infections, catheter-associated bloodstream infections occurred most commonly in patients with hematologic malignancies (58 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/10\">",
"     10",
"    </a>",
"    ]. M. mucogenicum was the most common species (30 percent), followed by M. fortuitum (22 percent), and M. chelonae (15 percent). The high rate of M. mucogenicum infection compared with other studies is most likely due to the fact that three of the studies included in this review involved outbreaks of infection caused by M. mucogenicum.",
"   </p>",
"   <p>",
"    RGM have also been reported as a cause of infection complicating long-term peritoneal dialysis catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of rapidly growing mycobacteria (RGM) infection is important because of the need to distinguish RGM from M. tuberculosis, since the latter requires public health tracking, whereas the former does not. In addition, the RGM are not susceptible in vitro to antituberculous drugs, and treatment requires antimicrobial therapy based on susceptibility results that vary between different RGM species. When cultures are submitted, the lab should be alerted to the possibility of RGM. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Susceptibility testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pulmonary disease caused by RGM is usually not difficult if a combination of clinical, radiographic, and bacteriologic criteria is used. Minimal evaluation should include three or more sputum samples for acid-fast bacilli (AFB) and efforts to exclude other confounding disorders, such as tuberculosis and lung malignancy. In most patients, a diagnosis can be made without a lung biopsy. Although American Thoracic Society criteria are based on experience with M. avium complex infection, there is no reason to believe these criteria would not be applicable to other species [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/14\">",
"     14",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    )&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\", section on 'Diagnostic criteria for pulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonpulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis for nonpulmonary disease is made by culture of the specific pathogen from drainage material or tissue biopsy. The isolation of organisms from sterile, closed sites, such as bone marrow or blood or from a skin biopsy (in the setting of multiple lesions), is diagnostic of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mycobacterial species identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important information clinicians require when the laboratory reports an AFB positive smear is whether the positive smear is due to M. tuberculosis or a nontuberculous mycobacterium (NTM).",
"   </p>",
"   <p>",
"    Most clinical and public health laboratories now use one or more rapid diagnostic methods for species identification [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/47\">",
"     47",
"    </a>",
"    ]. These rapid methods are recommended for identification of the NTM when possible; they include high-pressure liquid chromatography (HPLC), and commercial DNA probes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commercial nonradiolabeled DNA probes complementary to ribosomal RNA are available for identifying isolates of M. tuberculosis, M. gordonae, M. kansasii, M. avium, and M. intracellulare. They are highly sensitive and specific, providing species identification using a culture directly from BACTEC broth within two to four hours. There are no probes available for the RGM.",
"   </p>",
"   <p>",
"    The HPLC examines the mycolic acid fingerprint patterns that differ among most species or complexes of mycobacteria and can thus be used to speciate NTM, including RGM [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/48\">",
"     48",
"    </a>",
"    ]. However, HPLC cannot reliably differentiate between M. abscessus and M. chelonae. Only molecular methods, such as polymerase chain reaction (PCR) restriction endonuclease assay (PRA) can reliably differentiate between these two RGM species.",
"   </p>",
"   <p>",
"    Antibiotic susceptibility testing can also provide valuable clues to the species identification of RGM as each species has a relatively specific in vitro antibiotic susceptibility pattern (see below). As an example, M. abscessus, but not M. chelonae isolates, are usually susceptible in vitro to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility testing should be performed on all clinically significant isolates including isolates that have been recovered after treatment failure or relapse because of differences in susceptibilities among species of rapidly growing mycobacteria.",
"   </p>",
"   <p>",
"    Mycobacterium fortuitum, M. abscessus, and M. chelonae are resistant to the antituberculosis agents, but they are susceptible to a number of traditional antibacterial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/1,49-54\">",
"     1,49-54",
"    </a>",
"    ]. As a result, susceptibility testing of RGM should not be performed with the antituberculosis agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ), but should be performed with antibacterial drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , imipenem, the fluoroquinolones, a sulfonamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The susceptibility testing method for RGM recommended by the Clinical and Laboratory Standards Institute (CLSI) is the broth microdilution method.",
"   </p>",
"   <p>",
"    A novel macrolide resistance gene, erm, has been identified in M. fortuitum and M. abscessus subspecies abscessus, but not M. chelonae or M. abscessus ssp bolletii (also referred to as M. massiliense), which has an inactive erm gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/55\">",
"     55",
"    </a>",
"    ]. These taxonomic designations are confusing because many investigators still refer to the M. abscessus ssp without an active erm gene as M. massiliense as opposed to M. abscessus ssp bolletii. While accurate species and subspecies identification of these isolates is important, the most important information for the clinician is determination of whether a clinical isolate has an active erm gene. The erm gene is an inducible macrolide resistance gene that may not be reflected in the minimum inhibitory concentration (MIC) of the organism for macrolides. In other words, M. fortuitum and M. abscessus ssp abscessus isolates may be resistant to macrolides in vivo but may still exhibit a \"susceptible\" MIC in vitro on initial in vitro susceptibility testing. All M. abscessus isolates, including M. abscessus ssp abscessus and M. abscessus ssp bolletii (also referred to as M. massiliense) should have MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    determined before and after incubation with clarithromycin to evaluate the presence of an active erm gene. Mutations to this gene can occur that restore the in vivo macrolide susceptibility.",
"   </p>",
"   <p>",
"    The different macrolides appear to have variable effects on erm gene induction. In an in vitro study of clinical isolates of M. abscessus, the baseline MIC was lower with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/56\">",
"     56",
"    </a>",
"    ]. However, incubation with clarithromycin led to greater erm gene induction and higher MICs at 14 days compared with incubation with azithromycin. Accordingly, when tested in a mouse model of M. abscessus lung infection, short-term treatment with azithromycin led to greater declines in bacterial counts than clarithromycin. Such differences after exposure to clarithromycin versus azithromycin were not seen with clinical isolates of M. bolletii, which does not possess an inducible erm gene.",
"   </p>",
"   <p>",
"    The therapeutic implications of these findings &ndash; the presence of the erm gene and its variable induction by different macrolides &ndash; are unknown. However, the recognition of an inducible macrolide resistance gene may offer some explanation for the poor response of M. fortuitum and M. abscessus ssp abscessus to macrolide-based regimens. It is also apparent that M. abscessus isolates that do not have an active or functional erm gene respond better clinically to macrolide-based regimens than do those isolates with an active, functional erm gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled clinical trials of treatment for disease caused by rapidly growing mycobacteria (RGM), comparing one form of treatment with another or with no drug treatment at all, have been performed. Thus, our treatment suggestions are based on case series, in vitro susceptibility testing, and the clinical experience of experts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/49-52,57,58\">",
"     49-52,57,58",
"    </a>",
"    ]. Patients with RGM infections should be treated in consultation with an infectious diseases specialist.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    has historically been the mainstay of oral therapy for these species; however, with the demonstration of inducible resistance to macrolides in several RGM species, including M. abscessus and M. fortuitum, the role of macrolides in multidrug treatment regimens must be determined for each patient and each RGM clinical isolate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Susceptibility patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the rapidly growing mycobacteria are generally resistant to antituberculosis agents but are variably susceptible to a number of traditional antibacterial drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/1,49-54\">",
"     1,49-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. fortuitum is the most antibiotic-susceptible of the rapidly growing mycobacteria. The susceptibility pattern of isolates of M. fortuitum is generally:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (100 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      (100 percent)",
"     </li>",
"     <li>",
"      Sulfonamides (100 percent)",
"     </li>",
"     <li>",
"      Imipenem (100 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      (86 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      (80 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (80 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to note that an inducible macrolide resistance gene has been identified, which may lead to in vivo resistance despite in vitro susceptibility (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (50 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      (50 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The susceptibility pattern of isolates of M. abscessus ssp abscessus is generally:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (100 percent) on initial in vitro susceptibility testing; however, after incubation in vitro with clarithromycin and induction of the erm gene, most isolates will demonstrate MICs in the &ldquo;resistant&rdquo; range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to note that an inducible macrolide resistance gene has been identified, which may lead to in vivo resistance despite in vitro susceptibility (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clofazimine (90 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (90 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      (70 percent)",
"     </li>",
"     <li>",
"      Imipenem (50 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      (23 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The susceptibility pattern of isolates of M. abscessus ssp bolletii (M. massiliense) are similar to M. abscessus ssp abscessus with the notable exception that they do not demonstrate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance after exposure in vitro to clarithromycin.",
"   </p>",
"   <p>",
"    The susceptibility pattern of isolates of M. chelonae is generally:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (80 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       Tobramycin",
"      </a>",
"      (100 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (100 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      (75 percent)",
"     </li>",
"     <li>",
"      Imipenem (60 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      (54 percent)",
"     </li>",
"     <li>",
"      Clofazimine (25 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (25 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (20 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372828830\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of patients with M. abscessus pulmonary disease between 2001 and 2008 who were treated with medical therapy with or without surgical therapy, 69 patients were followed for a mean duration of 34 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/59\">",
"     59",
"    </a>",
"    ]. Antimicrobial regimens were chosen based upon drug susceptibility results and patient tolerance. Sixteen different antibiotics were used in 42 combinations. Ninety-seven percent of patients received a macrolide; 74 percent received a macrolide and IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    with or without another antibiotic. Patients received a mean of 4.6 drugs over the course of treatment, with a median of six months of IV antibiotic-months.",
"   </p>",
"   <p>",
"    Cough, sputum production, and fatigue remained stable, improved, or resolved in 80, 69, and 59 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/59\">",
"     59",
"    </a>",
"    ]. Twenty of 69 patients (29 percent) remained culture positive, 16 (23 percent) converted to negative but later relapsed, 33 (48 percent) converted to negative and remained negative, and 17 (16 percent) died during the study period. Significantly more cultures became negative and remained negative for at least one year among the 24 patients who underwent surgery compared with those who received only medical therapy. Indications for surgery included localized bronchiectasis (88 percent), cavitary disease (37 percent), and hemoptysis (11 percent). Surgical complications included postoperative hemorrhage, bronchopleural fistula, frozen shoulder, wound infection, brachial plexus injury, and respiratory failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death; each complication occurred in one patient.",
"   </p>",
"   <p>",
"    In another retrospective study of 65 patients with M. abscessus pulmonary disease between 2000 and 2007, patients were treated with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    in combination with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for one month, followed by a combination of clarithromycin, ciprofloxacin, and doxycycline; the median duration of therapy was 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/60\">",
"     60",
"    </a>",
"    ]. Response rates were 83 percent based on symptoms and 74 percent based on high-resolution computed tomography findings. Conversion of sputum cultures to negative with persistence of negative cultures for &gt;12 months occurred in 38 patients (58 percent). These rates were significantly lower in patients whose isolates were resistant to clarithromycin compared with those who isolates were susceptible or intermediate to clarithromycin (17 versus 64 percent). Because of adverse reactions (neutropenia, thrombocytopenia, hepatotoxicity), cefoxitin was discontinued in 60 percent of patients after treatment for a median of 22 days. Surgical resection was performed in 22 percent of patients.",
"   </p>",
"   <p>",
"    Although this study suggests that favorable outcomes can be achieved with a regimen that involves oral combination therapy for the majority of the treatment course, several important limitations have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/61\">",
"     61",
"    </a>",
"    ]. An additional issue for this and some other published studies is that some M. abscessus isolates are now subspeciated as M. abscessus subspecies bolletii (previously M. massiliense), which contains an inactive erm gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/42\">",
"     42",
"    </a>",
"    ]. If many of the isolates in this study represented M. abscessus subspecies bolletii, then a favorable response to the three drug oral regimen would have been expected. Another limitation of both of the studies described above is that the independent effect of surgery on response was not assessed. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Susceptibility testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is generally agreed that inclusion of a macrolide in the treatment regimen of an M. abscessus isolate without an active or functional erm gene is appropriate, while the inclusion of macrolide in the treatment regimen of an isolate with an active erm gene is still controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Limited skin and soft tissue infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest oral therapy with two agents for a minimum of four months to which the isolate is susceptible for limited skin and soft tissue infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Regimens include two of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (1 DS twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (100 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (500 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (250 to 500 mg daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to note that an inducible macrolide resistance gene has been identified among M. fortuitum and M. abscessus isolates (but not among M. chelonae isolates), which may lead to in vivo resistance despite in vitro susceptibility (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monotherapy with these agents should",
"    <strong>",
"     not",
"    </strong>",
"    be used because of acquired resistance and treatment failures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe disease due to RGM is considered infection that has progressed beyond localized skin involvement, including skin and soft tissue disease, bone involvement, pulmonary disease, and other forms of disseminated infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     M. fortuitum and M. chelonae",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend initial parenteral therapy with at least two agents to which the isolate is susceptible for severe infection due to M. fortuitum or M. chelonae until clinical improvement is evident (two to six weeks), followed by oral therapy with two agents if susceptibility patterns allow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/57\">",
"     57",
"    </a>",
"    ]. For severe skin and soft tissue infection, bone involvement, and disseminated disease, treatment duration is at least 6 to 12 months. For pulmonary disease, treatment duration includes 12 months of sputum culture negativity while on therapy.",
"   </p>",
"   <p>",
"    Possible parenteral agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily to adult patients with normal renal function); preferred aminoglycoside for M. fortuitum infection. The amikacin dose should be adjusted to provide peak serum levels in the 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      range. A lower dose (10",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      should be used in patients over the age of 50.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       Tobramycin",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously per day divided in two to three doses); preferred aminoglycoside for M. chelonae infection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      (12 g per day intravenously divided in four or six doses).",
"     </li>",
"     <li>",
"      Imipenem (1 g intravenously every six hours).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (500 to 750 mg intravenously or orally once daily).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A typical regimen includes an aminoglycoside plus two of the latter three drugs, although a combination of the latter three drugs can also be used, particularly in patients who cannot tolerate an aminoglycoside.",
"   </p>",
"   <p>",
"    Oral agents that can be used following parenteral therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (1 DS tab twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (100 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (500 to 750 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (250 to 500 mg daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to note that an inducible macrolide resistance gene has been identified, which may lead to in vivo resistance despite in vitro susceptibility (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     M. abscessus ssp abscessus",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. abscessus ssp abscessus pulmonary infection is more difficult to treat because isolates are usually susceptible in vitro only to the parenteral agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , and imipenem, and to the oral macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ). Despite aggressive medical therapy, cure is unusual with M. abscessus.",
"   </p>",
"   <p>",
"    We recommend initial combination therapy with three agents for severe infections, including pulmonary disease, due to M. abscessus ssp abscessus for four to eight weeks with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in two doses) plus either",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      (2 g intravenously every four hours) or",
"     </li>",
"     <li>",
"      Imipenem (1 g intravenously every six hours) plus",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (250 to 500 mg daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to note that an inducible macrolide resistance gene has been identified, which may lead to in vivo resistance despite in vitro susceptibility. Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      exposure appears to lead to greater macrolide resistance gene induction in M. abscessus than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , additional clinical studies are warranted before one macrolide can be recommended over another (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial therapy should be followed by an oral macrolide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) plus at least one other agent to which the organism is susceptible to complete a 6 to 12 month course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Additional oral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional oral agents with limited clinical experience but in vitro activity include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/53,62\">",
"     53,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy depends upon the site and severity of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For localized skin and soft tissue infections, we suggest a minimum of four months of therapy.",
"     </li>",
"     <li>",
"      For bone infections, we suggest a minimum of six months of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For severe infections, we suggest a minimum of six to twelve months of therapy; for patients with pulmonary disease, the duration should include at least twelve months of therapy once sputum cultures become negative. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Severe disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is generally indicated with extensive cutaneous disease, abscess formation, or when drug therapy is difficult. Removal of foreign bodies (eg, breast implants, percutaneous catheters) is essential for cure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/14\">",
"     14",
"    </a>",
"    ]. Surgical resection for limited pulmonary disease may be curative, however, the decision to perform surgery should be made by clinicians with experience in the treatment of nontuberculous mycobacterial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/7\">",
"     7",
"    </a>",
"    ]. Indications for considering lung surgery include poor response to drug therapy and significant disease related complications, such as hemoptysis. Lung surgery should be performed at centers with thoracic surgeons who are experienced with this type of surgery, because lung resectional surgery for mycobacterial disease can be associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/7\">",
"     7",
"    </a>",
"    ]. Thoracic surgery for M. abscessus infection, in particular, may be associated with significant complications even in expert hands and should only be performed in centers with extensive experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Monitoring for drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring for drug toxicity of patients who are being treated for nontuberculous mycobacterial (NTM) disease is important, given the number and type of drugs used and the older age of these patients. It should include the liver (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ); the kidney (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ); auditory and vestibular function (tobramycin, amikacin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ); and hematologic indices (sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the aminoglycosides, this monitoring should include routine questioning about balance, ability to walk (especially in the dark), tinnitus, dizziness, and difficulty hearing. Baseline blood urea nitrogen and creatinine measurements should be obtained. Periodic monitoring of renal function is recommended for high-risk patients receiving drugs daily or five times a week, especially with patients older than 50 years or who have impairment of renal function. A baseline hearing test should be considered, especially in high-risk patients, and then repeated if signs or symptoms of eighth nerve toxicity appear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372828889\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In retrospective studies, the mortality of M. abscessus infections treated with combination antibiotic regimens with or without surgery has been approximately 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/25/5530/abstract/7,59\">",
"     7,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapidly growing mycobacteria (RGM) include three clinically relevant species: M. fortuitum, M. chelonae, and M. abscessus (",
"      <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"       table 1",
"      </a>",
"      ). The RGM are environmental organisms found worldwide that grow in culture within one week. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical disease spectrum caused by the RGM (M. fortuitum, M. chelonae, and M. abscessus) varies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. fortuitum is the most common RGM isolated from clinical specimens and causes disease as a direct consequence of penetrating inoculation due to trauma or as a complication of surgery. It is rarely a significant respiratory pathogen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. chelonae most commonly causes infection in immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. abscessus ssp abscessus is the most pathogenic RGM causing pulmonary infection in patients with or without underlying lung disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of RGM infection is important because of the need to distinguish RGM from M. tuberculosis, since the latter requires public health tracking, whereas the former does not, and drug treatment for the two groups or organisms is very different. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pulmonary disease caused by RGM is based on the American Thoracic Society criteria for nontuberculous mycobacterial (NTM) lung disease, including M. avium complex pulmonary disease (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Pulmonary disease'",
"      </a>",
"      above)&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The diagnosis of nonpulmonary disease is made by culture of the specific pathogen from drainage material or tissue biopsy or the isolation of organisms from sterile, closed sites, such as bone marrow or blood or from a skin biopsy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonpulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Susceptibility testing should be performed on all clinically significant isolates as well as isolates that have been recovered after treatment failure or relapse because of differences in susceptibilities among species of rapidly growing mycobacteria. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with RGM infections should be treated in consultation with an infectious diseases specialist. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. fortuitum and M. abscessus ssp abscessus contain the erm gene, an inducible macrolide resistance gene that may confer in vivo resistance but may not be reflected in the MIC of the organism for these agents. In other words, M. fortuitum and M. abscessus ssp abscessus isolates may be resistant to macrolides in vivo but may still exhibit a \"susceptible\" MIC in vitro.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      appears more likely to induce the macrolide resistance gene than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . Although the therapeutic implications of these findings are unknown, the recognition of an inducible macrolide resistance gene may offer some explanation for the poor response of M. fortuitum and M. abscessus ssp abscessus to macrolide-based regimens. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640153961\">",
"    <span class=\"h3\">",
"     Limited skin and soft tissue infection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with limited skin and soft tissue infection, we suggest oral therapy with two agents to which the isolate is susceptible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Limited skin and soft tissue infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640153969\">",
"    <span class=\"h3\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe disease due to RGM is considered infection that has progressed beyond localized skin involvement, including skin and soft tissue disease, bone involvement, pulmonary disease, and other forms of disseminated infection. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Severe disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For severe infections due to M. fortuitum or M. chelonae, we suggest initial parenteral therapy with at least two agents to which the isolate is susceptible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should continue until clinical improvement is evident (two to six weeks), and be followed by oral therapy with two agents, if susceptibility patterns allow. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'M. fortuitum and M. chelonae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For severe infections, including pulmonary disease, due to M. abscessus ssp abscessus, we suggest initial combination therapy with three agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should continue for four to eight weeks and be followed by at least two agents to which the organism is susceptible to complete a 6 to 12 month course. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'M. abscessus ssp abscessus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640154009\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy depends upon the site and severity of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For localized skin and soft tissue infections, we suggest a minimum of four months of therapy.",
"     </li>",
"     <li>",
"      For bone infections, we suggest a minimum of six months of therapy.",
"     </li>",
"     <li>",
"      For severe infections, we suggest a minimum of six to twelve months of therapy; for patients with pulmonary disease, the duration should include at least twelve months of therapy once sputum cultures become negative. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Severe disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640154026\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is generally indicated with extensive cutaneous disease, abscess formation, or where drug therapy is difficult. Removal of foreign bodies (eg, breast implants, percutaneous catheters) is essential for cure. Surgical resection for limited pulmonary disease may be curative, however, the decision to perform surgery should be made by clinicians with experience in the treatment of nontuberculous mycobacterial disease. Thoracic surgery for M. abscessus infection may be associated with significant complications even in expert hands and should only be performed in centers with extensive experience. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/1\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/2\">",
"      Hoffman PC, Fraser DW, Robicsek F, et al. Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex. J Infect Dis 1981; 143:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/3\">",
"      Wallace RJ Jr, Swenson JM, Silcox VA, et al. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/4\">",
"      Chang MA, Jain S, Azar DT. Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthalmol 2004; 49:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/5\">",
"      Kuritsky JN, Bullen MG, Broome CV, et al. Sternal wound infections and endocarditis due to organisms of the Mycobacterium fortuitum complex. Ann Intern Med 1983; 98:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/6\">",
"      Park S, Suh GY, Chung MP, et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008; 102:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/7\">",
"      Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/8\">",
"      Varghese G, Shepherd R, Watt P, Bruce JH. Fatal infection with Mycobacterium fortuitum associated with oesophageal achalasia. Thorax 1988; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/9\">",
"      Rolston KV, Jones PG, Fainstein V, Bodey GP. Pulmonary disease caused by rapidly growing mycobacteria in patients with cancer. Chest 1985; 87:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/10\">",
"      Redelman-Sidi G, Sepkowitz KA. Rapidly growing mycobacteria infection in patients with cancer. Clin Infect Dis 2010; 51:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/11\">",
"      Dreisin RB, Scoggin C, Davidson PT. The pathogenicity of Mycobacterium fortuitum and Mycobacterium chelonei in man: a report of seven cases. Tubercle 1976; 57:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/12\">",
"      Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatr 1980; 96:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/13\">",
"      Awe RJ, Gangadharam PR, Jenkins DE. Clinical significance of Mycobacterium fortuitum infections in pulmonary disease. Am Rev Respir Dis 1973; 108:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/14\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/15\">",
"      Ingram CW, Tanner DC, Durack DT, et al. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis 1993; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/16\">",
"      Uslan DZ, Kowalski TJ, Wengenack NL, et al. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol 2006; 142:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/17\">",
"      Winthrop KL, Albridge K, South D, et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/18\">",
"      Winthrop KL, Abrams M, Yakrus M, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med 2002; 346:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/19\">",
"      Vugia DJ, Jang Y, Zizek C, et al. Mycobacteria in nail salon whirlpool footbaths, California. Emerg Infect Dis 2005; 11:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/20\">",
"      Stout JE, Gadkowski LB, Rath S, et al. Pedicure-associated rapidly growing mycobacterial infection: an endemic disease. Clin Infect Dis 2011; 53:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/21\">",
"      Sergeant A, Conaglen P, Laurenson IF, et al. Mycobacterium chelonae infection: a complication of tattooing. Clin Exp Dermatol 2013; 38:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/22\">",
"      Bechara C, Macheras E, Heym B, et al. Mycobacterium abscessus skin infection after tattooing: first case report and review of the literature. Dermatology 2010; 221:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/23\">",
"      Drage LA, Ecker PM, Orenstein R, et al. An outbreak of Mycobacterium chelonae infections in tattoos. J Am Acad Dermatol 2010; 62:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/24\">",
"      Kennedy BS, Bedard B, Younge M, et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N Engl J Med 2012; 367:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Tattoo-associated nontuberculous mycobacterial skin infections - multiple States, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/26\">",
"      LeBlanc PM, Hollinger KA, Klontz KC. Tattoo ink-related infections--awareness, diagnosis, reporting, and prevention. N Engl J Med 2012; 367:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/27\">",
"      Mateo L, Ruf&iacute; G, Nolla JM, Alcaide F. Mycobacterium chelonae tenosynovitis of the hand. Semin Arthritis Rheum 2004; 34:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/28\">",
"      Franklin DJ, Starke JR, Brady MT, et al. Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Am J Otol 1994; 15:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/29\">",
"      Sharma S, Tleyjeh IM, Espinosa RE, et al. Pacemaker infection due to Mycobacterium fortuitum. Scand J Infect Dis 2005; 37:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/30\">",
"      Eid AJ, Berbari EF, Sia IG, et al. Prosthetic joint infection due to rapidly growing mycobacteria: report of 8 cases and review of the literature. Clin Infect Dis 2007; 45:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/31\">",
"      Phillips MS, von Reyn CF. Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis 2001; 33:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Nontuberculous mycobacterial infections after cosmetic surgery--Santo Domingo, Dominican Republic, 2003-2004. MMWR Morb Mortal Wkly Rep 2004; 53:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/33\">",
"      Regnier S, Cambau E, Meningaud JP, et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis 2009; 49:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/34\">",
"      Rimmer J, Hamilton S, Gault D. Recurrent mycobacterial breast abscesses complicating reconstruction. Br J Plast Surg 2004; 57:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/35\">",
"      John T, Velotta E. Nontuberculous (atypical) mycobacterial keratitis after LASIK: current status and clinical implications. Cornea 2005; 24:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/36\">",
"      Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology 2003; 110:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/37\">",
"      Sampaio JL, Junior DN, de Freitas D, et al. An outbreak of keratitis caused by Mycobacterium immunogenum. J Clin Microbiol 2006; 44:3201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/38\">",
"      Toy BR, Frank PJ. Outbreak of Mycobacterium abscessus infection after soft tissue augmentation. Dermatol Surg 2003; 29:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Mycobacterium chelonae infections associated with face lifts--New Jersey, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/40\">",
"      Furuya EY, Paez A, Srinivasan A, et al. Outbreak of Mycobacterium abscessus wound infections among \"lipotourists\" from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008; 46:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/41\">",
"      Duarte RS, Louren&ccedil;o MC, Fonseca Lde S, et al. Epidemic of postsurgical infections caused by Mycobacterium massiliense. J Clin Microbiol 2009; 47:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/42\">",
"      Leao SC, Tortoli E, Euz&eacute;by JP, Garcia MJ. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/43\">",
"      van Dissel JT, Kuijper EJ. Rapidly growing mycobacteria: emerging pathogens in cosmetic procedures of the skin. Clin Infect Dis 2009; 49:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/44\">",
"      Raad II, Vartivarian S, Khan A, Bodey GP. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis 1991; 13:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/45\">",
"      Ellis EN, Schutze GE, Wheeler JG. Nontuberculous mycobacterial exit-site infection and abscess in a peritoneal dialysis patient. A case report and review of the literature. Pediatr Nephrol 2005; 20:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/46\">",
"      Vera G, Lew SQ. Mycobacterium fortuitum peritonitis in two patients receiving continuous ambulatory peritoneal dialysis. Am J Nephrol 1999; 19:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/47\">",
"      Huebner RE, Good RC, Tokars JI. Current practices in mycobacteriology: results of a survey of state public health laboratories. J Clin Microbiol 1993; 31:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/48\">",
"      Butler WR, Ahearn DG, Kilburn JO. High-performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Nocardia, Rhodococcus, and Mycobacterium species. J Clin Microbiol 1986; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/49\">",
"      Stone MS, Wallace RJ Jr, Swenson JM, et al. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob Agents Chemother 1983; 24:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/50\">",
"      Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/51\">",
"      Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/52\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/53\">",
"      Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/54\">",
"      Wallace RJ Jr, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/55\">",
"      Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/56\">",
"      Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/57\">",
"      Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/58\">",
"      Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/59\">",
"      Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/60\">",
"      Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/61\">",
"      Griffith DE. The talking Mycobacterium abscessus blues. Clin Infect Dis 2011; 52:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/25/5530/abstract/62\">",
"      Rodriguez D&iacute;az JC, L&oacute;pez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 21:585.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5347 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5530=[""].join("\n");
var outline_f5_25_5530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin and soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Musculoskeletal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prosthetic device infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonpulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mycobacterial species identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Susceptibility patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372828830\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Limited skin and soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - M. fortuitum and M. chelonae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - M. abscessus ssp abscessus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Additional oral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Monitoring for drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372828889\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H640153961\">",
"      - Limited skin and soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H640153969\">",
"      - Severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H640154009\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H640154026\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5347\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5347|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/48/11020\" title=\"table 2\">",
"      Criteria for NTM diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36457?source=related_link\">",
"      Prevention and management of tympanostomy tube otorrhea in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_25_5531="ADH and urine volume";
var content_f5_25_5531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effect of ADH on urine volume",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        ADH",
"       </td>",
"       <td class=\"subtitle1\">",
"        Urine osmolality mosmol/kg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Urine volume L/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of increasing levels of antidiuretic hormone (ADH) on urine volume in a subject excreting 800 mosmol of solute per day. The fifteen-fold variation in urine osmolality (80 to 1200 mosmol/kg) means that there is a similar variation in urine volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5531=[""].join("\n");
var outline_f5_25_5531=null;
var title_f5_25_5532="Diagnosis of vulvar pruritus";
var content_f5_25_5532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of vulvar pruritus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condylomata",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar intraepithelial neoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acrochordon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seborrheic keratosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perimenopausal atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexually transmitted diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seborrheic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen simplex chronicus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen sclerosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe contact dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediculosis pubis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5532=[""].join("\n");
var outline_f5_25_5532=null;
var title_f5_25_5533="Oral medications for dystonia";
var content_f5_25_5533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral medications for the treatment of dystonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pharmacologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Efficacy and comment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dopamine agonists",
"       </td>",
"       <td rowspan=\"2\">",
"        Dramatic response in the dopa responsive form of dystonia; effective in 10 to 15 percent of patients with other types of dystonia; more rapid upward titration possible",
"       </td>",
"       <td rowspan=\"2\">",
"        Nausea (especially at initiation of therapy); may worsen dystonia; rapid discontinuation possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carbidopa/Levodopa",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Anticholinergic/antihistaminic",
"       </td>",
"       <td rowspan=\"6\">",
"        Effective in approximately 40 percent of patients, mainly children; benefit limited by side effects; requires slow upward titration",
"       </td>",
"       <td rowspan=\"6\">",
"        Dry mouth (may lead to dental caries); blurred vision; exacerbation of acute-angle glaucoma; urinary retention; memory problems; sedation; confusion; hallucinations; heat intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trihexyphenidyl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benztropine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Procyclidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diphenhydramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ethopropazine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Baclofen",
"       </td>",
"       <td>",
"        Effective in approximately 20 percent of patients; high doses tolerated in children; benefits limited by side effects; intrathecal baclofen minimally successful; withdrawal effects on sudden discontinuation",
"       </td>",
"       <td>",
"        Nausea; sedation; dysphoria; muscle weakness (in those with spasticity associated)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Clonazepam",
"       </td>",
"       <td>",
"        Effective in approximately 15 percent of patients; possibility for addiction; withdrawal effects on sudden discontinuation",
"       </td>",
"       <td>",
"        Sedation; depression; confusion; dependence",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Muscle relaxants",
"       </td>",
"       <td rowspan=\"3\">",
"        Limited benefit in some patients; side effects frequent",
"       </td>",
"       <td rowspan=\"3\">",
"        Sedation; dysphoria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tizanidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclobenzaprine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Anticonvulsant medications",
"       </td>",
"       <td rowspan=\"3\">",
"        Benefit in less than 10 percent of patients",
"       </td>",
"       <td rowspan=\"3\">",
"        Ataxia; sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gabapentin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Dopamine-depleting agents",
"       </td>",
"       <td rowspan=\"3\">",
"        Requires a very slow upward titration (4 weeks between dose increases)",
"       </td>",
"       <td rowspan=\"3\">",
"        Depression; dysphoria; parkinsonism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tetrabenazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reserpine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dopamine receptor blocking agents",
"       </td>",
"       <td>",
"        Effective in up to 25 percent of patients; clozapine requires weekly blood counts and may cause life threatening agranulocytosis",
"       </td>",
"       <td>",
"        The possibility of tardive dyskinesia and the other adverse effects from this class of medications severely limits usefulness; not recommended for dystonia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5533=[""].join("\n");
var outline_f5_25_5533=null;
var title_f5_25_5534="Contents: HIV and AIDS";
var content_f5_25_5534=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       HIV and AIDS",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			HIV and AIDS",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Body fluid exposure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18931\">",
"           Patient information: Blood or body fluid exposure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31282\">",
"           Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35009\">",
"           Patient information: Dementia with HIV (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"./kaposis-sarcoma-the-basics\">",
"           Patient information: Kaposi���������s sarcoma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18931\">",
"           Patient information: Blood or body fluid exposure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21907\">",
"           Patient information: HIV/AIDS (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31282\">",
"           Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7170\">",
"           Patient information: Symptoms of HIV infection (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10451\">",
"           Patient information: Tests to monitor HIV (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV testing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1986\">",
"           Patient information: Testing for HIV (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Opportunistic infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44658\">",
"           Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy and HIV",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/29/7635\">",
"           Patient information: HIV and pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15861\">",
"           Patient information: Initial treatment of HIV (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/44/22210\">",
"           Patient information: Starting treatment for HIV (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10451\">",
"           Patient information: Tests to monitor HIV (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/56/2946\">",
"           Patient information: Tips for taking HIV medications (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36498\">",
"           Patient information: Vaccines for people with HIV (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaccines",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36498\">",
"           Patient information: Vaccines for people with HIV (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D6DA087000-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_25_5534=[""].join("\n");
var outline_f5_25_5534=null;
var title_f5_25_5535="Blood pressure measurement";
var content_f5_25_5535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blood pressure measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The blood pressure should be measured with the arm supported and the cubital fossa at the level of the heart. The stethoscope bell is placed over the brachial artery pulse below the bottom edge of the cuff, which should be about 2 cm above the cubital fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 1996; 98:649.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_25_5535=[""].join("\n");
var outline_f5_25_5535=null;
